RESULT_COUNT: 643,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors,2017-10-20 11:00:00 +0000,https://finance.yahoo.com/news/alnylam-collaborators-present-apollo-phase-110000113.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloidosis, will be presented at the 1st European ATTR Amyloidosis Meeting for Patients and Doctors being held November 2-3, 2017 in Paris, France...."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to partner with Scangos-led biotech on infectious disease drugs,2017-10-18 15:35:08 +0000,http://finance.yahoo.com/r/fd906079-34cb-3c8f-9655-6be8ac7c9661/alnylam-to-partner-with-scangos-led-biotech-on.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Vir Biotechnology, a San Francisco-based startup led by former Biogen CEO George Scangos, said Wednesday that it will work with Alnylam Pharmaceuticals to develop infectious disease treatments using the Cambridge company’s experimental technology.  Under the agreement, the companies will collaborate to develop one of Alnylam’s (ALNY) potential drugs for hepatitis B, plus up to four additional treatments for infectious diseases.  Alnylam will be eligible to receive over $1 billion in payments if the drugs hit certain milestones."
ALNY,ALNY:UW,BBG000BFGYR2,"UPDATE 1-Alnylam, Vir partner on RNAi-based hep B treatment",2017-10-18 15:09:56 +0000,https://finance.yahoo.com/news/alnyalm-vir-partner-rnai-based-132741004.html?.tsrc=rss,"Drug developer Alnylam Pharmaceuticals  Inc said on Wednesday it would scrap its hepatitis B  (HBV) drug development and instead work with Vir Biotechnology  on a new treatment for the disease.  The partnership with Vir includes development of drugs for  four other infectious diseases using RNAi technology, which aims  to silence targeted genes to curb the production of  disease-causing proteins and have limited side-effects.  Under the deal, the drug developer would receive an  undisclosed upfront payment and more than $1 billion in  potential milestone payments among other things."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam, Vir partner on RNAi-based drugs for infectious diseases",2017-10-18 15:07:46 +0000,https://finance.yahoo.com/news/alnyalm-vir-partner-rnai-based-124458505.html?.tsrc=rss,"Drug developer Alnylam Pharmaceuticals  Inc entered into an agreement with privately held Vir  Biotechnology on Wednesday to develop a new class of RNAi-based  treatments for infectious diseases, including chronic hepatitis  B.  Alnylam said it would receive an upfront payment, comprising  cash and Vir's shares under the deal terms, and would be  eligible for more than $1 billion in potential milestone  payments among other things.  The company also said it would terminate development of its  hepatitis B drug and would work on a new treatment along with  Vir for the disease, apart from collaborating on therapies for  four other infectious diseases."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's stock set to rally after exclusive license deal with Vir Biotechnology,2017-10-18 11:15:15 +0000,http://finance.yahoo.com/r/009d8f85-089a-34e4-8274-f605a03d31bc/Story.aspx?guid=66AE0E40-47E0-41EC-8848-05511CBD4E2F&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Alnylam Pharmaceuticals Inc. said Wednesday it has entered into an exclusive license agreement with privately-held Vir Biotechnology to develop and sell RNAi therapeutics for infectious diseases, including ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases,2017-10-18 11:01:00 +0000,https://finance.yahoo.com/news/alnylam-vir-form-strategic-alliance-110100154.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people with serious infectious diseases, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus infection."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam, Vir Biotechnology To Advance RNAi Therapeutics For Infectious Diseases",2017-10-18 07:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZHJ-aheAhvo/alnylam-vir-biotechnology-to-advance-rnai-therapeutics-for-infectious-diseases-20171018-00367,"Alnylam, Vir Biotechnology To Advance RNAi Therapeutics For Infectious Diseases"
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-10-17 12:06:08 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120608562.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,SPDR S&P Biotech ETF Experiences Big Outflow,2017-10-13 16:12:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y2YeC8dLonY/spdr-sp-biotech-etf-experiences-big-outflow-cm859407,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 65 4 million dollar outflow that s a 1 5 decrease week over week from 49 500 000
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-10-13 12:07:14 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120714686.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $1.26 billion."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-10-09 12:07:37 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120737380.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,"XLF, FNY: Big ETF Inflows",2017-10-06 16:43:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yoZN_6ROYRI/xlf-fny-big-etf-inflows-cm856306,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Financial Select Sector SPDR Fund which added 36 700 000 units or a 3 5 increase week over week Among the largest underlying components of XLF in morning
ALNY,ALNY:UW,BBG000BFGYR2,Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September,2017-10-05 16:48:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p1PWZd_hJXY/heres-why-alnylam-pharmaceuticals-rallied-327-in-september-cm855822,What happened Powered by encouraging phase 3 results 160 for an important pipeline drug shares of clinical stage biotech Alnlyam Pharmaceuticals NASDAQ ALNY which focuses on RNAi treatments gained 33 in September according to data from S amp P Global Market
ALNY,ALNY:UW,BBG000BFGYR2,Here&apos;s Why Alnylam Pharmaceuticals Rallied 32.7% in September,2017-10-05 15:28:00 +0000,http://finance.yahoo.com/r/ac586127-c9ff-3069-aa8e-e14714967903/heres-why-alnylam-pharmaceuticals-rallied-327-in-s.aspx?yptr=yahoo&.tsrc=rss,Positive results from an important phase 3 clinical trial fueled optimism about the biotech.
ALNY,ALNY:UW,BBG000BFGYR2,"FXH, ALNY, ALGN, GILD: Large Inflows Detected at ETF",2017-10-04 16:31:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dDXAdlwo8Oc/fxh-alny-algn-gild-large-inflows-detected-at-etf-cm855246,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the First Trust Health Care AlphaDEX Fund Symbol FXH where we have detected an approximate 146 6 million dollar inflow that s a 13 9 increase week over week
ALNY,ALNY:UW,BBG000BFGYR2,Analysts Act on Health Care Stocks,2017-10-03 16:20:26 +0000,https://finance.yahoo.com/news/analysts-act-health-care-stocks-162026822.html?.tsrc=rss,Leerink upgrades AbbVie to Outperform
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-10-02 12:05:41 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120541510.html?.tsrc=rss,Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
ALNY,ALNY:UW,BBG000BFGYR2,Why Biotech and Tech Will Push Stocks Higher In 4Q,2017-09-29 14:54:00 +0000,http://finance.yahoo.com/r/7401e074-5696-3c53-a9d6-89edc9f17f89/why-biotech-and-tech-will-push-stocks-higher-4q?partner=YahooSA&yptr=yahoo&.tsrc=rss,"The tech and biotech sectors have buoyed the broader market this year, and they're not letting up anytime soon."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-09-27 12:05:41 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120541187.html?.tsrc=rss,Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS),2017-09-26 12:00:00 +0000,https://finance.yahoo.com/news/alnylam-initiates-phase-2-clinical-120000764.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran , a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases."
ALNY,ALNY:UW,BBG000BFGYR2,Gene Therapy: A Big Week for Many Names,2017-09-25 13:57:00 +0000,http://finance.yahoo.com/r/d83c2532-8e77-327e-a958-c7fa98ebcf0a/gene-therapy-a-big-week-for-many-names-1506347828?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"It’s been a big week for the gene therapy universe.  Of course, there’s the latest Barron’s  cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena.  Last week, Ultragenyx Pharmaceutical (RARE) offered to buy  Dimension Therapeutics (DMTX) for at $5.50 per share in cash."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on ""Enhanced Stabilization Chemistry Plus"" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society",2017-09-25 12:00:00 +0000,https://finance.yahoo.com/news/alnylam-continues-leadership-rnai-technologies-120000934.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation “Enhanced Stabilization Chemistry Plus” GalNAc-siRNA conjugate platform at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society , held September 24 – 27, 2017 in Bordeaux, France."
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT,2017-09-24 11:36:32 +0000,https://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-041239928.html?.tsrc=rss,Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call
ALNY,ALNY:UW,BBG000BFGYR2,3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?,2017-09-23 15:48:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oWzczwlRIWo/3-biotech-stocks-that-skyrocketed-this-week-can-they-go-higher-cm850027,One great thing about the biotech industry is that there are nearly always some winners Regardless of what s going on in the world or in the broader market at least a few biotech stocks are likely to gain momentum week in and week out Three such winners over the past five days
ALNY,ALNY:UW,BBG000BFGYR2,3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?,2017-09-23 14:34:00 +0000,http://finance.yahoo.com/r/53590c3b-90fd-34fc-bae4-16adc0a8b55a/3-biotech-stocks-that-skyrocketed-this-week-can-th.aspx?yptr=yahoo&.tsrc=rss,"Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week&apos;s biggest biotech winners."
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Alnylam's New Medicine To Enter Pricing Debate,2017-09-22 11:30:05 +0000,http://finance.yahoo.com/r/14b8b343-c3ad-3d1a-916d-6ddfb1d6678d/alnylams-new-medicine-to-enter-pricing-debate-1506079800?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
ALNY,ALNY:UW,BBG000BFGYR2,Versartis Loses VELOCITY - What Other Pharma Stocks Made News This Week?,2017-09-22 00:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2gr6-fmdAYU/versartis-loses-velocity--what-other-pharma-stocks-made-news-this-week-20170922-00016,Versartis Loses VELOCITY - What Other Pharma Stocks Made News This Week?
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Is Entering &apos;New Chapter,&apos; But Ionis Still Has A Chance",2017-09-21 20:16:22 +0000,http://finance.yahoo.com/r/fc49b25d-6917-3630-8d06-05bd5a8c7b92/alnylam-is-entering-new-chapter-but-ionis-still-has-a-chance?src=A00220&yptr=yahoo&.tsrc=rss,"Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals: Bet or Fold?,2017-09-21 19:19:00 +0000,http://finance.yahoo.com/r/cb4dd2d3-099c-348c-8170-519a8161ed6a/alnylam-pharmaceuticals-bet-or-fold-1506021550?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in?  In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking.  Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals CEO: Trial results open up the do...,2017-09-21 18:37:00 +0000,https://finance.yahoo.com/video/alnylam-pharmaceuticals-ceo-trial-results-183700947.html?.tsrc=rss,"Alnylam Pharmaceuticals CEO John Maraganore discusses his company's successful drug trial to treat a rare nerve disorder, and what he sees for the underlying technology. With CNBC's Meg Tirrell."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up",2017-09-21 17:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rYtUU_ZPQQE/alnylamsanofis-rnai-drug-meets-endpoint-in-study-stock-up-cm849108,Shares of Alnylam Pharmaceuticals Inc ALNY soared by more than 50 after the company and its partner Sanofi SNY announced that a pivotal phase III study on its pipeline candidate patisiran met its primary as well as all secondary endpoints Alnylam s shares have outperformed the industry
ALNY,ALNY:UW,BBG000BFGYR2,"Company News For Sep 21, 2017",2017-09-21 16:40:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NC18bCISYHA/company-news-for-sep-21-2017-cm849085,Shares of Bed Bath amp Beyond Inc 160 BBBY plummeted almost 16 after reporting second quarter 2017 earnings per share of 0 75 missing the Zacks Consensus Estimate of 0 95 Shares of FedEx Corp FDX gained 2 1 after the company posted first quarter 2018 revenues
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam/Sanofi&apos;s RNAi Drug Meets Endpoint in Study, Stock Up",2017-09-21 15:01:03 +0000,https://finance.yahoo.com/news/alnylam-sanofi-apos-rnai-drug-150103739.html?.tsrc=rss,Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session,2017-09-21 14:40:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ESZU7XcS_3U/alnylam-pharmaceuticals-alny-soars-stock-adds-517-in-session-cm848917,Alnylam Pharmaceuticals Inc ALNY was a big mover last session as the company saw its shares rise nearly 52 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading
ALNY,ALNY:UW,BBG000BFGYR2,"Company News For Sep 21, 2017",2017-09-21 14:26:02 +0000,https://finance.yahoo.com/news/company-news-sep-21-2017-142602818.html?.tsrc=rss,"Companies in the news are: BBBY,FDX,ALNY,GIS"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : September 21, 2017",2017-09-21 13:22:50 +0000,http://finance.yahoo.com/r/c1b590f1-700c-39c3-918f-e22c360af175/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-alny-us-september-21-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session,2017-09-21 12:56:12 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-soars-stock-125612727.html?.tsrc=rss,"Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes."
ALNY,ALNY:UW,BBG000BFGYR2,Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Arbutus Biopharma,2017-09-21 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-122000893.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 21, 2017 / Shares of Alnylam and Airbus soared to new highs on Wednesday after Alnylam announced that an important key study met its primary efficacy endpoint and ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam shares surge 40% on drug results that may herald a new type of medicine,2017-09-21 10:50:27 +0000,http://finance.yahoo.com/r/45c7865b-8c50-3454-9e46-7544ff98b9b2/Story.aspx?guid=9DFBA2DE-9E08-11E7-8DA8-70A592F3D9E7&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Many companies backed away from the gene silencing technique when big investments in the field didn’t pan out — but not Alnylam.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Shows Market Leadership With Jump To 98 RS Rating,2017-09-21 07:00:00 +0000,http://finance.yahoo.com/r/a96d2176-5a04-3ec1-885c-a27e611b36db/alnylam-pharmaceuticals-shows-market-leadership-with-jump-to-98-rs-rating?src=A00220&yptr=yahoo&.tsrc=rss,"Alnylam Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating."
ALNY,ALNY:UW,BBG000BFGYR2,Here's Why Arbutus Biopharma Corp. Stock Soared Today,2017-09-20 22:36:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kTbbZCac6XY/heres-why-arbutus-biopharma-corp-stock-soared-today-cm848713,What happened Shares of Arbutus Biopharma Corp NASDAQ ABUS rode some mighty coattails today This morning Alnylam Pharmaceuticals Inc NASDAQ ALNY announced highly positive data for a candidate that employs delivery technology it licensed from Arbutus The
ALNY,ALNY:UW,BBG000BFGYR2,What Happened in the Stock Market Today,2017-09-20 22:35:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YwZzTN0-NBc/what-happened-in-the-stock-market-today-cm848702,Stocks dipped Wednesday when the Federal Reserve announced plans to reduce its bond portfolio and hinted at another hike in the federal funds rate before the end of the year but mostly recovered by the end of the day The Dow Jones Industrial Average DJINDICES DJI 160 and
ALNY,ALNY:UW,BBG000BFGYR2,"ALNY In Top Form, LENS Catches Investors' Eyes, PRQR, AXON Inch Closer To D-Day",2017-09-20 22:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sTm4BIxPB4I/alny-in-top-form-lens-catches-investors-eyes-prqr-axon-inch-closer-to-dday-20170920-01304,"ALNY In Top Form, LENS Catches Investors' Eyes, PRQR, AXON Inch Closer To D-Day"
ALNY,ALNY:UW,BBG000BFGYR2,Boosting Fair Value on Alnylam After Drug Trial,2017-09-20 21:45:00 +0000,https://finance.yahoo.com/news/boosting-fair-value-alnylam-drug-214500668.html?.tsrc=rss,"Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough",2017-09-20 21:35:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CrnY1ybW7Wk/alnylam-pharmaceuticals-inc-alny-stock-soars-on-drug-breakthrough-cm848708,InvestorPlace Stock Market News Stock Advice amp Trading Tips Alnylam Pharmaceuticals Inc NASDAQ ALNY shares were skyrocketing Wednesday as the company unveiled the latest results of one of its drugs The pharmaceutical company
ALNY,ALNY:UW,BBG000BFGYR2,What Happened in the Stock Market Today,2017-09-20 21:05:27 +0000,http://finance.yahoo.com/r/99dd8f73-a886-36e3-af1b-821b716fbdd2/what-happened-in-the-stock-market-today.aspx?yptr=yahoo&.tsrc=rss,"On a day stocks gyrated in response to Federal Reserve announcements, Bed Bath & Beyond fell sharply on earnings, and Alnylam Pharmaceuticals soared on a successful drug trial."
ALNY,ALNY:UW,BBG000BFGYR2,"Close Update: Dow, S&P 500 Hit Records as Wobbly Session Sees Financials Gain After Fed",2017-09-20 20:56:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nO9BNzvkTBg/close-update-dow-sp-500-hit-records-as-wobbly-session-sees-financials-gain-after-fed-cm848690,Wall Street came under selling pressure on Wednesday before clawing back most of the losses as investors digested the latest Federal Open Market Committee statement where the target range on the Fed funds rate was held but projections affirmed expectations for a third 2017 hike Wall Street
ALNY,ALNY:UW,BBG000BFGYR2,Here&apos;s Why Arbutus Biopharma Corp. Stock Soared Today,2017-09-20 20:32:00 +0000,http://finance.yahoo.com/r/4cd291a3-ff1e-3b7d-9b45-df94b5b68329/heres-why-arbutus-biopharma-corp-stock-soared-toda.aspx?yptr=yahoo&.tsrc=rss,A new drug candidate that licences Arbutus Biopharma&apos;s proprietary technology passed an important milestone.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks,2017-09-20 20:07:58 +0000,http://finance.yahoo.com/r/2e8fce35-8e87-3d5f-a227-3a7bff17a846/alnylam-rockets-on-strong-rare-disease-drug-data-ionis-tanks-2?src=A00220&yptr=yahoo&.tsrc=rss,Alnylam gapped up Wednesday — to Ionis&apos; detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Alnylam Pharma Shares Climb After Positive Phase 3 Results,2017-09-20 19:41:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T1nrxlRsml4/mid-afternoon-market-update-crude-oil-up-over-2-alnylam-pharma-shares-climb-after-positive-phase-3-results-cm848649,Toward the end of trading Wednesday the Dow traded down 0 19 percent to 22 328 28 while the NASDAQ declined 0 66 percent to 6 418 93 The S amp P also fell dropping 0 36 percent to 2 497 76 Leading and Lagging Sectors Wednesday afternoon the energy shares surged 0 79
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Notches a Game-Changing RNAi Win,2017-09-20 19:37:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SCWBPt8KenI/alnylam-notches-a-game-changing-rnai-win-cm848613,Alnylam Pharmaceuticals Inc NASDAQ ALNY is researching therapies that can treat genetic diseases by interfering with gene expression Though Alnylam has yet to validate its approach with a Food and Drug Administration approval for one of its drugs that could change following
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam's RNAi drug succeeds in key study, shares soar",2017-09-20 19:29:16 +0000,https://finance.yahoo.com/news/alnylams-genetic-disease-drug-clears-121442063.html?.tsrc=rss,"Alnylam Pharmaceuticals Inc's  RNAi-based drug that targets a rare genetic disease met the main  goal of a key study, in a breakthrough for the new class of  medicines that works by blocking disease-causing proteins.  Alnylam's patisiran belongs to a class of drugs that uses  the Nobel-prize winning RNA interference (RNAi) mechanism to  manipulate ribonucleic acid, which interferes with or ""silences""  targeted genes, and stops the formation of proteins that can  cause diseases."
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today",2017-09-20 18:38:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FKnwBNPUD1Q/why-alnylam-pharmaceuticals-inc-skyrocketed-and-ionis-pharmaceuticals-inc-sank-today-cm848562,What happened Alnylam Pharmaceuticals NASDAQ ALNY is up more than 40 at 11 53 a m EDT after the company released positive phase 3 trial data for the Apollo trial testing its RNAi drug 160 patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Notches a Game-Changing RNAi Win,2017-09-20 18:01:00 +0000,http://finance.yahoo.com/r/e364dc63-d14b-3f29-bcff-a14bb39e9a1a/alnylam-notches-a-game-changing-rnai-win.aspx?yptr=yahoo&.tsrc=rss,"Phase 3 trials of Alnylam&apos;s patisiran were a success, paving the way to an FDA filing for approval later this year."
ALNY,ALNY:UW,BBG000BFGYR2,"What's Next for Alnylam Pharmaceuticals, Inc.?",2017-09-20 17:39:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sxbn0otWeYE/whats-next-for-alnylam-pharmaceuticals-inc-cm848507,The past 15 years haven t been easy for Alnylam Pharmaceuticals Inc NASDAQ ALNY shareholders The company s new drug candidates are based on science that earned a Nobel Prize in 2006 but proving a clear clinical benefit that outweighs any safety concerns hasn t been nearly as
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Day Market Update: Bed Bath & Beyond Drops On Earnings Miss; DelMar Pharmaceuticals Shares Plunge,2017-09-20 17:36:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ixND4_v56aU/mid-day-market-update-bed-bath-beyond-drops-on-earnings-miss-delmar-pharmaceuticals-shares-plunge-cm848545,Midway through trading Wednesday the Dow traded down 0 01 percent to 22 370 10 while the NASDAQ declined 0 11 percent to 6 454 34 The S amp P also fell dropping 0 01 percent to 2 506 45 Leading and Lagging Sectors On Wednesday the energy shares surged 0 45 percent Meanwhile
ALNY,ALNY:UW,BBG000BFGYR2,Wednesday's ETF with Unusual Volume: FNX,2017-09-20 17:35:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8UpY13MJTjc/wednesdays-etf-with-unusual-volume-fnx-cm848497,The First Trust Mid Cap Core AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday with over 154 000 shares traded versus three month average volume of about 35 000 Shares of FNX were up about 0 3 on the day Components of that ETF with the highest volume
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today",2017-09-20 17:18:00 +0000,http://finance.yahoo.com/r/1fa4a774-2d08-3834-9e0b-5243e506652b/why-alnylam-pharmaceuticals-inc-skyrocketed-and-io.aspx?yptr=yahoo&.tsrc=rss,One biotech&apos;s phase 3 success means competition for the other.
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough",2017-09-20 17:14:28 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-stock-171428343.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were skyrocketing Wednesday as the company unveiled the latest results of one of its drugs.  The pharmaceutical company revealed how well the phase 3 clinical trial of patisiran went, which is Alnylam’s lead drug that is designed to treat a rare nerve disorder that’s known as familial amyloid polyneuropathy (FAP).  The safety profile of patisiran looks clean, which is perhaps even more important than the positive results as some of the company’s other pipeline drugs raised concerns regarding the toxicity levels they contained."
ALNY,ALNY:UW,BBG000BFGYR2,"Hurricanes, Earthquakes and Record-High Markets",2017-09-20 16:41:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vwNrBDvOpvs/hurricanes-earthquakes-and-record-high-markets-cm848472,Wednesday September 20 2017 While new hurricane concerns surround the events in Puerto Rico and elsewhere two earthquakes registering 8 1 and 7 1 major by any measure have hit Mexico in the last few days Earthquakes tend to reverberate over time resulting in after shocks and
ALNY,ALNY:UW,BBG000BFGYR2,Calamities Couldn't Spoil The Bullish Run,2017-09-20 16:39:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R5lcXgByioU/calamities-couldnt-spoil-the-bullish-run-cm848416,While new hurricane concerns surround the events in Puerto Rico and elsewhere two earthquakes registering 8 1 and 7 1 major by any measure have hit Mexico in the last few days Earthquakes tend to reverberate over time resulting in after shocks and those we have seen as well Mexico
ALNY,ALNY:UW,BBG000BFGYR2,Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program,2017-09-20 16:23:17 +0000,https://finance.yahoo.com/news/arbutus-lnp-licensee-alnylam-announces-162317491.html?.tsrc=rss,"Arbutus’ LNP Technology Further Validated with New Results. Arbutus to Receive Single Digit Royalties on Sales of Patisiran. VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 20, 2017-- Arbutus Biopharma ..."
ALNY,ALNY:UW,BBG000BFGYR2,Major Averages Close Mixed Following Fed Announcement - U.S. Commentary,2017-09-20 16:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9P04JOBigjo/major-averages-close-mixed-following-fed-announcement--us-commentary-20170920-01081,Major Averages Close Mixed Following Fed Announcement - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,"What&apos;s Next for Alnylam Pharmaceuticals, Inc.?",2017-09-20 16:14:00 +0000,http://finance.yahoo.com/r/238533de-7b53-355b-911c-8415fe641ed8/whats-next-for-alnylam-pharmaceuticals-inc.aspx?yptr=yahoo&.tsrc=rss,Get ready for a flurry of activity from this biotech pioneer.
ALNY,ALNY:UW,BBG000BFGYR2,"After 20 Years, A Drug That Silences Genes Succeeds",2017-09-20 15:37:00 +0000,http://finance.yahoo.com/r/4e06dae7-1d21-3267-a80f-b79f097c890e/after-20-years-a-drug-that-silences-genes-succeeds?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,A 1998 laboratory breakthrough that upended scientists’ understanding of how genes work finally looks set to yield a new treatment for a rare hereditary disorder – and maybe a whole new type of drug.
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Morning Market Update: Markets Edge Lower; General Mills Earnings Miss Estimates,2017-09-20 15:36:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WwqTppWQMgI/mid-morning-market-update-markets-edge-lower-general-mills-earnings-miss-estimates-cm848388,Following the market opening Wednesday the Dow traded down 0 03 percent to 22 365 17 while the NASDAQ declined 0 09 percent to 6 455 31 The S amp P also fell dropping 0 03 percent to 2 505 88 Leading and Lagging Sectors Wednesday morning the energy shares surged 0 55
ALNY,ALNY:UW,BBG000BFGYR2,"Cheer Alnylam's Drug, Pause on Its Platform",2017-09-20 15:36:13 +0000,http://finance.yahoo.com/r/a45871bd-4572-3034-91ff-5c54b71e6de7/alnylam-patisiran-trial-cheer-the-drug-pause-on-the-platform?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Investors are betting on unbridled pipeline success based on one medicine.
ALNY,ALNY:UW,BBG000BFGYR2,Calamities Couldn&apos;t Spoil The Bullish Run,2017-09-20 14:48:02 +0000,https://finance.yahoo.com/news/calamities-couldn-apos-t-spoil-144802980.html?.tsrc=rss,Calamities Couldn&apos;t Spoil The Bullish Run
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Holding On To Substantial Gain In Afternoon Trading,2017-09-20 14:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/abIHXkeCnJA/alnylam-pharmaceuticals-holding-on-to-substantial-gain-in-afternoon-trading-20170920-01000,Alnylam Pharmaceuticals Holding On To Substantial Gain In Afternoon Trading
ALNY,ALNY:UW,BBG000BFGYR2,"Hurricanes, Earthquakes and Record-High Markets",2017-09-20 14:23:02 +0000,https://finance.yahoo.com/news/hurricanes-earthquakes-record-high-markets-142302387.html?.tsrc=rss,"With Hurricane Maria striking Puerto Rico and two major earthquakes destroying parts of Mexico, markets continue to reach for new record highs."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers,2017-09-20 14:16:00 +0000,http://finance.yahoo.com/r/e959e218-4667-35d0-b790-35b14e747aae/alnylam-shares-jump-on-clinical-study-results.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy."
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Most Active for Sep 20, 2017 :  NBRV, FWONK, BBBY, ALNY, CHU, RAD, DB, MU, WDC, TEVA, S, BBU",2017-09-20 12:55:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yWhqoW4N1iE/pre-market-most-active-for-sep-20-2017-nbrv-fwonk-bbby-alny-chu-rad-db-mu-wdc-teva-s-bbu-cm848219,The NASDAQ 100 Pre Market Indicator is down 4 19 to 5 986 89 The total Pre Market volume is currently 3 161 824 shares traded The following are the most active stocks for the pre market session Nabriva Therapeutics plc NBRV is 0 47 at 8 72 with 791 213 shares
ALNY,ALNY:UW,BBG000BFGYR2,Why Alnylam Pharmaceuticals Inc (ALNY) Could Be A Buy,2017-09-20 12:51:23 +0000,https://finance.yahoo.com/news/why-alnylam-pharmaceuticals-inc-alny-125123100.html?.tsrc=rss,"Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in theRead More..."
ALNY,ALNY:UW,BBG000BFGYR2,UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment,2017-09-20 11:39:05 +0000,http://finance.yahoo.com/r/d498e6c8-b8ac-360a-846f-0ce86251cd7e/Story.aspx?guid=1A6EC022-CB0A-426A-A856-C7B6AF5520F9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares ...
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's genetic disease drug meets main goal in key study,2017-09-20 11:25:48 +0000,https://finance.yahoo.com/news/alnylams-genetic-disease-drug-meets-112548621.html?.tsrc=rss,"Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease. The drug, patisiran, was being evaluated for ..."
ALNY,ALNY:UW,BBG000BFGYR2,Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy,2017-09-20 11:00:05 +0000,https://finance.yahoo.com/news/sanofi-alnylam-report-positive-topline-110005856.html?.tsrc=rss,Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy - Investigational RNAi Therapeutic Patisiran ...
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy,2017-09-20 11:00:00 +0000,https://finance.yahoo.com/news/alnylam-sanofi-report-positive-topline-110000100.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints."
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Nearly Flat As Fed Announcement Looms - U.S. Commentary,2017-09-20 10:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_eN52b2G8Qg/stocks-nearly-flat-as-fed-announcement-looms--us-commentary-20170920-00773,Stocks Nearly Flat As Fed Announcement Looms - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Inc. (ALNY) Has Jumped To A New High On Study Results,2017-09-20 09:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9eITz5ulkWY/alnylam-pharmaceuticals-inc-alny-has-jumped-to-a-new-high-on-study-results-20170920-00671,Alnylam Pharmaceuticals Inc. (ALNY) Has Jumped To A New High On Study Results
ALNY,ALNY:UW,BBG000BFGYR2,Stocks May Lack Of Direction Ahead Of Fed Announcement - U.S. Commentary,2017-09-20 08:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wOPV478iqa4/stocks-may-lack-of-direction-ahead-of-fed-announcement--us-commentary-20170920-00534,Stocks May Lack Of Direction Ahead Of Fed Announcement - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Investor Conference Call At 8:30 AM ET,2017-09-20 07:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vapnR-TzY3A/alnylam-pharmaceuticals-investor-conference-call-at-830-am-et-20170920-00338,Alnylam Pharmaceuticals Investor Conference Call At 8:30 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma: Patisiran Phase 3 Study Meets Endpoints - Quick Facts,2017-09-20 07:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_RDAkkeyIaY/alnylam-pharma-patisiran-phase-3-study-meets-endpoints--quick-facts-20170920-00302,Alnylam Pharma: Patisiran Phase 3 Study Meets Endpoints - Quick Facts
ALNY,ALNY:UW,BBG000BFGYR2,Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?,2017-09-18 14:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_bwsKgVau78/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-cm847017,Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets As such the quarterly 13F filings of his namesake fund Soros Fund Management are must read material for any serious investor The latest
ALNY,ALNY:UW,BBG000BFGYR2,Billionaire George Soros&apos; Fund Bought These 3 Pharma Stocks: Should You?,2017-09-18 13:00:00 +0000,http://finance.yahoo.com/r/bf6570c6-54bf-3f7b-aae6-6af1c170e2b0/billionaire-george-soros-fund-bought-these-3-stock.aspx?yptr=yahoo&.tsrc=rss,These three orphan drugmakers were on Soros&apos; radar last quarter.
ALNY,ALNY:UW,BBG000BFGYR2,"Notable Friday Option Activity: ALNY, CVA, TWTR",2017-09-15 20:38:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JKkn_Byp0OI/notable-friday-option-activity-alny-cva-twtr-cm846526,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Alnylam Pharmaceuticals Inc Symbol ALNY where a total volume of 5 879 contracts has been traded thus far today a contract volume which is representative of
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-09-15 12:07:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120709440.html?.tsrc=rss,Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-09-14 12:07:24 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120724059.html?.tsrc=rss,Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Gets More Forgiving, But Riskier",2017-09-13 14:16:59 +0000,http://finance.yahoo.com/r/807e0575-c811-3032-a8b1-57ee5643e19d/biotech-stocks-now-more-forgiving-but-riskier?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Last year biotech could do no right. Now it can do no wrong.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At Morgan Stanley Conference; Webcast At 9:55 AM ET,2017-09-13 08:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Cwqs2-8nhI/alnylam-pharma-to-present-at-morgan-stanley-conference-webcast-at-955-am-et-20170913-00551,Alnylam Pharma To Present At Morgan Stanley Conference; Webcast At 9:55 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-09-12 12:08:53 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120853309.html?.tsrc=rss,Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
ALNY,ALNY:UW,BBG000BFGYR2,"INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc.",2017-09-09 03:34:00 +0000,https://finance.yahoo.com/news/investor-alert-goldberg-law-pc-033400068.html?.tsrc=rss,"Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ."
ALNY,ALNY:UW,BBG000BFGYR2,"ETFs with exposure to Alnylam Pharmaceuticals, Inc. : September 9, 2017",2017-09-09 03:20:04 +0000,http://finance.yahoo.com/r/cf333b5a-61eb-3d52-9dc3-da98df8497e3/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-september-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alnylam Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALNY-US. Comparing the performance and risk of Alnylam Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Shares Plunge on Patient Death, Dosing Suspended",2017-09-08 15:55:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dMaS-fS3ENA/alnylam-shares-plunge-on-patient-death-dosing-suspended-cm842932,Alnylam Pharmaceuticals Inc s ALNY shares plunged 15 7 on Thursday in response to a death event reported by the company in an open label extension phase II study on fitusiran Alnylam has stopped dosing in all ongoing studies on its hemophilia candidate fitusiran following the fatal
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)",2017-09-08 14:38:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-143800625.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 8, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. (""Alnylam"" or the ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Shares Plunge on Patient Death, Dosing Suspended",2017-09-08 13:53:01 +0000,https://finance.yahoo.com/news/alnylam-shares-plunge-patient-death-135301488.html?.tsrc=rss,"Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient&apos;s death in a phase II study."
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc.",2017-09-08 00:36:00 +0000,https://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-003600554.html?.tsrc=rss,"Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ."
ALNY,ALNY:UW,BBG000BFGYR2,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted",2017-09-07 22:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UtajTIgaUI/nlnk-rallies-on-indoximod-data-vrna-breathes-easy-alny-jolted-20170907-01658,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted"
ALNY,ALNY:UW,BBG000BFGYR2,What Happened in the Stock Market Today,2017-09-07 22:51:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47UxXo__RSo/what-happened-in-the-stock-market-today-cm842642,Stocks fluctuated between positive and negative territory on Thursday with the Dow Jones Industrial Average DJINDICES DJI 160 and the S amp P 500 SNPINDEX GSPC 160 eventually closing narrowly in the red Today s stock market
ALNY,ALNY:UW,BBG000BFGYR2,What Happened in the Stock Market Today,2017-09-07 21:08:00 +0000,http://finance.yahoo.com/r/6d35c00a-bd5b-3eac-ac12-f2a3d4edfedc/what-happened-in-the-stock-market-today.aspx?yptr=yahoo&.tsrc=rss,"On a mixed day for the market, RH soared thanks to a surprisingly good quarter, while Alnylam Pharmaceuticals fell after it halted trials of a new drug."
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 09/07/2017: SGRY,NLNK,ALNY",2017-09-07 20:29:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E-HzhD2ol4k/health-care-sector-update-for-09072017-sgrynlnkalny-cm842572,Top Health Care StocksTop Health Care Stocks JNJ 1 17 JNJ 1 17 PFE 0 06 PFE 0 06 ABT 0 49 ABT 0 49 MRK 0 42 MRK 0 42 AMGN 1 28 AMGN 1 28 Health care stocks were outpaced all other industry sectors today with the NYSE Health Care Index were rising about 1 1 while shares of
ALNY,ALNY:UW,BBG000BFGYR2,Breaking Down Barclays' New Bullish Calls On Biotech,2017-09-07 19:32:52 +0000,https://finance.yahoo.com/news/breaking-down-barclays-bullish-calls-193252995.html?.tsrc=rss,"Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a Positive view, as it expects the outperformance of the sector relative to the S&P 500 to continue in the next 12-18 ..."
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alnylam Pharmaceuticals, Inc.",2017-09-07 19:25:00 +0000,https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-192500824.html?.tsrc=rss,"Levi & Korsinsky announces it has commenced an investigation of Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)",2017-09-07 19:23:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-192300828.html?.tsrc=rss,"NEW YORK , Sept. 7, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. (""Alnylam"" ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 09/07/2017: EKSO, NLNK, ALNY",2017-09-07 18:29:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6yW6K0vZEIM/health-care-sector-update-for-09072017-ekso-nlnk-alny-cm842508,Top Health Care StocksTop Health Care Stocks JNJ 1 39 JNJ 1 39 PFE 0 25 PFE 0 25 ABT 0 66 ABT 0 66 MRK 0 50 MRK 0 50 AMGN 2 18 AMGN 2 18 Health care stocks were easily outpacing gains among other industry sectors today with the NYSE Health Care Index were rising nearly 1 3
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY",2017-09-07 18:03:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-180300068.html?.tsrc=rss,"NEW YORK , Sept. 7, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (""Alnylam"" or the ""Company"") (NASDAQ:  ALNY). Such ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today",2017-09-07 17:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vYBQs7QhsGM/heres-why-alnylam-pharmaceuticals-inc-is-slipping-today-cm842446,What happened Shares of Alnylam Pharmaceuticals Inc NASDAQ ALNY 160 a clinical stage biotech developing RNA based therapies to treat rare diseases announced an immediate halt to all studies with one of the more advanced drugs in its clinical stage development pipeline
ALNY,ALNY:UW,BBG000BFGYR2,"Here&apos;s Why Alnylam Pharmaceuticals, Inc. Is Slipping Today",2017-09-07 16:30:00 +0000,http://finance.yahoo.com/r/e6475213-13c5-3bbb-a8cc-f5ab456e9a95/heres-why-alnylam-pharmaceuticals-inc-is-slipping.aspx?yptr=yahoo&.tsrc=rss,A patient death forced the company to slam the brakes on trials with an otherwise promising hemophilia candidate.
ALNY,ALNY:UW,BBG000BFGYR2,"​Alnylam halts hemophilia drug trial due to patient death, renewing worries over safety",2017-09-07 14:45:10 +0000,http://finance.yahoo.com/r/52660d9b-4ef2-3b10-8f04-61c6507b11e9/alnylam-halts-hemophilia-drug-trial-due-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Alnylam Pharmaceuticals, one of the state’s largest and most valuable biotechs, has temporarily halted a mid-stage trial of one of its experimental drugs for hemophilia after one patient died, shaving $1 billion from its market cap.  Cambridge-based Alnylam (ALNY) said Thursday that it had suspended the Phase 2 trial of fitusiran after a patient died of brain swelling triggered by a blood clot.  Shares of Alnylam fell 13 percent as of 10:30 a.m., cutting the company’s market cap from $7.9 billion to $6.9 billion."
ALNY,ALNY:UW,BBG000BFGYR2,Morning Movers: Barnes & Noble Sinks on Earnings; Hertz Jumps,2017-09-07 13:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t55QuGz89O4/morning-movers-barnes-noble-sinks-on-earnings-hertz-jumps-cm842092,Stocks look set to open little changed this morning even as jobless claims spiked due to the impact of Hurricane Harvey Stocks look set to open little changed this morning even asjobless claims spiked due to the impact of Hurricane Harvey Getty Images Getty Images S amp P
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Posting Steep Loss After Suspending Fitusiran Dosing,2017-09-07 13:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/toXb_o4z-UA/alnylam-pharmaceuticals-posting-steep-loss-after-suspending-fitusiran-dosing-20170907-01246,Alnylam Pharmaceuticals Posting Steep Loss After Suspending Fitusiran Dosing
ALNY,ALNY:UW,BBG000BFGYR2,Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers,2017-09-07 13:29:00 +0000,http://finance.yahoo.com/r/8f2b7ce8-abdd-3ea5-88b8-088fdf9ad9d6/intra-cellular-leaps-schizophrenia-drug-shows-less-side-effects-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia."
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Most Active for Sep 7, 2017 :  CAB, BLDR, GPRO, TVIX, IRT, GE, INSM, AZN, WLL, BAC, ALNY, QQQ",2017-09-07 12:59:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QKePUYa1frw/pre-market-most-active-for-sep-7-2017-cab-bldr-gpro-tvix-irt-ge-insm-azn-wll-bac-alny-qqq-cm842093,The NASDAQ 100 Pre Market Indicator is up 3 58 to 5 954 71 The total Pre Market volume is currently 4 600 813 shares traded The following are the most active stocks for the pre market session Cabela s Inc CAB is 7 79 at 61 23 with 527 359 shares traded CAB s
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017",2017-09-07 12:56:40 +0000,http://finance.yahoo.com/r/c5c39dd7-6851-3ed3-90e1-ed88da9212b1/alnylam-pharmaceuticals-inc-alny-us-earnings-analysis-q2-2017-by-the-numbers-september-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Alnylam Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Alnylam Pharmaceuticals, Inc. – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., PAREXEL International Corporation, Medicines Company, Regulus Therapeutics Inc., Sanofi Sponsored ADR, Novartis ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam suspends dosing in bleeding disorder study after patient death,2017-09-07 12:11:49 +0000,https://finance.yahoo.com/news/alnylam-suspends-dosing-bleeding-disorder-121149798.html?.tsrc=rss,"Alnylam Pharmaceuticals Inc said  on Thursday it stopped giving doses of its experimental drug for  a rare bleeding disorder to patients enrolled in its clinical  studies after one patient died.  Shares of the U.S. drug developer fell 14 percent to $74.00  in premarket trading.  A patient suffering from hemophilia A enrolled in a  mid-stage study of Alnylam's experimental treatment, fitusiran,  died after developing a blood clot, the company said."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam suspends bleeding disorder trial dosing after patient death,2017-09-07 11:43:35 +0000,https://finance.yahoo.com/news/alnylam-suspends-bleeding-disorder-trial-114335041.html?.tsrc=rss,U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's ...
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals' stock plunges after 'fatal' event in hemophilia drug program,2017-09-07 11:33:08 +0000,http://finance.yahoo.com/r/fc887204-6c14-3765-adfe-d493a053edba/Story.aspx?guid=C0683F82-9C24-4B66-A029-BECA7BD9759F&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Alnylam Pharmaceuticals Inc. plunged 13% in premarket trade Thursday, after the RNAi therapeutics company said it has suspended fitusiran dosing after a ""fatal thrombotic event."" The ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs,2017-09-07 11:00:00 +0000,https://finance.yahoo.com/news/alnylam-provides-pipeline-fitusiran-givosiran-110000270.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today an update on the company's fitusiran and givosiran investigational RNAi therapeutic programs."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Suspends Fitusiran Dosing - Quick Facts,2017-09-07 07:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/knVGvBUlVuo/alnylam-pharma-suspends-fitusiran-dosing--quick-facts-20170907-00418,Alnylam Pharma Suspends Fitusiran Dosing - Quick Facts
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Investor Conference Call At 8:00 AM ET,2017-09-07 07:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ormz73JSbik/alnylam-pharmaceuticals-investor-conference-call-at-800-am-et-20170907-00413,Alnylam Pharmaceuticals Investor Conference Call At 8:00 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Noteworthy Wednesday Option Activity: PII, ALNY, GPI",2017-09-06 20:50:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ya0PBCxHks/noteworthy-wednesday-option-activity-pii-alny-gpi-cm841905,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Polaris Industries Inc Symbol PII where a total volume of 2 965 contracts has been traded thus far today a contract volume which is representative of approximately 296
ALNY,ALNY:UW,BBG000BFGYR2,Why September Will Be A &apos;Make Or Break&apos; Month For These Biotechs,2017-09-06 17:35:39 +0000,http://finance.yahoo.com/r/d6499b8b-8e1f-34a1-b979-ad8b9a581567/why-september-will-be-a-make-or-break-month-for-these-biotechs?src=A00220&yptr=yahoo&.tsrc=rss,September will be a critical month for a number of biotechs expected to present Phase 3 data in coming weeks.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference,2017-09-05 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-webcast-presentation-15th-annual-200000082.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, today announced that management will present a company overview at the 15th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2017 at 9:55 am ET at the Grand Hyatt in New York City."
ALNY,ALNY:UW,BBG000BFGYR2,4 Biotech Stocks That More Than Doubled This Year,2017-09-05 18:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MKeRpA6t2eo/4-biotech-stocks-that-more-than-doubled-this-year-cm841184,InvestorPlace Stock Market News Stock Advice amp Trading Tips The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in
ALNY,ALNY:UW,BBG000BFGYR2,ALNY Crosses Above Average Analyst Target,2017-09-05 02:49:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/etlp1V2Dc4o/alny-crosses-above-average-analyst-target-cm840811,In recent trading shares of Alnylam Pharmaceuticals Inc Symbol ALNY have crossed above the average analyst 12 month target price of 86 69 changing hands for 88 91 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on
ALNY,ALNY:UW,BBG000BFGYR2,4 Biotech Stocks That More Than Doubled This Year,2017-09-01 17:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TjlzxDn0C5c/4-biotech-stocks-that-more-than-doubled-this-year-cm840378,The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in the quarter Total earnings increased 11 2 in the second quarter on the back of 5 6
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Co's Inclisiran Positive in Extension Study,2017-08-29 23:49:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b1S9tPbWAWI/the-medicines-cos-inclisiran-positive-in-extension-study-cm838889,The Medicines Company MDCO along with partner Alnylam Pharmaceuticals Inc ALNY announced new one year safety and efficacy data from the ongoing ORION 1 phase II study evaluating pipeline candidate Inclisiran PCSK9 Inhibitor for the treatment of hypercholesterolemia This new
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Co&apos;s Inclisiran Positive in Extension Study,2017-08-29 21:41:09 +0000,https://finance.yahoo.com/news/medicines-co-apos-inclisiran-positive-214109955.html?.tsrc=rss,The Medicines Company (MDCO) and partner Alnylam publish new one-year safety and efficacy data from phase II extension study of Inclisiran for hypercholesterolemia.
ALNY,ALNY:UW,BBG000BFGYR2,Sangamo Therapeutics Initiates Dosing in Hemophilia A Study,2017-08-28 13:54:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W_dxMDSplT0/sangamo-therapeutics-initiates-dosing-in-hemophilia-a-study-cm837928,Sangamo Therapeutics Inc SGMO and partner Pfizer Inc PFE announced the dosing of first patient in a phase I II study on its gene therapy candidate SB 525 for treating hemophilia A In fact SB 525 is considered to be one of Sangamo s four leading product candidates In May 2017
ALNY,ALNY:UW,BBG000BFGYR2,Sangamo Therapeutics Initiates Dosing in Hemophilia A Study,2017-08-28 12:09:12 +0000,https://finance.yahoo.com/news/sangamo-therapeutics-initiates-dosing-hemophilia-120912622.html?.tsrc=rss,"Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525."
ALNY,ALNY:UW,BBG000BFGYR2,"New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials",2017-08-28 11:00:00 +0000,https://finance.yahoo.com/news/one-data-orion-1-phase-110000444.html?.tsrc=rss,"The Medicines Company and Alnylam Pharmaceuticals, Inc. today announced new, positive data from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment of hypercholesterolemia."
ALNY,ALNY:UW,BBG000BFGYR2,Medicines Co. Announces New Data From ORION-1 Phase II Study Of Inclisiran,2017-08-28 07:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xW9r00EG_BQ/medicines-co-announces-new-data-from-orion1-phase-ii-study-of-inclisiran-20170828-00244,Medicines Co. Announces New Data From ORION-1 Phase II Study Of Inclisiran
ALNY,ALNY:UW,BBG000BFGYR2,3 Biotech Stocks That Could Soar in September,2017-08-27 12:49:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jii3x9r6Fc4/3-biotech-stocks-that-could-soar-in-september-cm837607,Winter seems to always be coming in Game of Thrones but here in the real world autumn is on the way While the leaves will start falling in September some biotech stocks could be set to soar Quite a few biotechs have important catalysts coming up in the next month Three
ALNY,ALNY:UW,BBG000BFGYR2,3 Biotech Stocks That Could Soar in September,2017-08-27 11:27:00 +0000,http://finance.yahoo.com/r/7c57af97-5681-3d49-954b-a35676515cd6/3-biotech-stocks-that-could-soar-in-september.aspx?yptr=yahoo&.tsrc=rss,"Alnylam, PTC Therapeutics, and Zogenix have major catalysts on the way."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : August 23, 2017",2017-08-23 21:15:39 +0000,http://finance.yahoo.com/r/54a253c0-91da-33ad-85d2-1a7c47e13a66/alnylam-pharmaceuticals-inc-value-analysis-nasdaqalny-august-23-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alnylam Pharmaceuticals, Inc. a score of 21. Our analysis is based on comparing Alnylam Pharmaceuticals, Inc. with the following peers – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Medicines Company, Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., PAREXEL International Corporation, OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Monday's ETF with Unusual Volume: BBH,2017-08-21 18:38:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R-oiXcoVdjI/mondays-etf-with-unusual-volume-bbh-cm834883,The Biotech ETF BBH is seeing unusually high volume in afternoon trading Monday with over 115 000 shares traded versus three month average volume of about 32 000 Shares of BBH were up about 0 4 on the day Components of that ETF with the highest volume on Monday were Gilead
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-18 12:07:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120633131.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,Featured Company News - Portola Pharmaceuticals' AndexXa(R) Biologics License Application Resubmission Accepted for Review by US FDA,2017-08-17 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-portola-pharmaceuticals-114000882.html?.tsrc=rss,"Research Desk Line-up: Alnylam Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Portola ..."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-16 12:05:45 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120705386.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-15 12:07:15 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120715224.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,Merck CEO resigns from Trump council over Charlottesville,2017-08-14 23:48:30 +0000,https://finance.yahoo.com/news/merck-ceo-resigns-trump-council-133725768.html?.tsrc=rss,"Merck & Co Inc Chief Executive  Kenneth Frazier resigned from U.S. President Donald Trump's  American Manufacturing Council on Monday, saying he was taking a  stand against intolerance and extremism.  Trump denounced neo-Nazis and the Ku Klux Klan as criminals  and thugs on Monday, bowing to mounting political pressure after  initially saying many sides were to blame after a  white-nationalist rally turned deadly in Virginia.  Frazier, who is African-American, is the only CEO so far to  leave one of Trump's advisory councils because of his reaction  to the violence in Virginia, although the AFL-CIO said it was  considering pulling its representative on the committee."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo",2017-08-14 19:34:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SLaxo_QUn8I/alnylam-pharmaceuticals-inc-earnings-waiting-for-apollo-cm831838,Alnylam Pharmaceuticals NASDAQ ALNY reported 160 second quarter earnings last week and for the record the company lost 118 4 million but without any products on the market the focus of the earnings call was the biotech s pipeline and the potential for revenue in
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo",2017-08-14 18:22:00 +0000,http://finance.yahoo.com/r/89fa07d3-a9c9-317b-89d9-da0c9c478845/alnylam-pharmaceuticals-inc-earnings-waiting-for-a.aspx?yptr=yahoo&.tsrc=rss,Next month&apos;s phase 3 data are much more important than the biotech&apos;s second-quarter earnings release.
ALNY,ALNY:UW,BBG000BFGYR2,"Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up",2017-08-14 14:41:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XfhtaWqRs38/ionis-pharmaceuticals-retains-rights-to-inotersen-stock-up-cm831620,Ionis Pharmaceuticals Inc IONS shares were up almost 2 6 on Friday after it announced that GlaxoSmithKline plc GSK has declined its option to develop Inotersen and IONIS FB L Rx Ionis now retains all rights to the candidates and will develop them independently So far this year
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-14 12:06:00 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120600922.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-12 12:07:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120751181.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,"Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs",2017-08-11 21:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0PNx02wL43U/ionis-pharmaceuticals-inc-growing-royalties-an-advancing-pipeline-and-getting-back-rights-to-some-drugs-cm831170,Ionis Pharmaceuticals NASDAQ IONS reported second quarter earnings earlier this week and then followed up on Friday with a disclosure that it s getting full rights back to two of its drugs inotersen and IONIS FB LRx after GlaxoSmithKline NYSE GSK decided not to license
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : August 11, 2017",2017-08-11 14:14:47 +0000,http://finance.yahoo.com/r/b03bbb59-ab16-337e-b896-147adcb38c4d/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-alny-us-august-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-11 12:06:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120652022.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,"The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss",2017-08-10 22:37:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/of36tncPCgA/the-medicines-company-mdco-q2-loss-widens-revenues-miss-cm830606,The Medicines Company 160 MDCO reported second quarter 2017 loss of 5 52 per share massively wider than the Zacks Consensus Estimate of a loss of 1 29 However adjusted loss per share was 1 02 excluding the impact of share based compensation expenses versus a loss of 69 cents in
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss",2017-08-10 22:36:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VDi00Dw7axU/alnylam-alny-q2-loss-narrower-than-expected-sales-miss-cm830594,Alnylam Pharmaceuticals Inc ALNY reported a loss of 1 34 per share in the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 1 45 but wider than the year ago loss of 1 05 Alnylam Pharmaceuticals Inc Price and EPS
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss",2017-08-10 20:31:08 +0000,https://finance.yahoo.com/news/alnylam-alny-q2-loss-narrower-203108127.html?.tsrc=rss,Alnylam&apos;s (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-10 12:07:04 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120704563.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,"After 10 months, Alnylam still can't explain patient trial deaths",2017-08-10 02:15:10 +0000,http://finance.yahoo.com/r/2892b4f0-1483-3bea-80ff-e30c07077cf1/after-10-months-alnylam-still-cant-explain-patient.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"More than 10 months after disclosing that patients who received one of its experimental drugs in a late-stage trial had died at a far higher rate than those on placebo, Cambridge-based Alnylam Pharmaceuticals still cannot conclusively explain what went wrong.  Alnylam (ALNY) on Wednesday released the results of its investigation into the deaths of older patients with heart problems who took revusiran, a potential treatment for a deadly inherited disease called hATTR cardiomyopathy.  In October, the company halted the trial after disclosing that 16 patients who received the drug had died due to heart failure and other cardiovascular issues, compared to two patients in the placebo arm who died."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 2Q loss,2017-08-10 01:22:13 +0000,https://finance.yahoo.com/news/alnylam-reports-2q-loss-202135830.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of $1.34 per share. Losses, adjusted for stock option expense, were $1.07 per share. The results exceeded Wall Street expectations. The average ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity,2017-08-09 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-second-quarter-200000237.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2017, and highlighted recent progress in advancing its pipeline."
ALNY,ALNY:UW,BBG000BFGYR2,"After-Hours Earnings Report for August 9, 2017 :  NTES, MFC, FOXA, SLF, AGU, LYV, UHAL, ALNY, MIDD, GXP, RGLD, CSRA",2017-08-09 19:19:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Utx-btVOc1Q/after-hours-earnings-report-for-august-9-2017-ntes-mfc-foxa-slf-agu-lyv-uhal-alny-midd-gxp-rgld-csra-cm829704,The following companies are expected to report earnings after hours on 08 09 2017 Visit our Earnings Calendar for a full list of expected earnings releases NetEase Inc NTES is reporting for the quarter ending June 30 2017 The internet software company
ALNY,ALNY:UW,BBG000BFGYR2,"Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call",2017-08-09 16:20:00 +0000,https://finance.yahoo.com/news/investor-network-alnylam-pharmaceuticals-inc-162000642.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 at ..."
ALNY,ALNY:UW,BBG000BFGYR2,See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.,2017-08-09 12:07:03 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120703239.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
ALNY,ALNY:UW,BBG000BFGYR2,"Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered",2017-08-08 20:37:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mi0Y7kDW1AM/endo-endp-beats-q2-earnings-sales-2017-guidance-lowered-cm829018,Endo International plc s ENDP second quarter 2017 earnings from continuing operations were 93 cents per share which topped the Zacks Consensus Estimate of 74 cents In fact the bottom line was also above the year ago figure of 86 cents by 8 Revenues came in at 875 7 million in the
ALNY,ALNY:UW,BBG000BFGYR2,"Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View",2017-08-08 20:36:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8CTg0B5JT3A/zoetis-zts-beats-on-q2-earnings-sales-ups-2017-view-cm829005,Zoetis Inc ZTS second quarter 2017 earnings of 53 cents per share increased 8 2 year over year and beat the Zacks Consensus Estimate of 52 cents Earnings were up 11 excluding the impact of currency Total revenue rose 5 year over year up 6 operationally excluding the impact of
ALNY,ALNY:UW,BBG000BFGYR2,3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings,2017-08-08 18:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiLnAav5guw/3-drug-stocks-poised-to-surpass-estimates-in-q2-earnings-cm828935,The pharma biotech sector has picked up pace this year after being battered by the drug pricing controversy in 2016 The first half has been pretty strong for companies in the space The sector does have its share of challenges in the form of rising competition high profile pipeline
ALNY,ALNY:UW,BBG000BFGYR2,"Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View",2017-08-08 18:19:06 +0000,https://finance.yahoo.com/news/zoetis-zts-beats-q2-earnings-181906660.html?.tsrc=rss,Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
ALNY,ALNY:UW,BBG000BFGYR2,"Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered",2017-08-08 18:02:06 +0000,https://finance.yahoo.com/news/endo-endp-beats-q2-earnings-180206825.html?.tsrc=rss,"Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio."
ALNY,ALNY:UW,BBG000BFGYR2,3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings,2017-08-08 16:42:04 +0000,https://finance.yahoo.com/news/3-drug-stocks-poised-surpass-164204298.html?.tsrc=rss,The first half has been pretty strong for companies in the space.
ALNY,ALNY:UW,BBG000BFGYR2,Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected,2017-08-08 16:38:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7TZWZuuc2Uk/arena-pharmaceuticals-arna-q2-loss-wider-than-expected-cm828849,Arena Pharmaceuticals Inc ARNA reported a loss of 77 cents per share in the second quarter of 2017 narrower than the year ago loss of 1 12 per share However the loss was wider than the Zacks Consensus Estimate loss of 68 cents In Jun 2017 the company completed a reverse stock split
ALNY,ALNY:UW,BBG000BFGYR2,Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season,2017-08-08 14:40:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0IcN-ijZasc/why-alnylam-pharmaceuticals-alny-might-surprise-this-earnings-season-cm828653,Investors are always looking for stocks that are poised to beat at earnings season and Alnylam Pharmaceuticals Inc ALNY may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Alnylam Pharmaceuticals
ALNY,ALNY:UW,BBG000BFGYR2,Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected,2017-08-08 14:30:02 +0000,https://finance.yahoo.com/news/arena-pharmaceuticals-arna-q2-loss-143002210.html?.tsrc=rss,"Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results."
ALNY,ALNY:UW,BBG000BFGYR2,Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season,2017-08-08 12:57:12 +0000,https://finance.yahoo.com/news/why-alnylam-pharmaceuticals-alny-might-125712559.html?.tsrc=rss,Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results,2017-08-01 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-webcast-conference-call-discussing-200000187.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2017 on Wednesday, August 9, 2017, after the U.S."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series,2017-07-27 12:00:00 +0000,https://finance.yahoo.com/news/alnylam-host-fourth-annual-rnai-120000192.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it plans to host its 4th annual series of “RNAi Roundtable” webcasts this summer and early fall."
ALNY,ALNY:UW,BBG000BFGYR2,ALNY Crosses Above Average Analyst Target,2017-07-21 14:05:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/28KfDhmtlNE/alny-crosses-above-average-analyst-target-cm819226,In recent trading shares of Alnylam Pharmaceuticals Inc Symbol ALNY have crossed above the average analyst 12 month target price of 78 54 changing hands for 80 51 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth,2017-07-13 12:45:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PQ3oFvEicfY/alnylam-alny-upgraded-to-buy-on-solid-pipeline-growth-cm815393,On Jul 11 Alnylam Pharmaceuticals Inc ALNY was upgraded to a Zacks Rank 2 Buy Why the Upgrade Alnylam s key pipeline candidate Fitusiran aRNA interference RNAi therapeutic being developed for the treatment of hemophilia A and B and rare bleeding disorders RBD has
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth,2017-07-12 22:18:10 +0000,https://finance.yahoo.com/news/alnylam-alny-upgraded-buy-solid-221810001.html?.tsrc=rss,"On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy)."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data,2017-07-11 22:45:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LsSBPP3mt5s/alnylam-alny-stock-down-despite-positive-hemophilia-data-cm814765,Alnylam Pharmaceuticals Inc ALNY and Sanofi s SNY specialty care global business unit Genzyme announced encouraging results from the ongoing phase II open label extension OLE study The evaluation was on fitusiran for the treatment of patients with hemophilia A and B with or
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data,2017-07-11 20:19:08 +0000,https://finance.yahoo.com/news/alnylam-alny-stock-down-despite-201908855.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi&apos;s (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study."
ALNY,ALNY:UW,BBG000BFGYR2,Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma,2017-07-11 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000383.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 11, 2017 / Hemispherx Biopharma, Inc.'s shares saw a modest pop in share price yesterday after the company released an announcement about its Ampligen candidate that is ..."
ALNY,ALNY:UW,BBG000BFGYR2,Are Medicines Company's Key Drugs Set for Growth in 2017?,2017-07-10 22:45:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DPnlWTr89fg/are-medicines-companys-key-drugs-set-for-growth-in-2017-cm814118,On Jul 7 2017 we issued an updated report on The Medicines Company MDCO The Medicines Co is a global biopharmaceutical company focused on advancing the treatment of critical care patients through delivery of innovative cost effective medicines to the worldwide hospital
ALNY,ALNY:UW,BBG000BFGYR2,Could Alnylam Have An Edge On This Smaller Biotech In Rare Disease?,2017-07-10 21:13:02 +0000,http://finance.yahoo.com/r/2a7cf857-6dad-3556-89c9-32d52f9e21d8/could-alnylam-have-an-edge-on-this-smaller-biotech-in-rare-disease?src=A00220&yptr=yahoo&.tsrc=rss,"Alnylam could have an edge on Ionis in treating a rare disease that results in organ and system damage, an analyst said Monday."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Commences Phase III Study for Hemophilia Candidate,2017-07-10 16:48:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O7pyN2eJUxM/alnylam-commences-phase-iii-study-for-hemophilia-candidate-cm813870,Alnylam Pharmaceuticals Inc ALNY and Sanofi s SNY announced that it has commenced phase III ATLAS study for its candidate fitusiran Fitusiran is an investigational RNA interference RNAi therapeutic being developed for the treatment of hemophilia and rare bleeding disorders RBD Shares
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Commences Phase III Study for Hemophilia Candidate,2017-07-10 14:13:02 +0000,https://finance.yahoo.com/news/alnylam-commences-phase-iii-study-141302565.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi&apos;s (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran."
ALNY,ALNY:UW,BBG000BFGYR2,InPlay from Briefing.com,2017-07-10 13:57:24 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
ALNY,ALNY:UW,BBG000BFGYR2,Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...,2017-07-10 13:32:01 +0000,https://finance.yahoo.com/news/sanofi-genzyme-alnylam-report-positive-133201965.html?.tsrc=rss,Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors ...
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors,2017-07-10 13:30:00 +0000,https://finance.yahoo.com/news/alnylam-sanofi-genzyme-report-positive-133000818.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing Phase 2 open-label extension study with fitusiran in patients with hemophilia A and B, with or without inhibitors ."
ALNY,ALNY:UW,BBG000BFGYR2,Sanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study,2017-07-10 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F-Fu_CVgXSQ/sanofi-genzyme-reports-results-from-phase-2-openlabel-extension-study-20170710-00746,Sanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study
ALNY,ALNY:UW,BBG000BFGYR2,"ITEK Disappoints, ALNY Maps Out ATLAS, ENTL Opens Wallet, D-day Nearing For OCUL",2017-07-09 23:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x14YhSc1tTU/itek-disappoints-alny-maps-out-atlas-entl-opens-wallet-dday-nearing-for-ocul-20170709-00082,"ITEK Disappoints, ALNY Maps Out ATLAS, ENTL Opens Wallet, D-day Nearing For OCUL"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why",2017-07-07 14:49:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xL6PMpCg0pI/alnylam-pharmaceuticals-inc-stock-perked-up-14-in-june-heres-why-cm812938,What happened Shares of Alnylam Pharmaceuticals Inc NASDAQ ALNY a clinical stage biotech gained 14 4 in June according to data from S amp P Global Market Intelligence Investors were encouraged by a breakthrough therapy designation announced at the end of
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here&apos;s Why",2017-07-07 13:11:00 +0000,http://finance.yahoo.com/r/dac4b428-a820-39a2-bf18-76a40afdca4e/alnylam-pharmaceuticals-inc-stock-perked-up-14-in.aspx?yptr=yahoo&.tsrc=rss,A new breakthrough designation and insider purchases helped Alnylam stock continue its terrific climb this year.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors,2017-07-07 11:30:00 +0000,https://finance.yahoo.com/news/alnylam-sanofi-genzyme-initiate-atlas-113000383.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the initiation of the ATLAS Phase 3 clinical program for fitusiran."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam, Sanofi Initiate ATLAS Phase 3 Program With RNAi Therapeutic Fitusiran",2017-07-07 07:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yxX7YPrV598/alnylam-sanofi-initiate-atlas-phase-3-program-with-rnai-therapeutic-fitusiran-20170707-00243,"Alnylam, Sanofi Initiate ATLAS Phase 3 Program With RNAi Therapeutic Fitusiran"
ALNY,ALNY:UW,BBG000BFGYR2,Biotechs Gained $1.7 Billion Last Week — Can They Keep Going?,2017-07-05 20:27:23 +0000,http://finance.yahoo.com/r/fecbe26f-18b8-3430-9054-2d980e960fd4/biotechs-gained-1-7-billion-last-week-can-they-keep-going?src=A00220&yptr=yahoo&.tsrc=rss,"Spark, Flexion and Alnylam were among those leading a biotech pop Wednesday as generalists become more comfortable with Donald Trump&apos;s potential effect on the sector."
ALNY,ALNY:UW,BBG000BFGYR2,3 Pivotal Drug Trials to Watch for Explosive Potential,2017-06-30 07:03:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uuxEsWGSVlY/3-pivotal-drug-trials-to-watch-for-explosive-potential-cm810308,InvestorPlace Stock Market News Stock Advice amp Trading Tips We re midway through the year and the U S Food and Drug Administration FDA has already approved just shy of 50 new drugs The second half of the year however promises to be just as interesting as the first
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod",2017-06-29 14:07:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jAAJmwPsq4w/biotech-stock-roundup-eu-nod-for-regeneron-ra-drug-portola-soars-on-fda-nod-cm809914,Biotech stocks have been in the news recently with expectations remaining high that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected Meanwhile companies like Portola PTLA and Regeneron REGN provided regulatory updates
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod",2017-06-29 12:40:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-eu-nod-124012930.html?.tsrc=rss,Key highlights in the biotech sector include FDA approval for Portola&apos;s (PTLA) anticoagulant and EU approval for Regeneron&apos;s rheumatoid arthritis (RA) drug.
ALNY,ALNY:UW,BBG000BFGYR2,5 Biotech Stocks With Major Catalysts in July,2017-06-28 22:04:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/97OY494xU7s/5-biotech-stocks-with-major-catalysts-in-july-cm809650,July brings fireworks and fun for many Americans The month will also bring major catalysts for several biotechs Those catalysts could provide a spark for the stocks and fun for investors or not Five drugmakers in particular await big news in the coming weeks
ALNY,ALNY:UW,BBG000BFGYR2,5 Biotech Stocks With Major Catalysts in July,2017-06-28 20:22:00 +0000,http://finance.yahoo.com/r/66aab481-87c1-3787-a38f-26ad86dee364/5-biotech-stocks-with-major-catalysts-in-july.aspx?yptr=yahoo&.tsrc=rss,"Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck."
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Alnylam Selloff Looks Like an Overreaction,2017-06-28 10:48:00 +0000,http://finance.yahoo.com/r/02cfd49c-dd1a-3ce4-b592-c39626473513/alnylam-selloff-looks-like-an-overreaction-1498646884?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Alnylam Pharmaceuticals (ALNY:Nasdaq)  By Credit Suisse ($85.21, June 26, 2017) We are raising our target price on Alnylam Pharmaceuticals to $96 from $90 as we increased our probability of success from 40% to 60% in porphyria.  At 100% success this adds $12 a share to our model (due to high operating leverage and modeling of fixed costs for the research platform).  At 0% success to porphyria our discounted-cash-flow model is $18 a share lower at $78 a share."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress,2017-06-26 20:01:00 +0000,https://finance.yahoo.com/news/alnylam-sanofi-genzyme-present-clinical-200100524.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2 open-label extension study with the investigational therapeutic, fitusiran, in patients with hemophilia A and B, with or without inhibitors, will be presented in an oral presentation at the International Society ..."
ALNY,ALNY:UW,BBG000BFGYR2,5 Best Biotech Stocks of 2017 So Far,2017-06-26 11:40:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZzZGqm-Y26c/5-best-biotech-stocks-of-2017-so-far-cm807879,We re almost halfway through 2017 The overall market is performing nicely Many biotech stocks have especially kicked into high gear recently There are plenty of big biotech winners over the last six months but none have achieved gains as impressive as Alnylam
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",2017-06-26 09:45:00 +0000,https://finance.yahoo.com/news/alnylam-reports-positive-clinical-results-094500245.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, announced today new positive interim results from Part C, cohorts 1-3, of its ongoing double-blind, randomized, placebo-controlled Phase 1 study, in addition to initial results from an open-label extension study with givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam: Givosiran Shows Positive Clinical Results In Acute Hepatic Porphyrias,2017-06-26 06:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v30WAfVgvnU/alnylam-givosiran-shows-positive-clinical-results-in-acute-hepatic-porphyrias-20170626-00159,Alnylam: Givosiran Shows Positive Clinical Results In Acute Hepatic Porphyrias
ALNY,ALNY:UW,BBG000BFGYR2,5 Best Biotech Stocks of 2017 So Far,2017-06-25 18:01:00 +0000,http://finance.yahoo.com/r/87deddbe-1f8b-3e81-8ff4-c80467e2f63f/5-best-biotech-stocks-of-2017-so-far.aspx?yptr=yahoo&.tsrc=rss,"How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term",2017-06-19 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-ceo-john-maraganore-named-200000262.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.D., has been elected as the Chair of the Biotechnology Innovation Organization Board of Directors for the 2017-2018 term."
ALNY,ALNY:UW,BBG000BFGYR2,Why is Alnylam's (ALNY) Stock Close to 100% this Year?,2017-06-15 16:10:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_cMnAtT_nS0/why-is-alnylams-alny-stock-close-to-100-this-year-cm803900,Shares of Alnylam Pharmaceuticals Inc ALNY soared 99 8 this year so far massively outperforming the 3 1 increase registered by the Zacks classified Biomed Genetics industry during this period Here we analyze the factors that led to the rally Alnylam Pharmaceuticals Inc is
ALNY,ALNY:UW,BBG000BFGYR2,Why is Alnylam&apos;s (ALNY) Stock Close to 100% this Year?,2017-06-15 13:48:01 +0000,https://finance.yahoo.com/news/why-alnylam-apos-alny-stock-134801485.html?.tsrc=rss,"Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office,2017-06-12 11:30:00 +0000,https://finance.yahoo.com/news/alnylam-significantly-expands-patent-portfolio-113000735.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that the United States Patent and Trademark Office has issued Notices of Allowance for two patent applications owned by Alnylam."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Still Has A Lot Of Upside: Bhavneesh Sharma's Idea Of The Month,2017-06-11 11:27:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F6mMhbaBXV8/alnylam-still-has-a-lot-of-upside-bhavneesh-sharmas-idea-of-the-month-cm801665,By Bhavneesh Sharma MBA ByBhavneesh Sharma MBA See also Q2 2017 S amp P 500 Earnings Will Likely See At Least 10 12 Y Y Growth on seekingalpha comSee alsoQ2 2017 S P 500 Earnings Will Likely See At Least 10 12 Y Y Growth on seekingalpha
ALNY,ALNY:UW,BBG000BFGYR2,Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?,2017-06-08 09:28:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g7v3tA7w7jc/why-is-alnylam-alny-up-312-since-the-last-earnings-report-cm800364,A month has gone by since the last earnings report for Alnylam Pharmaceuticals Inc ALNY Shares have added about 31 2 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before
ALNY,ALNY:UW,BBG000BFGYR2,Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?,2017-06-08 07:31:07 +0000,https://finance.yahoo.com/news/why-alnylam-alny-31-2-073107537.html?.tsrc=rss,Alnylam (ALNY) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18 Organizations,2017-06-07 12:30:00 +0000,https://finance.yahoo.com/news/alnylam-expands-third-annual-helping-123000437.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today kicked off its third annual company-wide “Helping Hands” Community Service Day benefiting 18 organizations in the Greater Boston area, Maidenhead, UK and Zug, Switzerland."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 9:00 AM ET,2017-06-06 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TQ-ChZh8yIY/alnylam-pharma-to-participate-in-jefferies-healthcare-conference-at-900-am-et-20170606-00435,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 9:00 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA,2017-06-02 00:31:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rHknMBf_Vrc/alnylams-givosiran-gets-breakthrough-therapy-status-by-fda-cm797746,Alnylam Pharmaceuticals Inc ALNY announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran ALN AS1 for the prophylaxis of attacks in patients with acute hepatic porphyria AHP We note that Givosiran is being evaluated for the
ALNY,ALNY:UW,BBG000BFGYR2,"Thursday 6/1 Insider Buying Report: PBF, ALNY",2017-06-01 16:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dOg6lbJsaBo/thursday-61-insider-buying-report-pbf-alny-cm797506,As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys At PBF Energy PBF a filing with the SEC revealed that on Tuesday Chief Executive
ALNY,ALNY:UW,BBG000BFGYR2,"Top Losers in the Healthcare Sector: May 22–26, 2017",2017-05-31 16:01:33 +0000,http://finance.yahoo.com/r/547c1ea6-b28f-3436-b92c-632256284434/top-losers-in-the-healthcare-sector-may-22-26-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"During the week ended May 26, 2017, Alexion Pharmaceuticals (ALXN) saw the biggest loss in the healthcare sector. ALXN's stock price witnessed a steep fall of ~14.2%."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designation,2017-05-31 11:59:09 +0000,https://finance.yahoo.com/news/alnylam-pharma-stock-rises-1-115909678.html?.tsrc=rss,"Alnylam Pharmaceuticals Inc. shares rose 1.5% in premarket trade Wednesday after the Food and Drug Administration gave its drug a ""breakthrough therapy"" designation, which is intended to get ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designation,2017-05-31 11:59:09 +0000,http://finance.yahoo.com/r/32be35a0-be48-3411-b69f-aaf396b955a1/Story.aspx?guid=E7A9D79D-375F-4AEF-A207-F17248F8CC21&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Alnylam Pharmaceuticals Inc. shares rose 1.5% in premarket trade Wednesday after the Food and Drug Administration gave its drug a ""breakthrough therapy"" designation, which is intended to get ..."
ALNY,ALNY:UW,BBG000BFGYR2,FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria,2017-05-31 11:30:00 +0000,https://finance.yahoo.com/news/fda-grants-breakthrough-therapy-designation-113000911.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration  for givosiran , an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1  for the prophylaxis of attacks in patients with acute hepatic porphyria ."
ALNY,ALNY:UW,BBG000BFGYR2,Biotech Musical Chairs: Who Leads Next,2017-05-31 10:00:00 +0000,http://finance.yahoo.com/r/798fae83-dc19-360c-a154-7db0f1650f11/biotech-musical-chairs-who-leads-next-ibb-nbix?partner=YahooSA&yptr=yahoo&.tsrc=rss,The biotech sector as measured by the iShares Nasdaq Biotech ETF is down another 1.40% today.
ALNY,ALNY:UW,BBG000BFGYR2,FDA Grants Breakthrough Therapy Designation For Alnylam's Givosiran,2017-05-31 07:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j8Oq7AGgjxU/fda-grants-breakthrough-therapy-designation-for-alnylams-givosiran-20170531-00357,FDA Grants Breakthrough Therapy Designation For Alnylam's Givosiran
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference,2017-05-30 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-webcast-presentation-jefferies-2017-200000192.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 9:00 am ET in New York City."
ALNY,ALNY:UW,BBG000BFGYR2,"Commit To Buy Alnylam Pharmaceuticals At $50, Earn 18% Annualized Using Options",2017-05-26 17:32:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gDO6JEsOlNo/commit-to-buy-alnylam-pharmaceuticals-at-50-earn-18-annualized-using-options-cm795413,Investors considering a purchase of Alnylam Pharmaceuticals Inc Symbol ALNY stock but tentative about paying the going market price of 68 43 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
ALNY,ALNY:UW,BBG000BFGYR2,Regeneron Presents Positive Phase II Data on HoFH Candidate,2017-05-25 16:32:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bupxEfVXGY/regeneron-presents-positive-phase-ii-data-on-hofh-candidate-cm794606,Regeneron Pharmaceuticals Inc REGN presented positive phase II data evaluating its investigational angiopoietin like 3 ANGPTL3 antibody evinacumab at the National Lipid Association s NLA Scientific Sessions The company also announced ANGPTL3 genetics publication in the New
ALNY,ALNY:UW,BBG000BFGYR2,Regeneron Presents Positive Phase II Data on HoFH Candidate,2017-05-25 14:27:02 +0000,https://finance.yahoo.com/news/regeneron-presents-positive-phase-ii-142702129.html?.tsrc=rss,"Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association&apos;s (NLA) Scientific Sessions."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline,2017-05-25 13:34:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qJrvtDr6u_k/alnylam-pharmaceuticals-alny-progressing-well-on-pipeline-cm794351,We issued an updated research report on Alnylam Pharmaceuticals Inc ALNY on May 23 2017 Alnylam s shares are up 86 5 year to date comparing favorably with an increase of 0 2 witnessed by the Zacks classified Medical Biomedical and Genetics industry Alnylam
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline,2017-05-25 11:43:11 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-progressing-well-114311598.html?.tsrc=rss,"We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017."
ALNY,ALNY:UW,BBG000BFGYR2,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI",2017-05-25 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofrEaaE3wzk/aeri-is-awesome-gwph-abuzz-fda-panel-nod-for-pbyi-20170525-00028,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI"
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Movers: Inovio, Neurocrine, Alnylam",2017-05-24 13:29:00 +0000,http://finance.yahoo.com/r/1e338e4a-4ca6-325e-bb8d-69848a2b10e3/biotech-movers-inovio-neurocrine-alnylam.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Prices Public Offering of Common Stock,2017-05-24 13:00:00 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-prices-public-offering-130000694.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share."
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Most Active for May 24, 2017 :  NOW, FGL, GLYC, FCAU, INO, LOW, STNG, BAC, NVDA, TTD, QQQ, ALNY",2017-05-24 12:51:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wMN7Mp6VCyo/pre-market-most-active-for-may-24-2017-now-fgl-glyc-fcau-ino-low-stng-bac-nvda-ttd-qqq-alny-cm793734,The NASDAQ 100 Pre Market Indicator is up 9 2 to 5 712 55 The total Pre Market volume is currently 14 433 292 shares traded The following are the most active stocks for the pre market session ServiceNow Inc NOW is 0 05 at 101 75 with 2 065 723 shares traded
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock,2017-05-23 20:04:00 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-announces-proposed-public-200400579.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reaches Analyst Target Price,2017-05-17 14:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/puOf3zxpfx8/alnylam-pharmaceuticals-reaches-analyst-target-price-cm790431,In recent trading shares of Alnylam Pharmaceuticals Inc Symbol ALNY have crossed above the average analyst 12 month target price of 70 69 changing hands for 72 01 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%,2017-05-16 13:18:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/izxOgLiXUVY/alnylam-pharmaceuticals-alny-looks-good-stock-jumps-163-cm789822,Alnylam Pharmaceuticals Inc ALNY was a big mover last session as the company saw its shares jump a little above 16 on the day The upside was driven by the news that its competing drug candidate patisiran is scheduled to announce its phase 3 results soon Also this led to far more
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%,2017-05-16 12:20:12 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-looks-good-122012008.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session."
ALNY,ALNY:UW,BBG000BFGYR2,"Gainers & Losers Of May 15: CBMG, ETRM, ALNY, EGRX, ONCS...",2017-05-15 23:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b_FEli62LMg/gainers--losers-of-may-15-cbmg-etrm-alny-egrx-oncs-20170515-01639,"Gainers & Losers Of May 15: CBMG, ETRM, ALNY, EGRX, ONCS..."
ALNY,ALNY:UW,BBG000BFGYR2,Biotech And Pharma Industry And Stock News,2017-05-15 20:17:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
ALNY,ALNY:UW,BBG000BFGYR2,How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial,2017-05-15 20:11:01 +0000,http://finance.yahoo.com/r/cab4d696-7de0-33fa-9d7b-110b8470f87b/how-ionis-spiked-rival-alnylam-but-tanked-itself-on-a-key-trial?src=A00220&yptr=yahoo&.tsrc=rss,Alnylam stock rocketed to a seven-month high Monday after a Phase 3 trial from rival Ionis de-risked a key Alnylam drug while indicating serious safety questions for Ionis&apos; drug.
ALNY,ALNY:UW,BBG000BFGYR2,Safety Concerns Ding Ionis,2017-05-15 18:21:00 +0000,https://finance.yahoo.com/news/safety-concerns-ding-ionis-182100876.html?.tsrc=rss,The string of severe adverse events with Ionis' inotersen program puts competitor Alnylam in a more favorable position.
ALNY,ALNY:UW,BBG000BFGYR2,"Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today",2017-05-15 18:16:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7lZn9-2yKUw/why-ionis-pharmaceuticals-inc-tanked-and-alnylam-pharmaceuticals-inc-is-soaring-today-cm789413,What happened Ionis Pharmaceuticals NASDAQ IONS is down 11 4 while Alnylam Pharmaceuticals NASDAQ ALNY is up 13 4 at 12 11 p m EDT for the same reason Ionis Pharmaceuticals issued clinical trial data for its familial amyloid polyneuropathy drug that has
ALNY,ALNY:UW,BBG000BFGYR2,"Noteworthy Monday Option Activity: AAP, WLB, ALNY",2017-05-15 17:15:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kbd4zEpq0h4/noteworthy-monday-option-activity-aap-wlb-alny-cm789348,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Advance Auto Parts Inc Symbol AAP where a total volume of 7 040 contracts has been traded thus far today a contract volume which is representative of approximately 704
ALNY,ALNY:UW,BBG000BFGYR2,"Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today",2017-05-15 16:45:00 +0000,http://finance.yahoo.com/r/2cb37600-8487-38da-a991-64e3076c7469/why-ionis-pharmaceuticals-inc-tanked-and-alnylam-p.aspx?yptr=yahoo&.tsrc=rss,Clinical trial data has Ionis falling while its competitor is on the rise.
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Most Active for May 15, 2017 :  PTHN, SAN, BP, NOK, SNAP, STM, FEYE, IONS, AAPL, TSLA, ALNY, JIVE",2017-05-15 12:54:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iMIWbbBYtu8/pre-market-most-active-for-may-15-2017-pthn-san-bp-nok-snap-stm-feye-ions-aapl-tsla-alny-jive-cm789095,The NASDAQ 100 Pre Market Indicator is up 8 5 to 5 695 31 The total Pre Market volume is currently 15 779 158 shares traded The following are the most active stocks for the pre market session Patheon N V PTHN is 8 73 at 34 73 with 6 636 960 shares traded As
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer",2017-05-12 20:00:00 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-reports-inducement-200000842.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has granted stock options to Manmeet S. Soni, the Company's newly appointed Chief Financial Officer."
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT,2017-05-12 17:00:55 +0000,https://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-121612380.html?.tsrc=rss,Q1 2017 Alnylam Pharmaceuticals Inc Earnings Call
ALNY,ALNY:UW,BBG000BFGYR2,"ETFs with exposure to Alnylam Pharmaceuticals, Inc. : May 11, 2017",2017-05-11 20:04:15 +0000,http://finance.yahoo.com/r/2ec07f3f-2cb8-3be6-a1ba-e3e113b9e03c/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-may-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alnylam Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALNY-US. Comparing the performance and risk of Alnylam Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT,2017-05-11 01:00:46 +0000,http://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-121612380.html?.tsrc=rss,Q1 2017 Alnylam Pharmaceuticals Inc Earnings Call
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO",2017-05-10 22:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oBNttubzHQc/alnylam-pharmaceuticals-inc-earnings-all-eyes-on-apollo-cm787535,Alnylam Pharmaceuticals NASDAQ ALNY released first quarter earnings on Friday but without any drugs on the market investors are rightfully focused on the biotech s pipeline Alnylam Pharmaceuticals results The only number that really
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO",2017-05-10 20:20:00 +0000,http://finance.yahoo.com/r/a87564f3-fb90-3f99-8458-66f3702e8737/alnylam-pharmaceuticals-inc-earnings-all-eyes-on-a.aspx?yptr=yahoo&.tsrc=rss,Results from the APOLLO clinical trial testing the biotech&apos;s lead drug are expected in the September time frame.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming May Investor Conferences,2017-05-10 20:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentations-upcoming-may-200000261.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 at 8:40 am PT at the Encore at Wynn Las Vegas in Las Vegas, Nevada, and at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:00 am ET at the Grand Hyatt New ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017",2017-05-09 15:30:08 +0000,http://finance.yahoo.com/r/20d1579e-ab72-3470-99db-9832cbeb3ed0/alnylam-pharmaceuticals-inc-alny-us-earnings-analysis-q1-2017-by-the-numbers-may-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Alnylam Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Alnylam Pharmaceuticals, Inc. – Arrowhead Pharmaceuticals, Inc., Medicines Company, Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., PAREXEL International Corporation, Regulus Therapeutics Inc. and Novartis AG Sponsored ADR (ARWR-US, MDCO-US, ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders,2017-05-09 12:00:00 +0000,http://finance.yahoo.com/news/alnylam-expands-leadership-team-multiple-120000264.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y",2017-05-08 20:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WBGwk4Yjl4E/alnylam-alny-q1-loss-wider-than-expected-revenues-up-yy-cm786085,Alnylam Pharmaceuticals Inc ALNY reported a loss of 1 25 per share in the first quarter of 2017 wider than the Zacks Consensus Estimate of a loss of 1 22 and the year ago loss of 1 21 Quarterly revenues rose 160 3 to 19 0 million However revenues missed the Zacks Consensus
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y",2017-05-08 17:59:05 +0000,http://finance.yahoo.com/news/alnylam-alny-q1-loss-wider-175905786.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21."
ALNY,ALNY:UW,BBG000BFGYR2,Health Care Sector Update for 05/05/2017: ALNY,2017-05-05 14:00:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X2FthPsWSKY/health-care-sector-update-for-05052017-alny-cm784897,Top Health care stocks Top Health care stocks JNJ 0 2 JNJ 0 2 PFE 0 2 PFE 0 2 ABT flatABT flat MRK 0 2 MRK 0 2 AMGN 0 4 AMGN 0 4 Health care shares were mixed in pre market trade on Friday Health care shares were mixed in pre market trade on Friday In health care
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 1Q loss,2017-05-05 12:06:27 +0000,http://finance.yahoo.com/news/alnylam-reports-1q-loss-120627239.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.25. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity,2017-05-05 12:00:00 +0000,http://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-first-quarter-120000445.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2017, and highlighted recent progress in advancing its pipeline."
ALNY,ALNY:UW,BBG000BFGYR2,"Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call",2017-05-05 11:00:00 +0000,http://finance.yahoo.com/news/investor-network-alnylam-pharmaceuticals-inc-110000839.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 5, 2017 / Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY ) will be discussing their earnings results in their Q1 Earnings Call to be held May 5, 2017 at 8:30 AM Eastern Time. ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Earnings Reaction History: Alnylam Pharmaceuticals Inc., 40.0% Follow-Through Indicator, 7.6% Sensitive",2017-05-05 10:40:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9D0ovsO-8pc/earnings-reaction-history-alnylam-pharmaceuticals-inc-400-follow-through-indicator-76-sensitive-cm784718,Expected Earnings Release 05 05 2017 PremarketExpected Earnings Release 05 05 2017 Premarket Avg Extended Hours Dollar Volume 2 409 859Avg Extended Hours Dollar Volume 2 409 859 Alnylam Pharmaceuticals Inc ALNY is due to issue its quarterly earnings report in the
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Earnings Report for May 5, 2017 :  CI, TRP, CTSH, HCN, MCO, CNP, BPL, JLL, SNH, CFX, ALNY, VWR",2017-05-04 20:19:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OvFFZWz_fxY/pre-market-earnings-report-for-may-5-2017-ci-trp-ctsh-hcn-mco-cnp-bpl-jll-snh-cfx-alny-vwr-cm784550,The following companies are expected to report earnings prior to market open on 05 05 2017 Visit our Earnings Calendar for a full list of expected earnings releases Cigna Corporation CI is reporting for the quarter ending March 31 2017 The
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results,2017-04-27 20:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-conference-call-discussing-200000298.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the U.S."
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Company (MDCO) Q1 Loss Wider Than Expected,2017-04-27 15:29:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D99dWKkZ4m4/the-medicines-company-mdco-q1-loss-wider-than-expected-cm780246,The Medicines Company MDCO reported a loss of 1 44 per share in first quarter 2017 wider than the Zacks Consensus Estimate of a loss of 1 13 Including share based compensation expenses however adjusted loss was 1 14 per share The reported figure widened from the year ago loss of 1
ALNY,ALNY:UW,BBG000BFGYR2,Blog Coverage Medicines Co. Reaches Agreement with FDA for the Phase III Trial for Inclisiran,2017-04-27 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-medicines-co-reaches-121500891.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / April 27, 2017 / Active Wall St. blog coverage looks at the headline from The Medicines Co. (NASDAQ: MDCO ) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ). On April 26, 2017, ..."
ALNY,ALNY:UW,BBG000BFGYR2,ALNY Makes Bullish Cross Above Critical Moving Average,2017-04-26 17:04:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1NBgarAXO18/alny-makes-bullish-cross-above-critical-moving-average-cm779622,In trading on Wednesday shares of Alnylam Pharmaceuticals Inc Symbol ALNY crossed above their 200 day moving average of 52 65 changing hands as high as 53 44 per share Alnylam Pharmaceuticals Inc shares are currently trading up about 3 7 on the day The chart below shows the one
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis",2017-04-26 12:00:00 +0000,http://finance.yahoo.com/news/alnylam-reports-final-24-month-120000184.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today final 24-month results from its Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis."
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran,2017-04-26 11:00:00 +0000,http://finance.yahoo.com/news/medicines-company-alnylam-pharmaceuticals-announce-110000255.html?.tsrc=rss,"The Medicines Company and Alnylam Pharmaceuticals, Inc. today announced that The Medicines Company has agreed with the U.S. Food and Drug Administration on plans for the Phase III clinical program for inclisiran, which is designed to support the submission of a New Drug Application ."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : April 20, 2017",2017-04-20 18:47:16 +0000,http://finance.yahoo.com/r/751d388b-826d-31fd-a786-ff5befa51b7c/alnylam-pharmaceuticals-inc-value-analysis-nasdaqalny-april-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alnylam Pharmaceuticals, Inc. a score of 21. Our analysis is based on comparing Alnylam Pharmaceuticals, Inc. with the following peers – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Medicines Company, Regeneron Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., PAREXEL International Corporation, OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : April 19, 2017",2017-04-19 12:30:53 +0000,http://finance.yahoo.com/r/d7e35566-c894-3dd5-a496-bb814b9a3505/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-alny-us-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now,2017-04-12 13:57:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WCuCqBZObT0/5-reasons-why-sanofi-sny-is-a-good-stock-to-buy-now-cm773194,Paris France based Sanofi SNY is a global healthcare company possessing a diversified product portfolio It has a presence in several therapeutic areas including cardiovascular diseases diabetes oncology and central nervous system disorders among others It looks like a great stock to
ALNY,ALNY:UW,BBG000BFGYR2,Regeneron's Evinacumab Gets Breakthrough Therapy by FDA,2017-04-07 16:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6RT332GkS4U/regenerons-evinacumab-gets-breakthrough-therapy-by-fda-cm771439,Regeneron Pharmaceuticals Inc REGN announced that the FDA has granted Breakthrough Therapy Designation status to its pipeline candidate evinacumab for the treatment of hypercholesterolemia in patients with Homozygous Familial Hypercholesterolemia HoFH Notably HoFH is an inherited
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : April 6, 2017",2017-04-06 12:30:29 +0000,http://finance.yahoo.com/r/c8dc51c1-3b07-3a80-a1b6-cbb3257949c7/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-alny-us-april-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals To Present At Needham Conference; Webcast At 11:20 AM ET,2017-04-05 10:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1OjT7AqaLjU/alnylam-pharmaceuticals-to-present-at-needham-conference-webcast-at-1120-am-et-20170405-00757,Alnylam Pharmaceuticals To Present At Needham Conference; Webcast At 11:20 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Beaten-Down Biotechs May Be Worth Buying,2017-04-04 15:05:00 +0000,http://finance.yahoo.com/r/fbd1819b-97a9-3c1e-a1f5-27590ead42ea/beaten-down-biotechs-may-be-worth-buying-1491318338?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  We also think all the biotech companies highlighted below represent interesting opportunities where sentiment is negative (Gilead Sciences, Alexion Pharmaceuticals and Alnylam Pharmaceuticals) or under significant debate (Tesaro, Gilead)."
ALNY,ALNY:UW,BBG000BFGYR2,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 13:36:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r9wOg8-QRto/5-deadliest-diseases-in-the-us-and-the-top-drugs-potentially-on-the-way-to-treat-them-cm768774,Just five diseases caused the deaths of roughly 1 6 million Americans in 2015 the most recent year for which the Centers for Disease Control and Prevention CDC has statistics Many more patients suffer from the diseases Promising drugs could be on the way to treat these
ALNY,ALNY:UW,BBG000BFGYR2,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 11:23:00 +0000,https://www.fool.com/investing/2017/04/02/5-deadliest-diseases-in-the-us-and-the-top-drugs-p.aspx,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
ALNY,ALNY:UW,BBG000BFGYR2,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 11:23:00 +0000,http://finance.yahoo.com/r/58ac3440-3f9d-385a-ad3a-27f1c34c8411/5-deadliest-diseases-in-the-us-and-the-top-drugs-p.aspx?yptr=yahoo&.tsrc=rss,Promising treatments could be on the way to address the diseases causing the most American deaths.
ALNY,ALNY:UW,BBG000BFGYR2,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?,2017-03-31 16:21:20 +0000,http://www.investors.com/news/technology/will-trumps-fda-chill-innovation-or-speed-up-to-kill-astronomical-prices/?src=A00220A,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
ALNY,ALNY:UW,BBG000BFGYR2,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?,2017-03-31 16:21:20 +0000,http://finance.yahoo.com/r/bd5e67bf-29a5-3bd0-abac-8ebe582d4d95/will-trumps-fda-chill-innovation-or-speed-up-to-kill-astronomical-prices?src=A00220A&yptr=yahoo&.tsrc=rss,"It seems clear President Trump wants a leaner and meaner Food and Drug Administration, but how lean and how mean?"
ALNY,ALNY:UW,BBG000BFGYR2,The 3 Best Cholesterol Drug Stocks to Buy in 2017,2017-03-30 21:59:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KE6xzQP6vr8/the-3-best-cholesterol-drug-stocks-to-buy-in-2017-cm768027,No cholesterol drug is likely to ever reach the sales level that Lipitor was able to achieve but investors can still profit buying stock in companies developing drugs for patients with high cholesterol where Lipitor or other statins aren t enough to bring patients cholesterol levels
ALNY,ALNY:UW,BBG000BFGYR2,The 3 Best Cholesterol Drug Stocks to Buy in 2017,2017-03-30 20:20:00 +0000,http://finance.yahoo.com/r/f11f721d-fa53-3132-97bb-9b627bd44756/the-3-best-cholesterol-drug-stocks-to-buy-in-2017.aspx?yptr=yahoo&.tsrc=rss,Investors should benefit from these biotechs' cholesterol drugs.
ALNY,ALNY:UW,BBG000BFGYR2,The 3 Best Cholesterol Drug Stocks to Buy in 2017,2017-03-30 20:20:00 +0000,https://www.fool.com/investing/2017/03/30/the-3-best-cholesterol-drug-stocks-to-buy-in-2017.aspx,The 3 Best Cholesterol Drug Stocks to Buy in 2017
ALNY,ALNY:UW,BBG000BFGYR2,Coverage initiated on Alnylam Pharma by UBS,2017-03-30 13:10:33 +0000,http://finance.yahoo.com/q/ud?s=ALNY,Coverage initiated on Alnylam Pharma by UBS
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference,2017-03-28 20:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentation-16th-annual-200000227.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference,2017-03-28 20:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentation-16th-annual-200000227.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City."
ALNY,ALNY:UW,BBG000BFGYR2,"Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can",2017-03-23 18:07:53 +0000,http://www.investors.com/news/technology/regeneron-sanofi-look-to-crush-amgen-and-these-rivals-agree/?src=A00220A,"Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can"
ALNY,ALNY:UW,BBG000BFGYR2,"Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can",2017-03-23 18:07:53 +0000,http://finance.yahoo.com/r/4a8d8ba0-9960-3f18-b9d3-ede454727461/regeneron-sanofi-look-to-crush-amgen-and-these-rivals-agree?src=A00220A&yptr=yahoo&.tsrc=rss,Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.
ALNY,ALNY:UW,BBG000BFGYR2,How This Company Is Taking on Amgen,2017-03-23 15:02:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o3sFnPtudZk/how-this-company-is-taking-on-amgen-cm764633,The Medicines Company NASDAQ MDCO recently announced positive phase 2 trial data for its cholesterol lowering drug inclisiran and if inclisiran can duplicate those results in a larger phase 3 study then it could end up challenging Amgen NASDAQ AMGN for market share
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?,2017-03-23 12:00:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90_rxQOHZho/alnylam-alny-up-145-since-earnings-report-can-it-continue-cm764503,It has been about a month since the last earnings report for Alnylam Pharmaceuticals Inc ALNY Shares have added about 14 5 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?,2017-03-23 10:16:10 +0000,http://finance.yahoo.com/news/alnylam-alny-14-5-since-101610173.html,Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?,2017-03-23 10:16:10 +0000,http://finance.yahoo.com/news/alnylam-alny-14-5-since-101610173.html?.tsrc=rss,Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALNY,ALNY:UW,BBG000BFGYR2,Could Biogen Spinoff Bleed This Biotech In Hemophilia?,2017-03-22 20:21:28 +0000,http://www.investors.com/news/technology/could-biogen-spinoff-bleed-this-biotech-in-hemophilia/?src=A00220A,Could Biogen Spinoff Bleed This Biotech In Hemophilia?
ALNY,ALNY:UW,BBG000BFGYR2,Could Biogen Spinoff Bleed This Biotech In Hemophilia?,2017-03-22 20:21:28 +0000,http://finance.yahoo.com/r/0675d1a5-7666-3689-93b5-1f0e15c78045/could-biogen-spinoff-bleed-this-biotech-in-hemophilia?src=A00220A&yptr=yahoo&.tsrc=rss,"Alnylam's fitusiran will pull in $989 million in 2025, but won't launch until 2020 amid competition with Biogen spinoff Bioverativ."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's LDL-Lowering Drug Positive in Phase II Study,2017-03-21 00:07:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TYYIozDtmz0/alnylams-ldl-lowering-drug-positive-in-phase-ii-study-cm763209,Alnylam Pharmaceuticals Inc ALNY and its partner The Medicines Company MDCO announced positive final results from the phase II study ORION 1 on their experimental PCSK9 inhibitor inclisiran which is being developed for the treatment of hypercholesterolemia Alnylam s share price
ALNY,ALNY:UW,BBG000BFGYR2,​Alnylam CEO’s pay fell nearly 80 percent in 2016,2017-03-20 23:55:09 +0000,http://finance.yahoo.com/r/27977f6a-0ad8-376b-9178-03446d9e7402/alnylam-ceo-s-pay-fell-nearly-80-percent-in-2016.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The CEO of Alnylam Pharmaceuticals saw his compensation drop precipitously in 2016 as the Cambridge biotech lost about half of its market value, according to a federal filing.  John Maraganore received about $1.7 million in total compensation in 2016, down from nearly $8.3 million in 2015, a decrease of nearly 80 percent, according to the filing on Friday.  The filing shows that Maraganore realized nearly $4.9 million in value by exercising options in 2016."
ALNY,ALNY:UW,BBG000BFGYR2,​Alnylam CEO’s pay fell nearly 80 percent in 2016,2017-03-20 23:55:09 +0000,http://www.bizjournals.com/boston/news/2017/03/20/alnylam-ceo-s-pay-fell-nearly-80-percent-in-2016.html?ana=yahoo,​Alnylam CEO’s pay fell nearly 80 percent in 2016
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's LDL-Lowering Drug Positive in Phase II Study,2017-03-20 22:11:10 +0000,http://finance.yahoo.com/news/alnylams-ldl-lowering-drug-positive-221110144.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's LDL-Lowering Drug Positive in Phase II Study,2017-03-20 22:11:10 +0000,http://finance.yahoo.com/news/alnylams-ldl-lowering-drug-positive-221110144.html,Alnylam's LDL-Lowering Drug Positive in Phase II Study
ALNY,ALNY:UW,BBG000BFGYR2,Esperion And Medicines Co. Recover From Amgen-Induced Pitfall,2017-03-20 20:09:59 +0000,http://www.investors.com/news/technology/esperion-medicines-recover-from-amgen-induced-pitfall-on-trial-action/?src=A00220A,Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
ALNY,ALNY:UW,BBG000BFGYR2,Esperion And Medicines Co. Recover From Amgen-Induced Pitfall,2017-03-20 20:09:59 +0000,http://finance.yahoo.com/r/79605871-198c-3800-b970-58b405bf14b4/esperion-medicines-recover-from-amgen-induced-pitfall-on-trial-action?src=A00220A&yptr=yahoo&.tsrc=rss,Esperion stock recovered from an Amgen-induced pitfall on Monday after the biotech outlined its path to FDA approval for a cholesterol drug.
ALNY,ALNY:UW,BBG000BFGYR2,"AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA Contract",2017-03-20 00:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qOd4UEe4AAo/amgn-on-watch-gale-reports-positive-data-ebs-secures-barda-contract-20170320-00009,"AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA Contract"
ALNY,ALNY:UW,BBG000BFGYR2,Medicines Co and Alnylam Pharmaceuticals Inc Report Positive Final Results from ORION-1 Phase II Study of Inclisiran Call scheduled for 4:30 pm ET today,2017-03-17 20:30:00 +0000,http://biz.yahoo.com/cc/2/156032.html,Medicines Co and Alnylam Pharmaceuticals Inc Report Positive Final Results from ORION-1 Phase II Study of Inclisiran Call scheduled for 4:30 pm ET today
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam touts latest trial data as suggesting its drugs are safe,2017-03-17 19:00:09 +0000,http://www.bizjournals.com/boston/news/2017/03/17/alnylam-touts-latest-trial-data-as-suggesting-its.html?ana=yahoo,Alnylam touts latest trial data as suggesting its drugs are safe
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam touts latest trial data as suggesting its drugs are safe,2017-03-17 19:00:09 +0000,http://finance.yahoo.com/r/ae4d7dfb-a1b0-335a-b6ca-53d0d6661d63/alnylam-touts-latest-trial-data-as-suggesting-its.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Back in October, Alnylam Pharmaceuticals shelved its lead drug following the deaths of 19 patients in a late-stage trial, raising concerns among some investors that safety issues would plague the Cambridge firm’s entire pipeline.  The company has argued this isn’t the case.  Alnylam CEO John Maraganore said in a statement that the company was “delighted” with the data, which also showed that patients taking the drug experienced significant, long-lasting reductions in low-density lipoprotein cholesterol."
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran,2017-03-17 16:15:00 +0000,http://finance.yahoo.com/news/medicines-company-alnylam-pharmaceuticals-report-161500446.html?.tsrc=rss,"The Medicines Company and Alnylam Pharmaceuticals, Inc. today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment of hypercholesterolemia."
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran,2017-03-17 16:15:00 +0000,http://finance.yahoo.com/news/medicines-company-alnylam-pharmaceuticals-report-161500446.html,"[Business Wire] - The Medicines Company and Alnylam Pharmaceuticals, Inc. today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment of hypercholesterolemia."
ALNY,ALNY:UW,BBG000BFGYR2,5 Stocks The Best Performing Hedge Funds Are Piling Into,2017-03-16 21:35:26 +0000,http://www.insidermonkey.com/blog/5-stocks-the-best-performing-hedge-funds-are-piling-into-2-567008/,5 Stocks The Best Performing Hedge Funds Are Piling Into
ALNY,ALNY:UW,BBG000BFGYR2,5 Stocks The Best Performing Hedge Funds Are Piling Into,2017-03-16 21:35:26 +0000,http://finance.yahoo.com/r/43c33e41-c1ea-30c1-9a92-c0986007831c/5-stocks-the-best-performing-hedge-funds-are-piling-into-2-567008?yptr=yahoo&.tsrc=rss,"At Insider Monkey, we track more than 700 of the best hedge funds in the world and have developed various market-beating strategies over the years using the wealth of data we collect from their 13F filings. Our latest successful system is to select the 100 best-performing funds from the previous quarter and then identify their […]"
ALNY,ALNY:UW,BBG000BFGYR2,5:27 am Alnylam Pharma receives PRIME Designation from EMA for accelerated assessment of Givosiran,2017-03-01 10:27:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#alny,5:27 am Alnylam Pharma receives PRIME Designation from EMA for accelerated assessment of Givosiran
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",2017-03-01 10:15:00 +0000,http://finance.yahoo.com/news/alnylam-receives-european-medicines-agency-101500843.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the European Medicines Agency has granted access to its Priority Medicines scheme for givosiran , an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",2017-03-01 10:15:00 +0000,http://finance.yahoo.com/news/alnylam-receives-european-medicines-agency-101500843.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the European Medicines Agency has granted access to its Priority Medicines scheme for givosiran , an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias."
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 20:51:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DhyPAbFdy0U/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuticals-cm754355,In this edition of our ongoing Better Buy series we ve got two biotechs trading well off their highs bluebird bio NASDAQ BLUE peaked in the middle of 2015 when it appeared that the company s gene therapy was able to cure sickle cell anemia patients Subsequent patients didn
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 18:40:00 +0000,http://finance.yahoo.com/r/a1265d34-2d26-39a4-9f79-dc8383c7f7aa/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuti.aspx?yptr=yahoo&.tsrc=rss,A battle of knocked-down platform biotechs.
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals",2017-02-28 18:40:00 +0000,http://www.fool.com/investing/2017/02/28/better-buy-bluebird-bio-inc-vs-alnylam-pharmaceuti.aspx,"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis,2017-02-28 15:38:24 +0000,http://marketrealist.com/2017/02/alnylam-pharmaceuticals-continues-develop-innovative-therapies-treat-hattr-amyloidosis/?utm_source=yahoo&utm_medium=feed,Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis,2017-02-28 15:38:24 +0000,http://finance.yahoo.com/r/9f21dec4-b6c2-3c93-88aa-727562a66a0d/alnylam-pharmaceuticals-continues-develop-innovative-therapies-treat-hattr-amyloidosis?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Advances Its Patisiran Research Program,2017-02-28 14:09:18 +0000,http://finance.yahoo.com/r/0d006fbf-403f-3a88-af31-34712a55df27/alnylam-pharmaceuticals-continues-advance-patisiran-research-program-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In October 2016, the APOLLO data monitoring committee recommended that Alnylam Pharmaceuticals (ALNY) continue with the dosing in the trial without any modification to the study design."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Advances Its Patisiran Research Program,2017-02-28 14:09:18 +0000,http://marketrealist.com/2017/02/alnylam-pharmaceuticals-continues-advance-patisiran-research-program-2017/?utm_source=yahoo&utm_medium=feed,Alnylam Pharmaceuticals Advances Its Patisiran Research Program
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis,2017-02-28 13:52:00 +0000,http://finance.yahoo.com/news/alnylam-acknowledges-rare-disease-day-135200116.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today marked the 10th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers impacted by specific rare diseases, such as hereditary ATTR amyloidosis ."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis,2017-02-28 13:52:00 +0000,http://finance.yahoo.com/news/alnylam-acknowledges-rare-disease-day-135200116.html?.tsrc=rss,"Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today marked the 10th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers impacted by specific rare diseases, such as hereditary ATTR amyloidosis ."
ALNY,ALNY:UW,BBG000BFGYR2,How Do Analysts View Alnylam Pharmaceuticals in 2017?,2017-02-28 12:40:17 +0000,http://marketrealist.com/2017/02/analyst-recommendations-alnylam-pharmaceuticals-2017/?utm_source=yahoo&utm_medium=feed,How Do Analysts View Alnylam Pharmaceuticals in 2017?
ALNY,ALNY:UW,BBG000BFGYR2,"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today",2017-02-27 23:50:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bsdAcztbEZU/heres-why-alnylam-pharmaceuticals-inc-stock-bounced-up-101-today-cm753898,What happened Shares of Alnylam Pharmaceuticals Inc NASDAQ ALNY 160 a clinical stage biotech notched a 10 1 gain to end Monday s session It was a good day all around for biotechnology stocks The industry tracking iShares Nasdaq Biotechnology ETF NASDAQ
ALNY,ALNY:UW,BBG000BFGYR2,"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today",2017-02-27 22:27:11 +0000,http://www.fool.com/investing/2017/02/27/heres-why-alnylam-pharmaceuticals-inc-stock-bounce.aspx,"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming March Investor Conferences,2017-02-27 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentations-upcoming-march-210000058.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017 at 2:40 pm ET at the Boston Marriott Copley Place Hotel in Boston, Massachusetts and at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 9:30 am ET at the Loews ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Commit To Purchase Alnylam Pharmaceuticals At $35, Earn 20.9% Annualized Using Options",2017-02-23 18:49:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dEb4pTOYmCA/commit-to-purchase-alnylam-pharmaceuticals-at-35-earn-209-annualized-using-options-cm752210,Investors considering a purchase of Alnylam Pharmaceuticals Inc Symbol ALNY stock but cautious about paying the going market price of 45 91 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
ALNY,ALNY:UW,BBG000BFGYR2,Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain,2017-02-23 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-ocular-therapeutix-announced-131500482.html,"[Accesswire] - Upcoming AWS Coverage on Alnylam Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / February 23, 2017 / Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. (NASDAQ: ..."
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Financials",2017-02-22 18:04:21 +0000,http://finance.yahoo.com/q/is?s=alny,"ALNYLAM PHARMACEUTICALS, INC. Financials"
ALNY,ALNY:UW,BBG000BFGYR2,"FBT, ACAD, ALNY, KITE: ETF Outflow Alert",2017-02-21 17:07:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PXpGzWcwQ2Y/fbt-acad-alny-kite-etf-outflow-alert-cm750659,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the First Trust NYSE Arca Biotechnology Index Fund Symbol FBT where we have detected an approximate 15 3 million dollar outflow that s a 1 7 decrease week
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.",2017-02-20 14:57:38 +0000,http://www.fool.com/investing/2017/02/20/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc."
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.",2017-02-20 14:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gius2nIhMP8/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin-pharmaceutical-inc-cm750192,Late last year Alnylam Pharmaceuticals Inc NASDAQ ALNY took a big hit when the company scuttled an important development program because of safety concerns Meanwhile plenty of clinical stage programs at Biomarin Pharmaceutical Inc NASDAQ BMRN have been chugging
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report",2017-02-15 22:09:45 +0000,http://biz.yahoo.com/e/170215/alny10-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report"
ALNY,ALNY:UW,BBG000BFGYR2,"ETFs with exposure to Alnylam Pharmaceuticals, Inc. : February 14, 2017",2017-02-14 19:21:18 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-february-14-2017/,"ETFs with exposure to Alnylam Pharmaceuticals, Inc. : February 14, 2017"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017",2017-02-13 16:47:10 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-alny-us-earnings-analysis-2016-by-the-numbers-february-13-2017/,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017"
ALNY,ALNY:UW,BBG000BFGYR2,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout,2017-02-10 21:10:00 +0000,https://www.thestreet.com/story/13998228/1/5-stocks-trending-towards-big-breakouts.html?puc=yahoo&cm_ven=YAHOO,This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)",2017-02-10 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-reports-inducement-210000745.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors, approved a grant, effective as of February 6, 2017, to a vice president level employee of the Company, of a non-qualified stock option to purchase 50,000 shares of Alnylam's common stock."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017",2017-02-10 15:39:03 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-alny-us-earnings-analysis-q4-2016-by-the-numbers-february-10-2017/,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It",2017-02-09 22:19:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LbVpeB5PeXA/alnylam-pharmaceuticals-inc-presents-progress-investors-dig-it-cm745852,Alnylam Pharmaceuticals NASDAQ ALNY jumped as much as 14 5 today after announcing earnings after the bell yesterday As a development stage biotech it wasn t the revenue or the earnings that caused the spike but the progression of Allnylam s pipeline Nevertheless here s how
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold",2017-02-09 22:15:18 +0000,http://finance.yahoo.com/news/alnylams-healthy-earnings-boost-price-221518345.html,"Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It",2017-02-09 20:34:12 +0000,http://www.fool.com/investing/2017/02/09/alnylam-pharmaceuticals-inc-presents-progress-inve.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise",2017-02-09 18:18:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-yl-3XNw52s/alnylam-alny-q3-loss-narrower-than-expected-revenues-rise-cm745649,Alnylam Pharmaceuticals Inc ALNY reported a loss of 1 32 per share in the fourth quarter of 2016 narrower than both the Zacks Consensus Estimate loss of 1 35 and the year ago loss of 1 07 Quarterly revenues rose 131 1 to 17 5 million Additionally revenues were also above the
ALNY,ALNY:UW,BBG000BFGYR2,"Thursday's ETF Movers: XBI, GDX",2017-02-09 17:19:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xdFKbMx3QIc/thursdays-etf-movers-xbi-gdx-cm745599,In trading on Thursday the XBI SPDR S amp P Biotech ETF US Equities XBI is outperforming other ETFs up about 1 6 on the day Components of that ETF showing particular strength include shares of Acorda Therapeutics ACOR up about 12 7 and shares of Alnylam Pharmaceuticals
ALNY,ALNY:UW,BBG000BFGYR2,"​Alnylam shares jump on positive earnings, 2017 outlook",2017-02-09 16:45:08 +0000,http://www.bizjournals.com/boston/news/2017/02/09/alnylam-shares-jump-on-positive-earnings-2017.html?ana=yahoo,"​Alnylam shares jump on positive earnings, 2017 outlook"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise",2017-02-09 16:07:04 +0000,http://finance.yahoo.com/news/alnylam-alny-q3-loss-narrower-160704608.html,"Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise"
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 8-Feb-17 9:30pm GMT,2017-02-09 08:11:35 +0000,http://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-081135145.html,Edited Transcript of ALNY earnings conference call or presentation 8-Feb-17 9:30pm GMT
ALNY,ALNY:UW,BBG000BFGYR2,"AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban",2017-02-09 04:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/belLj8ylNro/agtc-on-watch-its-advantage-regn-no-need-for-fda-panel-review-for-betrixaban-20170209-00216,"AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban"
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements",2017-02-08 21:12:24 +0000,http://biz.yahoo.com/e/170208/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 4Q loss,2017-02-08 21:06:35 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-4q-loss-210635115.html,Alnylam reports 4Q loss
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity,2017-02-08 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-fourth-quarter-210000422.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2016, and highlighted recent progress in advancing its pipeline."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Q4 16 Earnings Conference Call At 4:30 PM ET,2017-02-08 15:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NoBnKwGNtcw/alnylam-pharmaceuticals-q4-16-earnings-conference-call-at-430-pm-et-20170208-01258,Alnylam Pharmaceuticals Q4 16 Earnings Conference Call At 4:30 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close,2017-02-08 12:07:06 +0000,http://biz.yahoo.com/research/earncal/20170208.html?t=alny,Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference,2017-02-07 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentation-leerink-partners-210000114.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 pm ET at the Lotte New York Palace Hotel in New York City."
ALNY,ALNY:UW,BBG000BFGYR2,Biotechnology Executives Oppose Trump Immigration Policy,2017-02-07 15:00:00 +0000,http://www.forbes.com/sites/matthewherper/2017/02/07/biotechnology-executives-oppose-trump-immigration-policy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Biotechnology Executives Oppose Trump Immigration Policy
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.",2017-02-07 14:45:20 +0000,http://www.fool.com/investing/2017/02/06/better-buy-agenus-inc-vs-alnylam-pharmaceuticals-i.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc."
ALNY,ALNY:UW,BBG000BFGYR2,"Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More",2017-02-07 14:06:02 +0000,http://finance.yahoo.com/news/drug-stock-q4-earnings-watch-140602999.html,"Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More"
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.",2017-02-06 16:19:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nN9vHYf5ODQ/better-buy-agenus-inc-vs-alnylam-pharmaceuticals-inc-cm743584,Agenus NASDAQ AGEN and Alnylam Pharmaceuticals NASDAQ ALNY are both clinical stage biotechs developing drugs that hold the potential to make a big difference for patients Shares of both companies have dropped dramatically since October Which biotech stock is now the
ALNY,ALNY:UW,BBG000BFGYR2,Why The Medicines Company Rocketed Higher Today,2017-02-04 00:04:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aFu6Rcegt4E/why-the-medicines-company-rocketed-higher-today-cm743169,Image source Getty Images What happened The Medicines Company NASDAQ MDCO shot up 21 today after competitor Amgen NASDAQ AMGN announced data from its FOURIER clinical trial Amgen s PCSK9 inhibitor Repatha significantly reduced the risk of cardiovascular
ALNY,ALNY:UW,BBG000BFGYR2,Why The Medicines Company Rocketed Higher Today,2017-02-03 21:32:59 +0000,http://www.fool.com/investing/2017/02/03/why-the-medicines-company-rocketed-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why The Medicines Company Rocketed Higher Today
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Presents New Data on Fitusiran at EAHAD,2017-02-02 16:45:00 +0000,http://finance.yahoo.com/news/alnylam-presents-data-fitusiran-eahad-164500332.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company today announced new results from an exploratory analysis of its Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B with or without inhibitors."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results,2017-02-01 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-conference-call-discussing-210000554.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S."
ALNY,ALNY:UW,BBG000BFGYR2,The Implied Analyst 12-Month Target For PBE,2017-01-24 15:32:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M7mvj0cWhO8/the-implied-analyst-12-month-target-for-pbe-cm737250,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Expects Better 2017 After Setbacks,2017-01-12 18:30:00 +0000,http://www.investopedia.com/news/alnylam-sees-better-future-drug-prospects-alny/?partner=YahooSA,Alnylam Expects Better 2017 After Setbacks
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge,2017-01-11 20:46:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/19Jr-qM3DhM/mid-afternoon-market-update-derma-sciences-climbs-on-acquisition-news-novadaq-shares-plunge-cm732423,Toward the end of trading Wednesday the Dow traded up 0 30 percent to 19 915 99 while the NASDAQ declined 0 14 percent to 5 544 03 The S amp P also rose gaining 0 04 percent to 2 269 69 Leading and Lagging Sectors Energy shares gained around 0 88 percent in trading on
ALNY,ALNY:UW,BBG000BFGYR2,"Wednesday Sector Laggards: Drugs, Biotechnology Stocks",2017-01-11 19:57:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZPZqyDm6Q2E/wednesday-sector-laggards-drugs-biotechnology-stocks-cm732368,In trading on Wednesday drugs shares were relative laggards down on the day by about 3 7 Helping drag down the group were shares of Diffusion Pharmaceuticals DFFN down about 35 3 and shares of Endo International ENDP off about 9 7 on the day Also lagging the market
ALNY,ALNY:UW,BBG000BFGYR2,"Wednesday's ETF Movers: OIH, XBI",2017-01-11 19:57:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gcq09Ja163I/wednesdays-etf-movers-oih-xbi-cm732364,In trading on Wednesday the Oil Services ETF OIH is outperforming other ETFs up about 1 6 on the day Components of that ETF showing particular strength include shares of Transocean RIG up about 4 4 and shares of Noble NE up about 4 2 on the day And
ALNY,ALNY:UW,BBG000BFGYR2,"​Cambridge’s most secretive biotech, Moderna, gives a rare glimpse of its projects",2017-01-09 22:50:08 +0000,http://www.bizjournals.com/boston/news/2017/01/09/cambridge-s-most-secretive-biotech-moderna-gives.html?ana=yahoo,"​Cambridge’s most secretive biotech, Moderna, gives a rare glimpse of its projects"
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Co LDL-Lowering Drug Positive in Phase II,2017-01-09 14:52:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OcJ2DNAj_Is/the-medicines-co-ldl-lowering-drug-positive-in-phase-ii-cm731030,The Medicines Company MDCO announced positive top line results from a Day 180 interim analysis of the ongoing ORION 1 phase II study on its pipeline candidate Inclisiran formerly PCSK9si for the treatment of hypercholesterolemia The Medicines Company is developing Inclisiran under
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Stock Is a 2017 Winner (ALNY)",2017-01-09 14:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pChfphhf8zY/why-alnylam-pharmaceuticals-inc-stock-is-a-2017-winner-alny-cm730919,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The pharmaceutical sector is well known as one of the most volatile and lucrative stock market sectors It can also be the most emotionally rewarding as you invest in companies that
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : January 9, 2017",2017-01-09 12:22:44 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-alny-us-january-9-2017/,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : January 9, 2017"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals To Present At J.P. Morgan Conference; Webcast At 12:00PM,2017-01-09 11:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cn4cAG3yzaM/alnylam-pharmaceuticals-to-present-at-jp-morgan-conference-webcast-at-1200pm-20170109-00717,Alnylam Pharmaceuticals To Present At J.P. Morgan Conference; Webcast At 12:00PM
ALNY,ALNY:UW,BBG000BFGYR2,Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016,2017-01-07 15:49:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FSW4HUp-V9M/heres-why-alnylam-pharmaceuticals-plunged-598-in-2016-cm730706,Image source Getty Images What happened 2016 was brutal for investors in Alnylam Pharmaceuticals NASDAQ ALNY 160 Shares of the RNAi focused biotech utterly collapsed falling by nearly 60 during the year according to data from S amp P Global Market
ALNY,ALNY:UW,BBG000BFGYR2,Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016,2017-01-07 14:42:28 +0000,http://www.fool.com/investing/2017/01/07/why-alnylam-pharmaceuticals-plunged-598-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
ALNY,ALNY:UW,BBG000BFGYR2,5 Stocks Setting Up for Big Breakouts,2017-01-06 19:33:00 +0000,https://www.thestreet.com/story/13945313/1/5-stocks-setting-up-for-big-breakouts.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Setting Up for Big Breakouts
ALNY,ALNY:UW,BBG000BFGYR2,A Winning Pharmaceutical Stock For 2017,2017-01-06 18:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xZg-yGOvHJM/a-winning-pharmaceutical-stock-for-2017-cm730524,The pharmaceutical sector is well known as one of the most volatile and lucrative stock market sectors It can also be the most emotionally rewarding as you invest in companies that are creating innovative life saving treatments for various illnesses But with high returns come
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 01/06/2017: MDCO, SNY, REGN, JNJ, PFE, ABT, MRK, AMGN",2017-01-06 14:37:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-FSw4rzCJ-4/health-care-sector-update-for-01062017-mdco-sny-regn-jnj-pfe-abt-mrk-amgn-cm730266,Top Health Care stocks Top Health Care stocks JNJ 0 1 JNJ 0 1 PFE flatPFE flat ABT 0 3 ABT 0 3 MRK flatMRK flat AMGN 4 6 AMGN 4 6 Health care shares were mixed in pre market trade Friday Health care shares were mixed in pre market trade Friday In health care stocks
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2017-01-03 22:22:16 +0000,http://biz.yahoo.com/e/170103/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Announces Management Change and Key Promotion,2017-01-03 21:03:23 +0000,http://www.publicnow.com/view/53EB5650F7F1CD27FD466A29AA8753FF90D7F664,"[at noodls] - 01.03.2017 - Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc.(Nasdaq:ALNY), ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Announces Management Change and Key Promotion,2017-01-03 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-announces-management-change-key-210000675.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that David-Alexandre ""DA"" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference,2017-01-03 13:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-presentation-35th-annual-130000147.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT at The Westin St."
ALNY,ALNY:UW,BBG000BFGYR2,Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals,2017-01-01 19:08:14 +0000,http://www.fool.com/investing/2016/12/31/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-ph.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals
ALNY,ALNY:UW,BBG000BFGYR2,Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals,2016-12-31 20:57:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mAbY-BiOxhs/better-buy-alnylam-pharmaceuticals-vs-ionis-pharmaceuticals-cm728243,Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine but it has been much less straightforward than biopharmaceutical companies had expected Two contenders in this area Alnylam
ALNY,ALNY:UW,BBG000BFGYR2,"Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today",2016-12-29 23:57:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mir5vmZtFwI/why-cliffs-natural-resources-groupon-and-alnylam-pharmaceuticals-slumped-today-cm727687,Thursday was another sluggish day on Wall Street with the Dow once again moving away from the 20 000 mark rather than toward it Most major market benchmarks were down slightly on the day as investors seemed content to coast into the end of the year as they wait to see whether things
ALNY,ALNY:UW,BBG000BFGYR2,"Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today",2016-12-29 22:46:00 +0000,http://www.fool.com/investing/2016/12/29/why-cliffs-natural-resources-groupon-and-alnylam-p.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Cliffs Natural Resources, Groupon, and Alnylam Pharmaceuticals Slumped Today"
ALNY,ALNY:UW,BBG000BFGYR2,Time for biotech to boom ... or bust?,2016-12-27 19:45:00 +0000,http://finance.yahoo.com/video/time-biotech-boom-bust-194500895.html,Time for biotech to boom ... or bust?
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : December 22, 2016",2016-12-22 12:28:00 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-alny-us-december-22-2016/,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : December 22, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals,2016-12-18 11:51:24 +0000,http://www.fool.com/investing/2016/12/17/better-buy-juno-therapeutics-vs-alnylam-pharmaceut.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals
ALNY,ALNY:UW,BBG000BFGYR2,Better Buy: Juno Therapeutics vs. Alnylam Pharmaceuticals,2016-12-17 12:56:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0mlwBFNuano/better-buy-juno-therapeutics-vs-alnylam-pharmaceuticals-cm722858,These aren t the best of times for Juno Therapeutics NASDAQ JUNO and Alnylam Pharmaceuticals NASDAQ ALNY Both have experienced major clinical setbacks this year Both biotechs have also lost over half of their market cap since then beginning of 2016 Which of these two
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy,2016-12-16 12:08:08 +0000,http://www.publicnow.com/view/A47A8AB0514F755FCB4714C3676928B44C333685,"[at noodls] - 12.16.2016 - Three Mid- to Late-Stage Programs Advancing Toward Potential Commercialization - - In Addition, Company Announces Positive Preliminary Results from Phase 1 Study of ALN-TTRsc02 - CAMBRIDGE, ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Announces Its Initial 2017 Pipeline Goals - Quick Facts,2016-12-16 07:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YcOFFnw4tH4/alnylam-pharma-announces-its-initial-2017-pipeline-goals--quick-facts-20161216-00166,Alnylam Pharma Announces Its Initial 2017 Pipeline Goals - Quick Facts
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals R&D Day At 8:00 AM ET,2016-12-16 06:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z93K1cZv66s/alnylam-pharmaceuticals-rd-day-at-800-am-et-20161216-00112,Alnylam Pharmaceuticals R&D Day At 8:00 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : December 13, 2016",2016-12-13 15:18:41 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-value-analysis-nasdaqalny-december-13-2016/,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : December 13, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,4 Red-Hot Biotechs Highlight Jefferies Top Stocks to Buy,2016-12-12 13:20:29 +0000,http://247wallst.com/healthcare-business/2016/12/12/4-red-hot-biotechs-highlight-jefferies-top-stocks-to-buy/,4 Red-Hot Biotechs Highlight Jefferies Top Stocks to Buy
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : December 12, 2016",2016-12-12 12:24:41 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-alny-us-december-12-2016/,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : December 12, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,Vetr Upgrades Alnylam On News Of Streamed Press Conference,2016-12-09 21:08:36 +0000,http://finance.yahoo.com/news/vetr-upgrades-alnylam-news-streamed-210836772.html,Vetr Upgrades Alnylam On News Of Streamed Press Conference
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast R&D Day,2016-12-08 21:00:00 +0000,http://finance.yahoo.com/news/alnylam-webcast-r-d-day-210000725.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the company’s website, www.alnylam.com, on the morning of December 16, 2016."
ALNY,ALNY:UW,BBG000BFGYR2,2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November,2016-12-07 18:57:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8dMWaYbry0g/2-reasons-why-alnylam-pharmaceuticals-stock-gained-185-in-november-cm718161,What happened According to data from S amp P Global Market Intelligence shares of the leading RNA interference drugmaker Alnylam Pharmaceuticals NASDAQ ALNY gained 18 5 last month The biotech s stock was lifted up by both the insurgent victory of Donald Trump
ALNY,ALNY:UW,BBG000BFGYR2,2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November,2016-12-07 17:24:05 +0000,http://www.fool.com/investing/2016/12/07/2-reasons-why-alnylam-pharmaceuticals-stock-gained.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Reasons Why Alnylam Pharmaceuticals Stock Gained 18.5% in November
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Hemophilia Drug Does Well In Study (ALNY),2016-12-06 15:15:00 +0000,http://www.investopedia.com/news/alnylam-reports-positive-hemophilia-drug-data-alny/?partner=YahooSA,Alnylam Hemophilia Drug Does Well In Study (ALNY)
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),2016-12-05 18:00:00 +0000,http://finance.yahoo.com/news/alnylam-presents-updated-results-phase-180000904.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component 5 for the treatment of complement-mediated diseases, in a poster presentation at the 58th Annual Meeting of the American Society of Hematology , held ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Positive Data on Fitusiran, Givosiran",2016-12-05 14:10:02 +0000,http://finance.yahoo.com/news/alnylam-reports-positive-data-fitusiran-141002646.html,"Alnylam Reports Positive Data on Fitusiran, Givosiran"
ALNY,ALNY:UW,BBG000BFGYR2,"ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC",2016-12-05 00:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GPggaNQCUwk/alny-in-motion-shire-finds-new-use-for-old-drug-tfx-snaps-up-vasc-20161205-00008,"ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC"
ALNY,ALNY:UW,BBG000BFGYR2,7 of the Most Shocking Biotech Pipeline Blowups of 2016,2016-12-04 18:04:17 +0000,http://www.fool.com/investing/2016/12/04/7-of-the-most-shocking-biotech-pipeline-blowups-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,7 of the Most Shocking Biotech Pipeline Blowups of 2016
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors,2016-12-04 17:00:00 +0000,http://finance.yahoo.com/news/alnylam-reports-positive-interim-clinical-170000853.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company today announced new positive results from its ongoing Phase 2 open-label extension study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B without inhibitors."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Says Positive Interim Results From Ongoing Study With Fitusiran,2016-12-04 01:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1cxPvBPL9uY/alnylam-pharma-says-positive-interim-results-from-ongoing-study-with-fitusiran-20161204-00001,Alnylam Pharma Says Positive Interim Results From Ongoing Study With Fitusiran
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors,2016-12-03 17:02:00 +0000,http://finance.yahoo.com/news/alnylam-reports-positive-interim-phase-170200799.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia with inhibitors."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",2016-12-03 17:00:00 +0000,http://finance.yahoo.com/news/alnylam-reports-positive-initial-clinical-170000833.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced positive initial results from Cohorts 1 and 2 of Part C of its Phase 1 study with givosiran , the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Hemophilia Drug Shows Early Success Among Hard-to-Treat,2016-12-03 14:00:00 +0000,http://www.bloomberg.com/news/articles/2016-12-03/alnylam-hemophilia-drug-shows-early-success-among-hard-to-treat?cmpid=yhoo.headline,Alnylam Hemophilia Drug Shows Early Success Among Hard-to-Treat
ALNY,ALNY:UW,BBG000BFGYR2,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline,2016-12-02 13:03:04 +0000,http://www.fool.com/investing/2016/12/01/3-things-you-need-to-know-about-ionis-pharmaceutic.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
ALNY,ALNY:UW,BBG000BFGYR2,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline,2016-12-01 14:17:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TeigZk1o1zc/3-things-you-need-to-know-about-ionis-pharmaceuticals-pipeline-cm716200,Few biotechs have as robust of a pipeline as Ionis Pharmaceuticals NASDAQ IONS The company has certainly experienced ups and downs in 2016 with its pipeline candidates but Ionis is ending the year on a good note Wade Walke vice president of corporate communications
ALNY,ALNY:UW,BBG000BFGYR2,"Is Alnylam Pharmaceuticals, Inc. (ALNY) A Good Stock To Buy Right Now?",2016-12-01 00:17:26 +0000,http://www.insidermonkey.com/blog/is-alnylam-pharmaceuticals-inc-alny-a-good-stock-to-buy-right-now-492950/,"Is Alnylam Pharmaceuticals, Inc. (ALNY) A Good Stock To Buy Right Now?"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Present At Piper Jaffray Conference; Webcast At 11:30 AM ET,2016-11-30 10:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pmIHiDUFHXw/alnylam-pharma-to-present-at-piper-jaffray-conference-webcast-at-1130-am-et-20161130-00697,Alnylam Pharma. To Present At Piper Jaffray Conference; Webcast At 11:30 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Commit To Buy Alnylam Pharmaceuticals At $35, Earn 19.1% Using Options",2016-11-22 18:20:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GwwqpZKEu9c/commit-to-buy-alnylam-pharmaceuticals-at-35-earn-191-using-options-cm712834,Investors considering a purchase of Alnylam Pharmaceuticals Inc Symbol ALNY stock but tentative about paying the going market price of 46 19 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
ALNY,ALNY:UW,BBG000BFGYR2,Analysts Forecast 20% Gains Ahead For The Holdings of FBT,2016-11-17 15:50:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdBzIEMb2nY/analysts-forecast-20-gains-ahead-for-the-holdings-of-fbt-cm710532,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 6:20 AM ET,2016-11-17 05:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bfMqnEw01aY/alnylam-pharma-to-participate-in-jefferies-healthcare-conference-at-620-am-et-20161117-00140,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 6:20 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 6:20 AM ET,2016-11-17 05:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2LVNdohDFtc/alnylam-pharma-to-participate-in-jefferies-healthcare-conference-at-620-am-et-20161117-00141,Alnylam Pharma. To Participate In Jefferies Healthcare Conference At 6:20 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster",2016-11-16 21:29:02 +0000,http://www.investors.com/news/technology/medicines-co-alnylam-split-on-amgen-rivaling-cholesterol-buster/,"Medicines Co., Alnylam Split On Amgen-Rivaling Cholesterol-Buster"
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved",2016-11-16 13:12:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-biotech-stocks-131201850.html,"Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At Stifel Healthcare Conference; Webcast At 9:30 AM ET,2016-11-16 08:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LRRrJdx8r5s/alnylam-pharma-to-present-at-stifel-healthcare-conference-webcast-at-930-am-et-20161116-00463,Alnylam Pharma To Present At Stifel Healthcare Conference; Webcast At 9:30 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si),2016-11-15 17:38:17 +0000,http://www.publicnow.com/view/DEF7E33466B78B042451EF73C0615EBB6EAFFD54,"[at noodls] - 11.15.2016 -Study meets all interim analysis goals- -A single injection of inclisiran (300 mg) lowered 'bad cholesterol' (LDL-C) by an average of 51%, and up to 76%- -Two injections of inclisiran (300 ..."
ALNY,ALNY:UW,BBG000BFGYR2,Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.,2016-11-15 16:31:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BsDv5OCn-Uo/sanofi-opts-into-alnylams-fitusiran-hemophilia-program-in-us-cm709457,Alnylam Pharmaceuticals Inc ALNY announced that Genzyme the specialty care global business unit of Sanofi SNY has elected to opt in to co develop and co commercialize fitusiran in the United States Canada and Western Europe Notably Fitusiran is an investigational RNA
ALNY,ALNY:UW,BBG000BFGYR2,Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.,2016-11-15 13:53:01 +0000,http://finance.yahoo.com/news/sanofi-opts-alnylams-fitusiran-hemophilia-135301377.html,Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision for Co-Development and Co-Commercialization of Fitusiran in Hemophilia and Rare Bleeding Disorders,2016-11-14 13:07:04 +0000,http://www.publicnow.com/view/4A392AAA1419A35D19527B2B088FE5B39DBD20BA,"[at noodls] - 11.14.2016 - Sanofi Genzyme Elects not to Opt in for ALN-AS1 in Acute Hepatic Porphyrias - - Alnylam Intends to Commercialize ALN-AS1 Globally upon Product Approval - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam : Sanofi Genzyme Opt-in Decision For Co-Commercialization Of Fitusiran,2016-11-14 08:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/avCDlvZbc3k/alnylam--sanofi-genzyme-optin-decision-for-cocommercialization-of-fitusiran-20161114-00490,Alnylam : Sanofi Genzyme Opt-in Decision For Co-Commercialization Of Fitusiran
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine,2016-11-13 22:57:10 +0000,http://www.publicnow.com/view/C376A912C3D1572102C50DDC30879ED811EB9009,[at noodls] - Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine The text version of this document is ...
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine,2016-11-13 21:56:00 +0000,http://finance.yahoo.com/news/alnylam-pharmaceuticals-medicines-company-announce-215600033.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, and The Medicines Company , a leading biopharmaceutical development and cardiovascular product company, today announced that results from the Phase 1 study of inclisiran , the recommended International Nonproprietary Name for ALN-PCSsc, were published in The New England Journal of Medicine ."
ALNY,ALNY:UW,BBG000BFGYR2,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 20:55:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8wMDZU5MkI/why-these-biotechs-saw-double-digit-gains-today-cm706737,Image source Getty Images What happened ImmunoGen NASDAQ IMGN Seattle Genetics NASDAQ SGEN Exelixis NASDAQ EXEL Alnylam Pharmaceuticals NASDAQ ALNY Momenta Pharmaceuticals NASDAQ MNTA and bluebird bio NASDAQ BLUE are all up at
ALNY,ALNY:UW,BBG000BFGYR2,Why These Biotechs Saw Double-Digit Gains Today,2016-11-09 19:25:20 +0000,http://www.fool.com/investing/2016/11/09/why-these-biotechs-saw-double-digit-gains-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why These Biotechs Saw Double-Digit Gains Today
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October",2016-11-08 17:37:34 +0000,http://www.fool.com/investing/2016/11/07/why-alnylam-pharmaceuticals-inc-took-a-475-dive-in.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October"
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October",2016-11-07 19:13:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UNz5fpqrKKE/why-alnylam-pharmaceuticals-inc-took-a-475-dive-in-october-cm705135,Image source Getty Images What happened Shares of RNA interference hopeful Alnylam Pharmaceuticals Inc NASDAQ ALNY 160 took a 47 5 leap downward in October according to data from S amp P Global Market Intelligence Bad news from data monitors caused
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Present At Credit Suisse Conference; Webcast At 12:30 PM ET,2016-11-07 11:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OPIiqHI9I0/alnylam-pharma-to-present-at-credit-suisse-conference-webcast-at-1230-pm-et-20161107-00923,Alnylam Pharma. To Present At Credit Suisse Conference; Webcast At 12:30 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data",2016-11-05 20:27:32 +0000,http://www.fool.com/investing/2016/11/04/alnylam-pharmaceuticals-inc-discloses-deaths-waits.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data",2016-11-04 21:48:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ifcUVC7Z2b0/alnylam-pharmaceuticals-inc-discloses-deaths-waits-for-more-data-cm704399,Image source Getty Images Alnylam Pharmaceuticals NASDAQ ALNY fell 12 6 on Thursday after reporting earnings Wednesday afternoon but it s recovered some of that today Of course it wasn t the actual earnings that caused the decline for the record the biotech lost
ALNY,ALNY:UW,BBG000BFGYR2,Friday's ETF with Unusual Volume: BBH,2016-11-04 18:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WoOGlq7FBns/fridays-etf-with-unusual-volume-bbh-cm704304,The Biotech ETF BBH is seeing unusually high volume in afternoon trading Friday with over 219 000 shares traded versus three month average volume of about 71 000 Shares of BBH were up about 1 5 on the day Components of that ETF with the highest volume on Friday were
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Slid 12.6% Today After Earnings,2016-11-03 23:08:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q40_KX3pedw/alnylam-pharmaceuticals-slid-126-today-after-earnings-cm703717,Image source Getty Images What happened Leading RNA interference RNAi company Alnylam Pharmaceuticals NASDAQ ALNY slid nearly 13 today after announcing third quarter 2016 earnings when the market closed yesterday So what This was the first major update provided since
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Slid 12.6% Today After Earnings,2016-11-03 21:07:11 +0000,http://www.fool.com/investing/2016/11/03/alnylam-pharmaceuticals-slid-126-today-after-earni.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Alnylam Pharmaceuticals Slid 12.6% Today After Earnings
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report",2016-11-03 20:06:05 +0000,http://biz.yahoo.com/e/161103/alny10-q.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report"
ALNY,ALNY:UW,BBG000BFGYR2,​Alnylam gives details on patient deaths in abandoned drug trial,2016-11-03 15:20:11 +0000,http://www.bizjournals.com/boston/news/2016/11/03/alnylam-gives-details-on-patient-deaths-in.html?ana=yahoo,​Alnylam gives details on patient deaths in abandoned drug trial
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up",2016-11-03 14:10:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0VuEQ4cZeFQ/alnylam-alny-q3-loss-wider-than-expected-revenues-up-cm703253,Alnylam Pharmaceuticals Inc ALNY reported a loss of 1 21 per share in the third quarter of 2016 wider than both the Zacks Consensus Estimate of a loss of 1 19 and the year ago figure of 91 cents FindTheCompany Graphiq Quarterly revenues on the other hand
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Present New Clinical Results at 58th Annual Meeting of the American Society of Hematology (ASH),2016-11-03 13:00:00 +0000,http://finance.yahoo.com/news/alnylam-present-clinical-results-58th-130000139.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present new results from clinical studies of three of its investigational RNAi therapeutics – fitusiran, ALN-AS1 and ALN-CC5 – at the 58th Annual Meeting of the American Society of Hematology being held December 3-6, 2016 in San Diego, California."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up",2016-11-03 12:45:12 +0000,http://finance.yahoo.com/news/alnylam-alny-q3-loss-wider-124512047.html,"Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up"
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 2-Nov-16 8:30pm GMT,2016-11-03 04:11:44 +0000,http://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-041144830.html,Edited Transcript of ALNY earnings conference call or presentation 2-Nov-16 8:30pm GMT
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 3Q loss,2016-11-02 20:57:38 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-3q-loss-205738592.html,Alnylam reports 3Q loss
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements",2016-11-02 20:12:39 +0000,http://biz.yahoo.com/e/161102/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity,2016-11-02 20:10:39 +0000,http://www.publicnow.com/view/16BA3DA4658ED2CD3207502D24D737F36FF77727,"[at noodls] - 11.02.2016 - Advanced RNAi Therapeutics Pipeline with Eight Active Clinical Programs and Multiple Clinical Data Presentations - - Discontinued Revusiran Development, Focusing on Patisiran and ESC-GalNAc ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Q3 16 Earnings Conference Call At 4:30 PM ET,2016-11-02 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r0SoSXnXh6s/alnylam-pharmaceuticals-q3-16-earnings-conference-call-at-430-pm-et-20161102-00551,Alnylam Pharmaceuticals Q3 16 Earnings Conference Call At 4:30 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close,2016-11-02 11:07:05 +0000,http://biz.yahoo.com/research/earncal/20161102.html?t=alny,Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close
ALNY,ALNY:UW,BBG000BFGYR2,"Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More",2016-11-01 12:20:12 +0000,http://finance.yahoo.com/news/drug-stocks-watch-earnings-nov-122012908.html,"Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming November Investor Conferences,2016-10-31 20:13:24 +0000,http://www.publicnow.com/view/AB56E965AFF6481C1FA87C833C39223E4BEC1C01,"[at noodls] - 10.31.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Lifshitz & Miller Law Firm Announces Investigation of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics,",2016-10-28 21:46:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-214600292.html,"[PR Newswire] - NEW YORK, Oct. 28, 2016 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation on behalf of ALNY investors. The investigation concerns whether ALNY adequately disclosed ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing Third Quarter 2016 Financial Results,2016-10-26 20:05:06 +0000,http://www.publicnow.com/view/C1CCBF89B02FA585845D1ACFBA2045B52743CBC8,"[at noodls] - 10.26.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ..."
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm",2016-10-25 14:51:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-145100966.html,"[Business Wire] - Khang & Khang LLP announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
ALNY,ALNY:UW,BBG000BFGYR2,Why Investors Should Take Another Look At Alnylam Pharmaceuticals,2016-10-24 19:31:19 +0000,http://finance.yahoo.com/news/why-investors-another-look-alnylam-193119603.html,Why Investors Should Take Another Look At Alnylam Pharmaceuticals
ALNY,ALNY:UW,BBG000BFGYR2,5 Stocks Insiders Love Right Now,2016-10-23 15:20:00 +0000,https://www.thestreet.com/story/13859356/1/5-stocks-insiders-love-right-now.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Insiders Love Right Now
ALNY,ALNY:UW,BBG000BFGYR2,"Famous Investor Continues Large Insider Buying: Lands’ End, Cree, Alnylam Pharmaceuticals, Cheniere Energy and More",2016-10-23 14:20:50 +0000,http://finance.yahoo.com/news/famous-investor-continues-large-insider-142050777.html,"Famous Investor Continues Large Insider Buying: Lands’ End, Cree, Alnylam Pharmaceuticals, Cheniere Energy and More"
ALNY,ALNY:UW,BBG000BFGYR2,The Medicines Co. Reports Positive Phase II Data on PCSK9si,2016-10-19 13:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XHtPaNtTCpE/the-medicines-co-reports-positive-phase-ii-data-on-pcsk9si-cm695305,The Medicines Company MDCO announced positive top line results from a Day 90 interim analysis of the ongoing ORION 1 phase II study of its pipeline candidate PCSK9si for the treatment of hypercholesterolemia PCSK9si earlier known as ALN PCSsc is a first in class
ALNY,ALNY:UW,BBG000BFGYR2,"Monday 10/17 Insider Buying Report: ALNY, RHP",2016-10-17 15:40:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g30Y0QJNmZ8/monday-1017-insider-buying-report-alny-rhp-cm694096,Bargain hunters are wise to pay careful attention to insider buying because although there are many various reasons for an insider to sell a stock presumably the only reason they would use their hard earned cash to make a purchase is that they expect to make money Today we look at
ALNY,ALNY:UW,BBG000BFGYR2,"SYNNEX, Hibbett Sports, and Alnylam Among 5 Stocks With Notable Insider Trading",2016-10-17 15:15:16 +0000,http://www.insidermonkey.com/blog/synnex-hibbett-sports-and-alnylam-among-5-stocks-with-notable-insider-trading-481639/,"SYNNEX, Hibbett Sports, and Alnylam Among 5 Stocks With Notable Insider Trading"
ALNY,ALNY:UW,BBG000BFGYR2,Surprising Analyst 12-Month Target For FBT,2016-10-17 13:41:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr-UILaU7EY/surprising-analyst-12-month-target-for-fbt-cm693974,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
ALNY,ALNY:UW,BBG000BFGYR2,Weekly Top Insider Buys Highlight for Week of Oct. 14,2016-10-16 23:35:31 +0000,http://finance.yahoo.com/news/weekly-top-insider-buys-highlight-233531020.html,Weekly Top Insider Buys Highlight for Week of Oct. 14
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) to Continue Phase III Study on Patisiran,2016-10-12 14:42:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIjah7JiKzM/alnylam-alny-to-continue-phase-iii-study-on-patisiran-cm692365,Alnylam Pharmaceuticals Inc ALNY announced that the Data Monitoring Committee DMC has recommended the continuation of the phase III APOLLO study on patisiran without any modification However the committee also stated that it will periodically meet to monitor the overall safety of
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 14:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xRxdEZs_O1o/biotech-stock-roundup-alnylam-slumps-on-revusiran-update-tesaro-impresses-at-esmo-cm692293,Alnylam ALNY focused on developing novel therapeutics based on RNA interference RNAi saw its shares slump on its decision to discontinue the development of a late stage pipeline candidate Meanwhile several biotech companies were present at the congress of the European Society for
ALNY,ALNY:UW,BBG000BFGYR2,Top Biotech Plays Highlight Jefferies Growth Stocks to Buy,2016-10-12 13:55:50 +0000,http://247wallst.com/healthcare-business/2016/10/12/top-biotech-plays-highlight-jefferies-growth-stocks-to-buy/,Top Biotech Plays Highlight Jefferies Growth Stocks to Buy
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) to Continue Phase III Study on Patisiran,2016-10-12 13:21:01 +0000,http://finance.yahoo.com/news/alnylam-alny-continue-phase-iii-132101604.html,Alnylam (ALNY) to Continue Phase III Study on Patisiran
ALNY,ALNY:UW,BBG000BFGYR2,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 12:39:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alnylam-slumps-123912498.html,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation,2016-10-10 19:06:00 +0000,https://www.thestreet.com/story/13847612/1/alnylam-pharmaceuticals-alny-stock-gains-on-late-stage-trial-continuation.html?puc=yahoo&cm_ven=YAHOO,Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.",2016-10-10 15:21:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uv8QkimZeNw/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-cm691031,IMAGE SOURCE GETTY IMAGES You might think that a biotech with a recent FDA regulatory win would automatically be a better investing pick than another biotech with no approved products That s sometimes the case but not always Sarepta Therapeutics NASDAQ SRPT now has
ALNY,ALNY:UW,BBG000BFGYR2,Kamada (KMDA) Extends Partnership with Shire for Glassia,2016-10-10 15:20:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ATtwZjtW_j8/kamada-kmda-extends-partnership-with-shire-for-glassia-cm690983,Kamada Ltd KMDA announced that it has extended the strategic partnership with Shire plc SHPG for Glassia for the fourth time since 2010 Glassia a ready to infuse liquid alpha1 proteinase inhibitor was approved in the U S in 2010 for the treatment of adults with clinically
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.",2016-10-10 15:00:07 +0000,http://www.fool.com/investing/2016/10/10/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc."
ALNY,ALNY:UW,BBG000BFGYR2,"Stocks to Watch: Mylan, Twitter, Dover",2016-10-10 14:12:34 +0000,http://blogs.wsj.com/moneybeat/2016/10/10/stocks-to-watch-mylan-twitter-dover/?mod=yahoo_hs,"Stocks to Watch: Mylan, Twitter, Dover"
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt,2016-10-10 12:35:34 +0000,http://www.wsj.com/articles/alnylam-says-trial-of-patisiran-can-continue-following-revusiran-halt-1476101991?mod=yahoo_hs,[$$] Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt
ALNY,ALNY:UW,BBG000BFGYR2,Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN),2016-10-10 11:13:10 +0000,http://www.publicnow.com/view/100513771D972FCB098421031B19546C94B1257E,"[at noodls] - 10.10.2016 - Expected Top-line Data Readout Remains Unchanged in Mid-2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt,2016-10-10 09:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BSdfv_BCrfM/alnylam-says-trial-of-patisiran-can-continue-following-revusiran-halt-20161010-00358,Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Says DMC Recommends Continuation Of Phase 3 Trial Of  Patisiran,2016-10-10 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7fhqjZM8VbI/alnylam-says-dmc-recommends-continuation-of-phase-3-trial-of--patisiran-20161010-00185,Alnylam Says DMC Recommends Continuation Of Phase 3 Trial Of  Patisiran
ALNY,ALNY:UW,BBG000BFGYR2,5 Companies That Destroyed Shareholders This Past Week,2016-10-08 13:55:53 +0000,http://247wallst.com/investing/2016/10/08/5-companies-that-destroyed-shareholders-this-past-week-2/,5 Companies That Destroyed Shareholders This Past Week
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's RNAi Failure Could Catch Monsanto Investors Off Guard,2016-10-07 21:43:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_FzBGnOjgz0/alnylams-rnai-failure-could-catch-monsanto-investors-off-guard-cm690548,Image source Getty Images The Nobel Prize made headlines on two occasions this week albeit for very different reasons As a handful of scientists across the globe joined an exclusive club of laureates the technology awarded the Nobel Prize in Physiology or Medicine in 2006 suffered
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's RNAi Failure Could Catch Monsanto Investors Off Guard,2016-10-07 20:22:06 +0000,http://www.fool.com/investing/2016/10/07/alnylams-rnai-failure-could-catch-monsanto-investo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Alnylam's RNAi Failure Could Catch Monsanto Investors Off Guard
ALNY,ALNY:UW,BBG000BFGYR2,"Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)",2016-10-07 18:13:39 +0000,http://www.insidermonkey.com/blog/heres-what-happened-with-alnylam-pharmaceuticals-inc-alny-and-tenax-therapeutics-inc-tenx-479440/,"Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)"
ALNY,ALNY:UW,BBG000BFGYR2,"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?",2016-10-07 15:46:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pMxfuBstiWo/whats-next-for-alnylam-pharmaceuticals-inc-after-its-phase-3-failure-cm690338,Image source Getty Images Another once promising drug has failed Alnylam Pharmaceuticals NASDAQ ALNY announced on Oct 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy hATTR CM The drug had been in a late
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades",2016-10-07 15:30:00 +0000,https://www.thestreet.com/story/13845989/1/alnylam-pharmaceuticals-alny-stock-lower-as-drug-development-stopped-downgrades.html?puc=yahoo&cm_ven=YAHOO,"Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam's Prospects Today,2016-10-07 15:00:00 +0000,http://finance.yahoo.com/news/alnylams-prospects-today-150000566.html,Alnylam's Prospects Today
ALNY,ALNY:UW,BBG000BFGYR2,"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?",2016-10-07 14:28:00 +0000,http://www.fool.com/investing/2016/10/07/whats-next-for-alnylam-pharmaceuticals-inc-after-i.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?"
ALNY,ALNY:UW,BBG000BFGYR2,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : October 7, 2016",2016-10-07 13:41:33 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-october-7-2016/,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : October 7, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,"Top Analyst Upgrades and Downgrades: AMD, Cliffs, Gap, KLA-Tencor, Regions Financial, Tyson Foods, Wal-Mart and More",2016-10-07 12:20:27 +0000,http://247wallst.com/investing/2016/10/07/top-analyst-upgrades-and-downgrades-amd-cliffs-gap-kla-tencor-regions-financial-tyson-foods-wal-mart-and-more/,"Top Analyst Upgrades and Downgrades: AMD, Cliffs, Gap, KLA-Tencor, Regions Financial, Tyson Foods, Wal-Mart and More"
ALNY,ALNY:UW,BBG000BFGYR2,"Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More",2016-10-07 12:12:00 +0000,http://finance.yahoo.com/news/analysts-actions-advanced-micro-alnylam-121200435.html,"Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More"
ALNY,ALNY:UW,BBG000BFGYR2,UPDATE: Alnylam: A $2.8 Billion Bad Day,2016-10-06 21:45:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/06/alnylam-a-2-8-billion-bad-day/?mod=yahoobarrons&ru=yahoo,UPDATE: Alnylam: A $2.8 Billion Bad Day
ALNY,ALNY:UW,BBG000BFGYR2,"INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",2016-10-06 21:23:00 +0000,http://finance.yahoo.com/news/investor-alert-goldberg-law-pc-212300665.html,"[Business Wire] - Goldberg Law PC announces that it is investigating Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 10/06/2016: PFE,PHMD,ALNY",2016-10-06 20:23:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MJR-Hkvecgg/health-care-sector-update-for-10062016-pfephmdalny-cm690025,Top Health Care StocksTop Health Care Stocks JNJ 0 57 JNJ 0 57 PFE 1 08 PFE 1 08 MRK 0 30 MRK 0 30 ABT 0 79 ABT 0 79 AMGN 0 35 AMGN 0 35 Health care stocks and in particular shares of drug companies continued to lose ground this afternoon dragging on the broader U S
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Halts Drug Testing After 18 Deaths; Value Seen In Cousin Drug,2016-10-06 20:15:41 +0000,http://www.investors.com/news/technology/alnylam-halts-drug-testing-after-18-deaths-still-value-in-cousin-drug/,Alnylam Halts Drug Testing After 18 Deaths; Value Seen In Cousin Drug
ALNY,ALNY:UW,BBG000BFGYR2,Credit Suisse Concerned Alnylam's Revusiran Trial Suspension Could Have Broader Pipeline Implications,2016-10-06 20:13:07 +0000,http://finance.yahoo.com/news/credit-suisse-concerned-alnylams-revusiran-201307853.html,Credit Suisse Concerned Alnylam's Revusiran Trial Suspension Could Have Broader Pipeline Implications
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam, Mylan Tumble into Thursday’s 52-Week Low Club",2016-10-06 20:04:49 +0000,http://247wallst.com/investing/2016/10/06/alnylam-mylan-tumble-into-thursdays-52-week-low-club/,"Alnylam, Mylan Tumble into Thursday’s 52-Week Low Club"
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Afternoon Market Update: Crude Oil Up 1.5%; Alnylam Pharma Shares Tumble On Revusiran Termination,2016-10-06 20:03:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1vdXtjBkWTE/mid-afternoon-market-update-crude-oil-up-15-alnylam-pharma-shares-tumble-on-revusiran-termination-cm690024,Toward the end of trading Thursday the Dow traded down 0 05 percent to 18 271 28 while the NASDAQ declined 0 11 percent to 5 310 15 However the S amp P 500 gained 0 10 percent to 2 161 89 Leading and Lagging Sectors Thursday afternoon energy shares gained by 0 67
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)",2016-10-06 19:44:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-194400616.html,"[PR Newswire] - NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Alnylam Pharmaceuticals, Inc. (""Alnylam"" ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Tanks By Half (ALNY),2016-10-06 19:41:00 +0000,http://www.investopedia.com/news/alnylam-tanks-half-alny/?partner=YahooSA,Alnylam Tanks By Half (ALNY)
ALNY,ALNY:UW,BBG000BFGYR2,Biotech ETFs Punished For Owning Alnylam,2016-10-06 19:21:00 +0000,http://blogs.barrons.com/focusonfunds/2016/10/06/biotech-etfs-punished-for-owning-alnylam/?mod=yahoobarrons&ru=yahoo,Biotech ETFs Punished For Owning Alnylam
ALNY,ALNY:UW,BBG000BFGYR2,Why The Medicines Company's Share Price Got Sick Today,2016-10-06 18:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aZxBPB7hZ6c/why-the-medicines-companys-share-price-got-sick-today-cm689946,Image source Getty Images What happened The Medicines Company NASDAQ MDCO is down 11 at 12 39 p m EDT after its partner Alnylam Pharmaceuticals NASDAQ ALNY announced yesterday afternoon that it s stopping development of one of its drug candidates revusiran
ALNY,ALNY:UW,BBG000BFGYR2,Here's a Reason Why Ionis Pharmaceuticals (IONS) Stock Is Slumping Today,2016-10-06 18:31:00 +0000,https://www.thestreet.com/story/13844806/1/here-s-a-reason-why-ionis-pharmaceuticals-ions-stock-is-slumping-today.html?puc=yahoo&cm_ven=YAHOO,Here's a Reason Why Ionis Pharmaceuticals (IONS) Stock Is Slumping Today
ALNY,ALNY:UW,BBG000BFGYR2,Biotech's bad year,2016-10-06 18:17:00 +0000,http://finance.yahoo.com/video/biotechs-bad-181700529.html,Biotech's bad year
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam’s discontinued drug raises bigger question about buzzy RNAi approach,2016-10-06 18:06:58 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=36360712-8BC5-11E6-9D07-90B77F20304B&siteid=yhoof2,Alnylam’s discontinued drug raises bigger question about buzzy RNAi approach
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 10/06/2016: SCYX, PHMD, ALNY, SLRC",2016-10-06 18:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5WP0GpIjB4M/health-care-sector-update-for-10062016-scyx-phmd-alny-slrc-cm689949,Top Health Care StocksTop Health Care Stocks JNJ 0 51 JNJ 0 51 PFE 0 94 PFE 0 94 MRK 0 30 MRK 0 30 ABT 1 04 ABT 1 04 AMGN 0 19 AMGN 0 19 Health care stocks and in particular shares of drug companies were dragging on the broader U S markets with the NYSE Health Care
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc. and Certain Officers and Directors",2016-10-06 18:03:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-180300928.html,"[Business Wire] - Levi & Korsinsky, LLP announces that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors."
ALNY,ALNY:UW,BBG000BFGYR2,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",2016-10-06 17:55:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-175500473.html,"[Business Wire] - Lundin Law PC announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide,2016-10-06 17:33:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hYlh4Ipg2a0/mid-day-market-update-aurinia-pharmaceuticals-gains-on-aurion-data-twitter-shares-slide-cm689938,Midway through trading Thursday the Dow traded down 0 10 percent to 18 263 74 while the NASDAQ declined 0 12 percent to 5 309 47 The S amp P also fell dropping 0 03 percent to 2 160 42 Leading and Lagging Sectors On Thursday non cyclical consumer goods amp services
ALNY,ALNY:UW,BBG000BFGYR2,Why The Medicines Company's Share Price Got Sick Today,2016-10-06 17:17:23 +0000,http://www.fool.com/investing/2016/10/06/why-the-medicines-companys-share-price-got-sick-to.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why The Medicines Company's Share Price Got Sick Today
ALNY,ALNY:UW,BBG000BFGYR2,A biotech company erased $3 billion in value overnight after one of its drugs failed a key trial,2016-10-06 17:12:05 +0000,http://finance.yahoo.com/news/biotech-company-lost-3-billion-171205784.html,A biotech company erased $3 billion in value overnight after one of its drugs failed a key trial
ALNY,ALNY:UW,BBG000BFGYR2,U.S. Stocks Flat Ahead of Jobs Report,2016-10-06 16:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CE0jpaaSUaI/us-stocks-flat-ahead-of-jobs-report-20161006-00976,U.S. Stocks Flat Ahead of Jobs Report
ALNY,ALNY:UW,BBG000BFGYR2,​Here’s what a more than $2B loss in market value at Alnylam could mean locally,2016-10-06 16:38:59 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/10/here-s-what-a-more-than-2b-loss-in-market-value.html?ana=yahoo,​Here’s what a more than $2B loss in market value at Alnylam could mean locally
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Little Changed Ahead of Jobs Report,2016-10-06 16:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n-XHEuUn27o/stocks-little-changed-ahead-of-jobs-report-20161006-00952,Stocks Little Changed Ahead of Jobs Report
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Close Roughly Flat Ahead Of Monthly Jobs Data - U.S. Commentary,2016-10-06 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hkk2yDQIHQU/stocks-close-roughly-flat-ahead-of-monthly-jobs-data--us-commentary-20161006-00943,Stocks Close Roughly Flat Ahead Of Monthly Jobs Data - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,Is Medicines Co. Getting Infected by Alnylam's Woes?,2016-10-06 16:15:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/06/is-medicines-co-getting-infected-by-alnylams-woes/?mod=yahoobarrons&ru=yahoo,Is Medicines Co. Getting Infected by Alnylam's Woes?
ALNY,ALNY:UW,BBG000BFGYR2,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY",2016-10-06 16:01:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-160100091.html,"[PR Newswire] - NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (""Alnylam"" or the ""Company"") (ALNY) (ISIN:US02043Q1076). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Alnylam and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934."
ALNY,ALNY:UW,BBG000BFGYR2,Why Alnylam Pharmaceuticals Is Getting Crushed Today,2016-10-06 15:47:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2SyJXivXIPM/why-alnylam-pharmaceuticals-is-getting-crushed-today-cm689782,Image source Getty Images What happened Shares of drugmaker Alnylam Pharmaceuticals NASDAQ ALNY which uses RNA interference RNAi technology dropped by more than 44 in pre market trading today due to a major clinical setback In short management decided to nix
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Crashes on Discontinued Late-Stage Trial,2016-10-06 15:35:26 +0000,http://finance.yahoo.com/news/alnylam-pharma-crashes-discontinued-stage-153526407.html,Alnylam Pharma Crashes on Discontinued Late-Stage Trial
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Swing Between Slight Gains and Losses,2016-10-06 15:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e2lazoIK58c/stocks-swing-between-slight-gains-and-losses-20161006-00800,Stocks Swing Between Slight Gains and Losses
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Morning Market Update: Markets Open Lower; Yum! Brands Sales Miss Estimates,2016-10-06 15:28:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3NL1RjvyDxQ/mid-morning-market-update-markets-open-lower-yum-brands-sales-miss-estimates-cm689800,Following the market opening Thursday the Dow traded down 0 64 percent to 18 164 68 while the NASDAQ declined 0 50 percent to 5 289 41 The S amp P also fell dropping 0 36 percent to 2 151 97 Leading and Lagging Sectors Thursday morning energy shares gained by 0 50
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded",2016-10-06 15:18:00 +0000,https://www.thestreet.com/story/13844235/1/alnylam-pharma-alny-stock-tumbles-on-discontinued-drug-downgraded.html?puc=yahoo&cm_ven=YAHOO,"Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Discontinues Phase III Study on Revusiran,2016-10-06 14:46:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1G3tzmtI3_A/alnylam-alny-discontinues-phase-iii-study-on-revusiran-cm689651,Alnylam Pharmaceuticals Inc ALNY announced that it has discontinued the phase III ENDEAVOUR study on revusiran for the treatment of hereditary ATTR amyloidosis hATTR with cardiomyopathy hATTR CM also known as familial amyloidotic cardiomyopathy FAC We expect investors to
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector,2016-10-06 14:33:00 +0000,https://www.thestreet.com/story/13843510/1/alnylam-gene-silencing-drug-blows-up-damage-could-spread-deep-into-biotech-sector.html?puc=yahoo&cm_ven=YAHOO,Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam shares plunge on abandoned study,2016-10-06 14:08:50 +0000,http://sg.finance.yahoo.com/news/alnylam-shares-plunge-abandoned-study-122306988.html,Alnylam shares plunge on abandoned study
ALNY,ALNY:UW,BBG000BFGYR2,Why Alnylam Pharmaceuticals Is Getting Crushed Today,2016-10-06 13:45:50 +0000,http://www.fool.com/investing/2016/10/06/why-alnylam-pharmaceuticals-is-getting-crushed-tod.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Alnylam Pharmaceuticals Is Getting Crushed Today
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns,2016-10-06 13:09:16 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C5BCF9BE-F24B-4B5F-A7F2-66961E5AAEDB&siteid=yhoof2,Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Discontinues Phase III Study on Revusiran,2016-10-06 13:00:01 +0000,http://finance.yahoo.com/news/alnylam-alny-discontinues-phase-iii-130001634.html,Alnylam (ALNY) Discontinues Phase III Study on Revusiran
ALNY,ALNY:UW,BBG000BFGYR2,"Pre-Market Most Active for Oct 6, 2016 :  TWTR, KLAC, AUPH, SNY, CRM, ALNY, RDS/B, NOK, LRCX, WMT, MDCO, JD",2016-10-06 12:53:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5k1OPsId62M/pre-market-most-active-for-oct-6-2016-twtr-klac-auph-sny-crm-alny-rdsb-nok-lrcx-wmt-mdco-jd-cm689589,The NASDAQ 100 Pre Market Indicator is up 19 to 4 877 94 The total Pre Market volume is currently 11 202 484 shares traded The following are the most active stocks for the pre market session Twitter Inc TWTR is 3 97 at 20 90 with 7 159 866 shares traded TWTR
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Has Had Its Share Of Recent Pipeline Setbacks; Barclays Cuts PT To $50,2016-10-06 12:44:18 +0000,http://finance.yahoo.com/news/alnylam-had-share-recent-pipeline-124418015.html,Alnylam Has Had Its Share Of Recent Pipeline Setbacks; Barclays Cuts PT To $50
ALNY,ALNY:UW,BBG000BFGYR2,Stock Futures Edge Lower as Jobless Claims Fall,2016-10-06 12:38:00 +0000,https://www.thestreet.com/story/13842998/1/stock-futures-edge-lower-ahead-of-friday-s-u-s-jobs-report.html?puc=yahoo&cm_ven=YAHOO,Stock Futures Edge Lower as Jobless Claims Fall
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Remains Sharply Lower After Initial Drop,2016-10-06 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvxEZumflTg/alnylam-remains-sharply-lower-after-initial-drop-20161006-00726,Alnylam Remains Sharply Lower After Initial Drop
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Nearly Flat After Recovering From Early Weakness - U.S. Commentary,2016-10-06 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RaHRAWr0cEc/stocks-nearly-flat-after-recovering-from-early-weakness--us-commentary-20161006-00714,Stocks Nearly Flat After Recovering From Early Weakness - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,"Analysts' Actions -- Alnylam, AutoNation, Tesla and More",2016-10-06 12:11:00 +0000,http://finance.yahoo.com/news/analysts-actions-alnylam-autonation-tesla-121100349.html,"Analysts' Actions -- Alnylam, AutoNation, Tesla and More"
ALNY,ALNY:UW,BBG000BFGYR2,Executive Edge: Mall of America to close on Thanksgiving ...,2016-10-06 10:42:00 +0000,http://finance.yahoo.com/video/executive-edge-mall-america-close-104200151.html,Executive Edge: Mall of America to close on Thanksgiving ...
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Move Back To The Downside Ahead Of Jobs Report - U.S. Commentary,2016-10-06 10:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yellFVy_nc8/stocks-move-back-to-the-downside-ahead-of-jobs-report--us-commentary-20161006-00606,Stocks Move Back To The Downside Ahead Of Jobs Report - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals (ALNY) Has Plunged To A New Low On Revusiran News,2016-10-06 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoN7rjXvUok/alnylam-pharmaceuticals-alny-has-plunged-to-a-new-low-on-revusiran-news-20161006-00531,Alnylam Pharmaceuticals (ALNY) Has Plunged To A New Low On Revusiran News
ALNY,ALNY:UW,BBG000BFGYR2,"Why Yum, Booz Allen Hamilton, Alnylam, and More Are in the Spotlight",2016-10-06 04:32:26 +0000,http://www.insidermonkey.com/blog/why-yum-booz-allen-hamilton-alnylam-and-more-are-in-the-spotlight-478914/,"Why Yum, Booz Allen Hamilton, Alnylam, and More Are in the Spotlight"
ALNY,ALNY:UW,BBG000BFGYR2,U.S. Stocks Steady Ahead of Jobs Report,2016-10-06 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9wfGDQkRAKQ/us-stocks-steady-ahead-of-jobs-report-20161006-00997,U.S. Stocks Steady Ahead of Jobs Report
ALNY,ALNY:UW,BBG000BFGYR2,"U.S. Stocks Mixed as Bonds Slip, Oil Rises",2016-10-06 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CMiKaaLTP64/us-stocks-mixed-as-bonds-slip-oil-rises-20161006-00766,"U.S. Stocks Mixed as Bonds Slip, Oil Rises"
ALNY,ALNY:UW,BBG000BFGYR2,U.S. Stocks Mixed Ahead of Jobs Data,2016-10-06 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3cB_AIAT8FA/us-stocks-mixed-ahead-of-jobs-data-20161006-00781,U.S. Stocks Mixed Ahead of Jobs Data
ALNY,ALNY:UW,BBG000BFGYR2,U.S. Stocks Decline Ahead of Friday's Jobs Report,2016-10-06 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/czNTpU1sEZQ/us-stocks-decline-ahead-of-fridays-jobs-report-20161006-00715,U.S. Stocks Decline Ahead of Friday's Jobs Report
ALNY,ALNY:UW,BBG000BFGYR2,"ALNY's ENDEAVOUR Goes In Vain, ALQA Gains Big In After-Hrs, SCYX On The Move",2016-10-06 02:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2SDigWNDUZE/alnys-endeavour-goes-in-vain-alqa-gains-big-in-afterhrs-scyx-on-the-move-20161006-01126,"ALNY's ENDEAVOUR Goes In Vain, ALQA Gains Big In After-Hrs, SCYX On The Move"
ALNY,ALNY:UW,BBG000BFGYR2,"ALNY's ENDEAVOUR Goes In Vain, ALQA Gains Big In After-Hrs, SCYX On The Move",2016-10-06 02:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WU-WqiLOTm0/alnys-endeavour-goes-in-vain-alqa-gains-big-in-afterhrs-scyx-on-the-move-20161006-00026,"ALNY's ENDEAVOUR Goes In Vain, ALQA Gains Big In After-Hrs, SCYX On The Move"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Discontinues Revusiran Development,2016-10-05 23:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q5raN1IrAuE/alnylam-pharma-discontinues-revusiran-development-20161005-01030,Alnylam Pharma Discontinues Revusiran Development
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Alnylam Shares Plunge as a Drug Candidate Is Discontinued,2016-10-05 22:35:02 +0000,http://www.wsj.com/articles/alnylam-shares-plunge-as-a-drug-candidate-is-discontinued-1475704970?mod=yahoo_hs,[$$] Alnylam Shares Plunge as a Drug Candidate Is Discontinued
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development",2016-10-05 21:53:00 +0000,https://www.thestreet.com/story/13843242/1/alnylam-pharma-alny-stock-plunges-in-after-hours-trading-halts-revusiran-development.html?puc=yahoo&cm_ven=YAHOO,"Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development"
ALNY,ALNY:UW,BBG000BFGYR2,Alynlam Dives After Ending Heart Drug Development On 'Mortality Imbalance',2016-10-05 21:41:20 +0000,http://www.investors.com/news/technology/alynlam-dives-after-ending-heart-drug-development-on-mortality-imbalance/,Alynlam Dives After Ending Heart Drug Development On 'Mortality Imbalance'
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam off as development of key drug discontinued,2016-10-05 21:11:00 +0000,http://finance.yahoo.com/video/alnylam-off-development-key-drug-211100357.html,Alnylam off as development of key drug discontinued
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Discontinues Revusiran Development,2016-10-05 20:58:05 +0000,http://www.publicnow.com/view/EF8FECDF5F0A83E0B04D78A926FA2D7F4E637799,"[at noodls] - 10.05.2016 - Decision Does Not Impact Patisiran or Any Other RNAi Therapeutic Program in Development - - Company to Host Conference Call Today at 5:00 p.m. ET - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Plunges 43% After Ending Development of a Lead Drug,2016-10-05 20:51:55 +0000,http://www.bloomberg.com/news/articles/2016-10-05/alnylam-ends-heart-drug-trial-as-more-patients-on-treatment-die?cmpid=yhoo.headline,Alnylam Plunges 43% After Ending Development of a Lead Drug
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-10-05 20:45:28 +0000,http://biz.yahoo.com/e/161005/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
ALNY,ALNY:UW,BBG000BFGYR2,[$$] U.S. Drug Firm Still Plans U.K. Location,2016-10-05 01:54:36 +0000,http://online.wsj.com/article/SB22466167522824294725904582353992202969090.html?ru=yahoo?mod=yahoo_itp,[$$] U.S. Drug Firm Still Plans U.K. Location
ALNY,ALNY:UW,BBG000BFGYR2,Which Biotechs Set Up For Q4 Boost From Drug Trial Results?,2016-10-04 20:23:36 +0000,http://www.investors.com/news/technology/which-biotechs-set-up-for-q4-boost-from-drug-trial-results/,Which Biotechs Set Up For Q4 Boost From Drug Trial Results?
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : October 3, 2016",2016-10-03 16:10:51 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-value-analysis-nasdaqalny-october-3-2016/,"Alnylam Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALNY) : October 3, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi,2016-10-03 13:00:00 +0000,http://finance.yahoo.com/news/alnylam-commemorates-10th-anniversary-nobel-130000588.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today commemorates the 10-year anniversary of the Nobel Prize in Physiology or Medicine awarded to Andrew Fire, Ph.D."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam CEO: Four Things To Learn From Medicine Development,2016-10-03 12:00:00 +0000,http://www.forbes.com/sites/sciencebiz/2016/10/03/alnylam-ceo-four-things-to-learn-from-medicine-development/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Alnylam CEO: Four Things To Learn From Medicine Development
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : September 30, 2016",2016-09-30 12:29:47 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-alny-us-september-30-2016/,"Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : September 30, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Day Market Update:  Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide,2016-09-29 17:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3nCc9fu5HQQ/mid-day-market-update-crude-oil-rises-over-2-intra-cellular-therapies-shares-slide-cm686716,Midway through trading Thursday the Dow traded down 0 10 percent to 18 321 30 while the NASDAQ declined 0 31 percent to 5 302 09 The S amp P also fell dropping 0 11 percent to 2 169 00 Leading and Lagging Sectors On Thursday energy shares gained 1 37 percent Meanwhile
ALNY,ALNY:UW,BBG000BFGYR2,Stocks Close Notably Lower As Deutsche Bank Tumbles - U.S. Commentary,2016-09-29 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sRTeFxp4rJE/stocks-close-notably-lower-as-deutsche-bank-tumbles--us-commentary-20160929-00933,Stocks Close Notably Lower As Deutsche Bank Tumbles - U.S. Commentary
ALNY,ALNY:UW,BBG000BFGYR2,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 15:22:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8WiNTJOkZs/mid-morning-market-update-markets-edge-lower-pepsico-beats-q3-expectations-cm686545,Following the market opening Thursday the Dow traded down 0 06 percent to 18 329 07 while the NASDAQ declined 0 16 percent to 5 310 17 The S amp P also fell dropping 0 11 percent to 2 169 03 Leading and Lagging Sectors Thursday morning energy shares gained 0 52
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Presents Clinical and Non-Clinical Data Demonstrating Continued RNAi Platform Optimization and Leadership in the Development of RNA-Based Therapeutics at 12th Annual Meeting of the Oligonucleotide Therapeutics Society,2016-09-28 20:00:00 +0000,http://finance.yahoo.com/news/alnylam-presents-clinical-non-clinical-200000530.html,"[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today new clinical and non-clinical research results demonstrating continued RNAi therapeutics platform innovation and optimization, including improved potency, durability, metabolic stability and tolerability with its GalNAc platform, as well as clinical translation across multiple pipeline programs."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1",2016-09-24 19:19:01 +0000,http://www.publicnow.com/view/B332A86177385E1BDAC3BF50FD4C3F76FEBB7604,"[at noodls] - 09.24.2016 - ALN-GO1 Achieves Human Proof of Concept with Statistically Significant Increases in Glycolate, a Biomarker of Effective Glycolate Oxidase Knockdown, in Healthy Adult Volunteers - - Single ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.",2016-09-24 13:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_HgkbjKwMjk/better-buy-ziopharm-oncology-inc-vs-alnylam-pharmaceuticals-inc-cm684147,IMAGE SOURCE GETTY IMAGES How good is any given stock It depends on your perspective Clinical stage biotechs Ziopharm Oncology NASDAQ ZIOP and Alnylam Pharmaceuticals NASDAQ ALNY for example have both suffered in 2016 Ziopharm s shares are down almost 20 year
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.",2016-09-24 12:01:07 +0000,http://www.fool.com/investing/2016/09/24/better-buy-ziopharm-oncology-inc-vs-alnylam-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer",2016-09-21 20:31:02 +0000,http://www.publicnow.com/view/302382ABBF0ABDE63942A35F03E4DA77A8FFA086,"[at noodls] - 09.21.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, ..."
ALNY,ALNY:UW,BBG000BFGYR2,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition",2016-09-20 18:01:38 +0000,http://www.fool.com/investing/2016/09/19/3-ways-ionis-pharmaceuticals-inc-is-beating-the-co.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition"
ALNY,ALNY:UW,BBG000BFGYR2,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition",2016-09-20 11:21:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G9gnf7EerNs/3-ways-ionis-pharmaceuticals-inc-is-beating-the-competition-cm681515,Image source Getty Images There are quite a few players on the field developing RNA based therapies along with Ionis Pharmaceuticals NASDAQ IONS Its biggest competitors Alnylam Pharmaceuticals NASDAQ ALNY Arrowhead Pharmaceuticals and privately held
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK",2016-09-20 06:58:02 +0000,http://www.publicnow.com/view/E23A205F4D7FBFEA3E44A9158FCC15F6B748807B,"[at noodls] - 09.20.2016 CAMBRIDGE, Mass. & MAIDENHEAD, United Kingdom--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the expansion of its global ..."
ALNY,ALNY:UW,BBG000BFGYR2,[$$] Alnylam to brave Brexit and set up European HQ in UK,2016-09-20 04:31:17 +0000,"http://www.ft.com/cms/s/9a14af72-7e64-11e6-bc52-0c7211ef3198,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Alnylam, one of the most promising US biotechnology companies, is to invest hundreds of millions of pounds to establish its European drug development and commercial headquarters in the UK. It will announce ..."
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or",2016-09-19 20:46:27 +0000,http://biz.yahoo.com/e/160919/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Expands and Strengthens Management Team as it Plans for Commercialization,2016-09-19 20:08:03 +0000,http://www.publicnow.com/view/FBAE4903565B75A229825715388A49D76EA5D447,"[at noodls] - 09.19.2016 - Dr. Yvonne Greenstreet and Dr. Emmanuel Dulac Join Alnylam, Bringing Significant Product Strategy, Portfolio Management, and Commercialization Experience - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At Bank Of America Conference; Webcast At 4:00 AM ET,2016-09-16 06:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qhFRkHdDNo0/alnylam-pharma-to-present-at-bank-of-america-conference-webcast-at-400-am-et-20160916-00106,Alnylam Pharma To Present At Bank Of America Conference; Webcast At 4:00 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals To Participate In BoA Merrill Lynch Conference At 4:00AM,2016-09-16 03:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ri_3-REz-cQ/alnylam-pharmaceuticals-to-participate-in-boa-merrill-lynch-conference-at-400am-20160916-00051,Alnylam Pharmaceuticals To Participate In BoA Merrill Lynch Conference At 4:00AM
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Present At Morgan Stanley Conference; Webcast At 2:10 PM ET,2016-09-14 13:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z_RXhtjgzIY/alnylam-pharma-to-present-at-morgan-stanley-conference-webcast-at-210-pm-et-20160914-00814,Alnylam Pharma. To Present At Morgan Stanley Conference; Webcast At 2:10 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,Low Valuation Ratios Lead to Strong Portfolio Returns,2016-09-13 20:48:34 +0000,http://finance.yahoo.com/news/low-valuation-ratios-lead-strong-204834828.html,Low Valuation Ratios Lead to Strong Portfolio Returns
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1,2016-09-08 16:21:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/erNtQWABBEw/alnylam-alny-reports-positive-phase-i-data-on-aln-as1-cm676329,Alnylam Pharmaceuticals Inc ALNY announced positive interim results from an ongoing phase I study evaluating its pipeline candidate ALN AS1 an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias enzyme deficiency in liver The phase I study is being
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1,2016-09-08 13:42:01 +0000,http://finance.yahoo.com/news/alnylam-alny-reports-positive-phase-134201609.html,Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias",2016-09-07 12:29:03 +0000,http://www.publicnow.com/view/22CF21EDA3BE80F004760403B5E34D22579BA9B3,"[at noodls] - 09.07.2016 - In Asymptomatic High Excreter (ASHE) Porphyria Subjects, Single and Multiple Doses of ALN-AS1 Achieve Rapid, Dose-Dependent, and Durable Lowering of Toxic Heme Synthesis Intermediates, with ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam: ALN-AS1 Phase 1 Study Shows Positive Data, Gets FDA Orphan Drug Status",2016-09-07 08:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x8UqyRf7hJk/alnylam-alnas1-phase-1-study-shows-positive-data-gets-fda-orphan-drug-status-20160907-00520,"Alnylam: ALN-AS1 Phase 1 Study Shows Positive Data, Gets FDA Orphan Drug Status"
ALNY,ALNY:UW,BBG000BFGYR2,"S&P 500, Nasdaq Futures, Sept. 7 -- Technical Analysis",2016-09-07 08:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dCrmOKVvDl4/sp-500-nasdaq-futures-sept-7--technical-analysis-20160907-00429,"S&P 500, Nasdaq Futures, Sept. 7 -- Technical Analysis"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming September Investor Conferences,2016-09-06 20:09:01 +0000,http://www.publicnow.com/view/66716652C59B3C766374931EF81D4BFF49F8DF3B,"[at noodls] - 09.06.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals",2016-09-03 15:06:37 +0000,http://www.fool.com/investing/2016/09/02/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-ph.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals"
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals",2016-09-02 16:20:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Eu5r_HIbSpk/better-buy-alnylam-pharmaceuticals-inc-vs-ionis-pharmaceuticals-cm674114,Image source Getty Images Whatever your political leanings might be you can t deny Hillary Clinton s influence on biotech stocks The presidential candidate s expression of outrage over 160 EpiPen price hikes carried over to the biotech industry knocking the iShares
ALNY,ALNY:UW,BBG000BFGYR2,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 24, 2016",2016-08-24 15:45:13 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-august-24-2016/,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 24, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,"Notable Monday Option Activity: SRPT, ALNY, SWFT",2016-08-22 17:40:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sxy8D3vYGks/notable-monday-option-activity-srpt-alny-swft-cm668569,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sarepta Therapeutics Inc (Symbol SRPT), where a total volume of 24,954 contracts has been traded thus far today, a contract volume"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Cranks Out the Data",2016-08-12 21:34:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mejcINpFEJc/alnylam-pharmaceuticals-inc-cranks-out-the-data-cm664913,Image source  Getty Images.  There isn't much to say about Alnylam Pharmaceuticals '(NASDAQ  ALNY) second quarter earnings    or lack thereof    but it certainly was a data
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. Cranks Out the Data",2016-08-12 20:10:00 +0000,http://www.fool.com/investing/2016/08/12/alnylam-pharmaceuticals-inc-cranks-out-the-data.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Alnylam Pharmaceuticals, Inc. Cranks Out the Data"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?",2016-08-10 15:56:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M46Y13pUGq8/alnylam-pharmaceuticals-alny-shares-march-higher-can-it-continue-cm663424,"As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. ALNY . The stock has moved higher by 19.4% in the past month, while it is also above its 20 Day"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?",2016-08-10 13:54:01 +0000,http://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-shares-march-135401474.html,"Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At Canaccord Genuity Conference; Webcast At 11:00 AM,2016-08-10 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eqhDCJPVURc/alnylam-pharma-to-present-at-canaccord-genuity-conference-webcast-at-1100-am-20160810-00512,Alnylam Pharma To Present At Canaccord Genuity Conference; Webcast At 11:00 AM
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At Canaccord Genuity Conference; Webcast At 11:00 AM,2016-08-10 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6zWsx_VG_dA/alnylam-pharma-to-present-at-canaccord-genuity-conference-webcast-at-1100-am-20160810-00511,Alnylam Pharma To Present At Canaccord Genuity Conference; Webcast At 11:00 AM
ALNY,ALNY:UW,BBG000BFGYR2,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 9, 2016",2016-08-09 17:17:08 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-alnylam-pharmaceuticals-inc-august-9-2016/,"ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 9, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016",2016-08-08 15:53:50 +0000,http://www.capitalcube.com/blog/index.php/alnylam-pharmaceuticals-inc-alny-us-earnings-analysis-q2-2016-by-the-numbers-august-8-2016/,"Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)",2016-08-08 12:08:04 +0000,http://www.publicnow.com/view/0A74F0D7B7EA42A5691EB3EE7B22B0CD98A7461F,"[at noodls] - 08.08.2016 - Company Remains on Track to Report Top Line Data in Early 2018 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today ..."
ALNY,ALNY:UW,BBG000BFGYR2,Dodge & Cox Balanced Fund Isn't for Everyone,2016-08-07 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=763802&SR=Yahoo,Dodge & Cox Balanced Fund Isn't for Everyone
ALNY,ALNY:UW,BBG000BFGYR2,Edited Transcript of ALNY earnings conference call or presentation 4-Aug-16 8:30pm GMT,2016-08-05 20:18:05 +0000,http://finance.yahoo.com/news/edited-transcript-alny-earnings-conference-201805992.html,Edited Transcript of ALNY earnings conference call or presentation 4-Aug-16 8:30pm GMT
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 2Q loss,2016-08-04 21:11:29 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-2q-loss-211129748.html,Alnylam reports 2Q loss
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today,2016-08-04 20:30:00 +0000,http://biz.yahoo.com/cc/9/153469.html,Alnylam Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress,2016-08-04 20:22:28 +0000,http://www.publicnow.com/view/E594A59168C1638CCED4C428867CC39C528CF0A9,[at noodls] - 08.04.2016 - Advanced Two Programs into Phase 1 Clinical Studies: ALN-TTRsc02 for Transthyretin-Mediated Amyloidosis and ALN-HBV for Chronic Hepatitis B Virus Infection - - Presented Clinical Data from ...
ALNY,ALNY:UW,BBG000BFGYR2,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements",2016-08-04 20:14:34 +0000,http://biz.yahoo.com/e/160804/alny8-k.html,"ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements"
ALNY,ALNY:UW,BBG000BFGYR2,"Earnings Reaction History: Alnylam Pharmaceuticals Inc., 50.0% Follow-Through Indicator, 6.1% Sensitive",2016-08-04 19:09:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cE1l6OcnRUE/earnings-reaction-history-alnylam-pharmaceuticals-inc-500-follow-through-indicator-61-sensitive-cm660659,"Expected Earnings Release 08 04 2016, After hours Avg. Extended Hours Dollar Volume $1,701,382 Alnylam Pharmaceuticals Inc. ( ALNY ) is due to issue its quarterly earnings report in the upcoming extended hours session. Given its history, traders can"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY,2016-08-04 17:55:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_Jwtn9BBves/alnylam-pharmaceuticals-breaks-above-200-day-moving-average-bullish-for-alny-cm660557,"In trading on Thursday, shares of Alnylam Pharmaceuticals Inc (Symbol ALNY) crossed above their 200 day moving average of $72.72, changing hands as high as $74.54 per share. Alnylam Pharmaceuticals Inc shares are currently trading up about 1.1% on"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Q2 16 Earnings Conference Call At 4:30 PM ET,2016-08-04 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yNcpH8tIXEs/alnylam-pharmaceuticals-q2-16-earnings-conference-call-at-430-pm-et-20160804-01128,Alnylam Pharmaceuticals Q2 16 Earnings Conference Call At 4:30 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Stock Gained 10.8% in July",2016-08-04 14:55:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2RSiZQw1jK8/why-alnylam-pharmaceuticals-inc-stock-gained-108-in-july-cm660293,"Image source  Getty Images.  What  Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ  ALNY) , a biopharmaceutical company developing novel therapeutics based on RNA interference, rose 10.8% last month, according to data from"
ALNY,ALNY:UW,BBG000BFGYR2,Jacobs Wins Contract for New Alnylam Biopharmaceutical Manufacturing Facility,2016-08-04 12:02:05 +0000,http://www.publicnow.com/view/5B90082BB14B494871453EDA678FBACFA75F5F62,"[at noodls] - PASADENA, Calif.--(BUSINESS WIRE)-- Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals' (Nasdaq: ..."
ALNY,ALNY:UW,BBG000BFGYR2,Q2 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close,2016-08-04 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20160804.html?t=alny,Q2 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close
ALNY,ALNY:UW,BBG000BFGYR2,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More,2016-08-03 15:59:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PYcNWphP2W0/5-drug-stocks-to-watch-for-earnings-on-aug-4-bmrn-more-cm659656,"With Q2 earnings season drawing to a close, we have seen about 317 S&P 500 members (representing 73.5% of the index's total market capitalization) announce quarterly results as of Jul 29. Reported results show a 3.3% year over year"
ALNY,ALNY:UW,BBG000BFGYR2,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More,2016-08-03 13:36:01 +0000,http://finance.yahoo.com/news/5-drug-stocks-watch-earnings-133601603.html,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
ALNY,ALNY:UW,BBG000BFGYR2,7 Biotech Stocks With Pivotal Catalysts in 2017,2016-08-02 22:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zs3zLoW4Ww/7-biotech-stocks-with-pivotal-catalysts-in-2017-cm659176,"When it comes to biotech stocks, it's no secret that regulatory and clinical catalysts can generate enormous returns    or losses    for investors in the blink of an eye. With this in"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference,2016-08-02 20:21:29 +0000,http://www.publicnow.com/view/A0FEE94E50B6DD30AC57DB7115398BAC61300B15,"[at noodls] - 08.02.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results,2016-07-28 20:08:03 +0000,http://www.publicnow.com/view/4FD6D7A8B164F172C35878078CE883DB80F677B6,"[at noodls] - 07.28.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Good News For GNVC, ACRS On Track, TBRA Tanks, FDA Says No To OCUL",2016-07-26 00:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oyqpXLRIxpo/good-news-for-gnvc-acrs-on-track-tbra-tanks-fda-says-no-to-ocul-20160726-00005,"Good News For GNVC, ACRS On Track, TBRA Tanks, FDA Says No To OCUL"
ALNY,ALNY:UW,BBG000BFGYR2,"Health Care Sector Update for 07/25/2016: ALNY,BIND,TBRA",2016-07-25 20:21:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mhy7NSJ1M0w/health-care-sector-update-for-07252016-alnybindtbra-cm654364,"Top Health Care Stocks JNJ 0.18% PFE 0.02% MRK +0.50% ABT 0.60% AMGN +0.70% Health care stocks pared some of their prior declines from today, with the NYSE Health Care Index falling about 0.4% while shares of health care"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders",2016-07-25 16:28:09 +0000,http://www.publicnow.com/view/864CF2995BB4CA83BF3F500C26B374F10A139D74,"[at noodls] - 07.25.2016 - Fitusiran Achieves Median Estimated Annualized Bleeding Rate of Zero in Patients without Inhibitors - - In Initial Low Dose Cohort of Patients with Inhibitors, Fitusiran Achieves Antithrombin ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress,2016-07-25 13:08:05 +0000,http://www.publicnow.com/view/83A284C5C0AC7B92A22B3F10394656AAC7648761,"[at noodls] - 07.25.2016 - New Phase 1 Results to Include Initial Data in Hemophilia A and B Patients with Inhibitors - - Company to Host Conference Call on Wednesday, July 27, 2016, at 1:00 p.m. ET to Discuss Results ..."
ALNY,ALNY:UW,BBG000BFGYR2,5 Toxic Stocks to Sell as Anxiety Creeps Higher,2016-07-15 12:53:00 +0000,https://www.thestreet.com/story/13641125/1/5-toxic-stocks-to-sell-as-anxiety-creeps-higher.html?puc=yahoo&cm_ven=YAHOO,5 Toxic Stocks to Sell as Anxiety Creeps Higher
ALNY,ALNY:UW,BBG000BFGYR2,ALNY Reports Positive Results from Open Label Extension Study of Revusiran,2016-07-14 15:05:11 +0000,http://marketrealist.com/2016/07/alnylam-pharmaceuticals-reports-positive-results-open-label-extension-study-revusiran/?utm_source=yahoo&utm_medium=feed,ALNY Reports Positive Results from Open Label Extension Study of Revusiran
ALNY,ALNY:UW,BBG000BFGYR2,ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016,2016-07-14 13:05:00 +0000,http://marketrealist.com/2016/07/alnylam-pharmaceuticals-expects-complete-enrollment-revusirans-endeavour-trial-late-2016/?utm_source=yahoo&utm_medium=feed,ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam to Host Third Annual ""RNAi Roundtable"" Webcast Series",2016-07-12 12:23:05 +0000,http://www.publicnow.com/view/DA87D22CCE86A2D62BD7254F806A50DB7B822F9D,"[at noodls] - 07.12.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announcedthat it plans to host its 3 Annual series of webcast 'RNAi ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug,2016-07-08 17:36:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-LsYDzdkkj8/alnylam-alny-begins-phase-iii-study-on-chronic-hbv-drug-cm646511,"Alnylam Pharmaceuticals, Inc.ALNY announced that it has initiated a phase I II study on one of its pipeline candidates, ALN HBV, which is a subcutaneously administered experimental RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection."
ALNY,ALNY:UW,BBG000BFGYR2,U.S. Stocks Extend Gains Following Better-Than-Expected Jobs Report,2016-07-08 13:36:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O691bsy6PDs/us-stocks-extend-gains-following-better-than-expected-jobs-report-cm646295,"U.S. equities futures extended earlier gains after the June jobs report topped consensus and the shooting of police officers in Dallas, Texas led investors to reward manufacturers of body worn cameras and firearms. Oil was set for a rebound"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection",2016-07-07 20:11:05 +0000,http://www.publicnow.com/view/185D729784089E3098E87B7E782928B6979987DB,"[at noodls] - 07.07.2016 - Company Expects to Report Initial Clinical Data in mid-2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Incyte",2016-07-07 14:40:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/of-gdjzmBzo/better-buy-alnylam-pharmaceuticals-inc-vs-incyte-cm645718,Image source Getty Images.  Shares of both Alnylam Pharmaceuticals (NASDAQ  ALNY) and Incyte (NASDAQ  INCY) are down heavily this year. Both biotech stocks have seen some recent lift but may still be
ALNY,ALNY:UW,BBG000BFGYR2,Better Buy: Ionis Pharmaceuticals vs. Alnylam Pharmaceuticals,2016-07-05 20:51:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wq98IuoNM_k/better-buy-ionis-pharmaceuticals-vs-alnylam-pharmaceuticals-cm644894,Image source  Getty Images.  This biotech develops drugs that work by interfering with messenger ribonucleic acid (RNA) to prevent the prodution of disease causing proteins. Shares of the biotech have plunged so far this
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Is Down 37.3% This Year",2016-07-05 19:49:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pIv74yEaOCI/why-alnylam-pharmaceuticals-inc-is-down-373-this-year-cm644872,"Image source  Getty Images.  What  Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ  ALNY) , a clinical stage biotech developing novel therapies based on RNA interference, tumbled earlier this year, and are still"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Stock Up on Favorable Patisiran and Revusiran Data,2016-07-05 16:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JPhgDgA5D-E/alnylam-stock-up-on-favorable-patisiran-and-revusiran-data-cm644735,"Alnylam Pharmaceuticals, Inc. 's ALNY shares jumped 10.7% after the company announced preliminary results from the ongoing phase II open label extension (OLE) studies on its pipeline candidates, patisiran and revusiran. Data are being presented at the XV International"
ALNY,ALNY:UW,BBG000BFGYR2,"BIND Gallups On Stalking Horse Offer, KBIO Is Back, ALNY Abuzz",2016-07-03 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JFidXcbDln4/bind-gallups-on-stalking-horse-offer-kbio-is-back-alny-abuzz-20160703-00040,"BIND Gallups On Stalking Horse Offer, KBIO Is Back, ALNY Abuzz"
ALNY,ALNY:UW,BBG000BFGYR2,"Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday",2016-07-01 22:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/00q8ZhIssMU/why-alnylam-pharmaceuticals-inc-jumped-107-on-friday-cm644087,Image source  Getty Images.  What  Alnylam Pharmaceuticals (NASDAQ  ALNY) closed up 10.7% on Friday after presenting data from its ongoing phase 2 open label extension trials for patisiran and revusiran at
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Reports New Results from Investigational RNAi Therapeutic Programs for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN) and Cardiomyopathy (hATTR-CM),2016-07-01 11:11:06 +0000,http://www.publicnow.com/view/F0696FF4F40E5C1971142D750A8A3A509AC14629,"[at noodls] - 07.01.2016 - At 24 Months, Patisiran Shows a Mean 6.7 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7), Comparing Favorably with an Expected Mean 26-30 Point Increase Estimated from Historical ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Reports Results From Phase 2 OLE Studies With Patisiran, Revusiran",2016-07-01 07:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uPfg7eXFa6A/alnylam-reports-results-from-phase-2-ole-studies-with-patisiran-revusiran-20160701-00141,"Alnylam Reports Results From Phase 2 OLE Studies With Patisiran, Revusiran"
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis,2016-06-27 12:21:09 +0000,http://www.publicnow.com/view/656493DD429F6D23E96BD60B9046120E8740B9D7,"[at noodls] - 06.27.2016 Company to Host Conference Call on Friday, July 1, 2016, at 8:30 am ET to Discuss Results CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics ..."
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual ""Helping Hands"" Community Service Day",2016-06-23 20:39:03 +0000,http://www.publicnow.com/view/E3FC5DA3917A2E0A9BC69256FE8C2B84EF4219FE,"[at noodls] - 06.23.2016 - Alnylam Community Gives Back in the Communities it Serves at Ten Local Non-Profit Organizations - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At JMP Securities Conference; Webcast At 9:30 AM ET,2016-06-22 08:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BdsrC7vVlVk/alnylam-pharma-to-present-at-jmp-securities-conference-webcast-at-930-am-et-20160622-00318,Alnylam Pharma To Present At JMP Securities Conference; Webcast At 9:30 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma To Present At JMP Securities Conference; Webcast At 9:30 AM ET,2016-06-22 08:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-1LSLm1955U/alnylam-pharma-to-present-at-jmp-securities-conference-webcast-at-930-am-et-20160622-00319,Alnylam Pharma To Present At JMP Securities Conference; Webcast At 9:30 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study,2016-06-11 11:19:05 +0000,http://www.publicnow.com/view/CB92386375C5988008693B7E6DA8F23804E55A74,[at noodls] - 06.11.2016 - Initial Data Support Potential for ALN-CC5 to Reduce Dose and Frequency of Eculizumab - - Initial Results Also Support Potential for ALN-CC5 to Improve Disease Control in Eculizumab Inadequate ...
ALNY,ALNY:UW,BBG000BFGYR2,"MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data",2016-06-09 22:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/79GGEf2nGOQ/mrk-opens-wallet-vrx-to-face-fda-panel-in-july-sphs-vaults-on-trial-data-20160609-01081,"MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data"
ALNY,ALNY:UW,BBG000BFGYR2,"MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data",2016-06-09 22:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aZZuA_mHmIs/mrk-opens-wallet-vrx-to-face-fda-panel-in-july-sphs-vaults-on-trial-data-20160609-01080,"MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data"
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis",2016-06-09 12:19:11 +0000,http://www.publicnow.com/view/0AD2035F437A9C0723C5AF3C76D1165A763BC68D,"[at noodls] - 06.09.2016 - Company Demonstrates Continued Commitment to ATTR Amyloidosis Patients with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen of ALN-TTRsc02 - - Company Expects to Present ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma Starts Phase 1 Clinical Trial For ALN-TTRsc02 - Quick Facts,2016-06-09 08:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4-FgUrLWLjA/alnylam-pharma-starts-phase-1-clinical-trial-for-alnttrsc02--quick-facts-20160609-00305,Alnylam Pharma Starts Phase 1 Clinical Trial For ALN-TTRsc02 - Quick Facts
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Present At Jefferies Conference; Webcast At 1:30 PM ET,2016-06-07 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/koLm_E9RONw/alnylam-pharma-to-present-at-jefferies-conference-webcast-at-130-pm-et-20160607-00849,Alnylam Pharma. To Present At Jefferies Conference; Webcast At 1:30 PM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharma. To Present At Goldman Sachs Conference; Webcast At 11:00 AM ET,2016-06-07 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o_6i82mcfwE/alnylam-pharma-to-present-at-goldman-sachs-conference-webcast-at-1100-am-et-20160607-00692,Alnylam Pharma. To Present At Goldman Sachs Conference; Webcast At 11:00 AM ET
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data,2016-06-03 12:15:05 +0000,http://www.publicnow.com/view/E01F9D30057BB7935643988C0DD6086CBFFB4170,"[at noodls] - 06.03.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming June Investor Conferences,2016-05-31 20:23:06 +0000,http://www.publicnow.com/view/1E9E2BB8C30B9B0A79239B7CDBC35F8A20A5D879,"[at noodls] - 05.31.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the ..."
ALNY,ALNY:UW,BBG000BFGYR2,Ionis shares plummet as GSK scraps heart drug trial plans,2016-05-26 20:08:20 +0000,http://sg.finance.yahoo.com/news/ionis-shares-slump-40-percent-183200177.html,Ionis shares plummet as GSK scraps heart drug trial plans
ALNY,ALNY:UW,BBG000BFGYR2,Ionis's Shares Fall After Co-Developer Opts Against Starting Late-Stage Trial,2016-05-26 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AWHkFWucumA/ioniss-shares-fall-after-codeveloper-opts-against-starting-latestage-trial-20160526-00531,Ionis's Shares Fall After Co-Developer Opts Against Starting Late-Stage Trial
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress,2016-05-02 20:30:14 +0000,http://www.publicnow.com/view/8CC9DB8FCCEA247F8605C59D04EF0E20BD58E805,"[at noodls] - 05.02.2016 -Advances Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Year - - Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 1Q loss,2016-05-02 20:11:27 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-1q-loss-201127054.html,Alnylam reports 1Q loss
ALNY,ALNY:UW,BBG000BFGYR2,"Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts",2016-04-28 11:22:10 +0000,http://www.publicnow.com/view/5D0D8CAF75FDEF233BB06CC4A7ACBDE1030CECF9,"[at noodls] - 04.28.2016 - 200,000 Square Foot State-of-the-Art Manufacturing Facility Supports Expanding Development Pipeline and Transition Toward Commercial Stage - - Facility Expected to be Operational in 2018 - ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Presentations at Upcoming May Investor Conferences,2016-04-26 20:14:51 +0000,http://www.publicnow.com/view/64A7D02CC3CE42C70A50C5C3AB61E417D74B4172,"[at noodls] - 04.26.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results,2016-04-25 20:14:04 +0000,http://www.publicnow.com/view/B822C9B6C1C800AD2359A75DD7B178AEA1EF0435,"[at noodls] - 04.25.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ..."
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 4Q loss,2016-02-11 21:15:37 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-4q-loss-211537133.html,Alnylam reports 4Q loss
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam reports 3Q loss,2015-11-09 12:09:27 +0000,http://sg.finance.yahoo.com/news/alnylam-reports-3q-loss-120927421.html,Alnylam reports 3Q loss
ALNY,ALNY:UW,BBG000BFGYR2,Medicines shares surge on upbeat cholesterol drug study,2015-08-31 11:49:45 +0000,http://sg.finance.yahoo.com/news/medicines-shares-surge-upbeat-cholesterol-114945443.html,Medicines shares surge on upbeat cholesterol drug study
ALNY,ALNY:UW,BBG000BFGYR2,Alnylam beats Street 3Q forecasts,2014-11-05 23:04:03 +0000,http://sg.finance.yahoo.com/news/alnylam-beats-street-3q-forecasts-230403127--finance.html,Alnylam beats Street 3Q forecasts
